# Cost-effectiveness of broadly neutralizing antibodies for infant HIV prophylaxis in settings with high HIV burdens: a simulation modeling study

## Appendix

# Contents

Supplementary Methods	3
Cohort weighting	3
Additional modeled strategies	3
Infant HIV prophylaxis model structure	4
Oral infant prophylaxis regimens and efficacy	4
BNAb efficacy and duration	5
BNAb cost estimates	6
Determining cost-effectiveness	6
Supplementary Figure 1. CEPAC-P infant prophylaxis module flowchart	8
Supplementary Figure 2. Schematic of modeled cohorts and bNAb strategies	9
Supplementary Figure 3. Efficiency frontier of all bNAb strategies assessed, by country	10
Supplementary Figure 4. Cumulative vertical transmission in standard-of-care and bNAb strategies, by country	11
Supplementary Figure 5. Breakdown of intrauterine/intrapartum infections occurring in each exposure grou	
Supplementary Figure 6. Cost-effective bNAb strategy across influential univariate sensitivity analyses, by country	
Supplementary Figure 7. Cost-effective bNAb strategy across non-influential univariate sensitivity analyse by country	
<b>Supplementary Figure 8.</b> Cost-effectiveness results of a three-way sensitivity analysis assessing bNAb efficacy, cost, and cost-effectiveness threshold, by country	15
<b>Supplementary Figure 9.</b> Cost-effectiveness results of a three-way sensitivity analysis assessing bNAb efficacy, cost, and efficacy duration, by country	16
Supplementary Table 1. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) check	
Supplementary Table 2. Extended model input parameters	18
Supplementary Table 3. Justification of sensitivity analysis ranges	23
Supplementary Table 4. Validation of CEPAC-P infant HIV vertical transmission projections	27
Supplementary Table 5. Clinical and economic outcomes of all modeled bNAb infant prophylaxis program by country	
<b>Supplementary Table 6.</b> Scenario analysis: bNAbs do not reduce intrapartum transmission (base case: 70% reduction)	
Supplementary Table 7. Scenario analysis: bNAbs replace WHO-recommended standard-of-care oral infan prophylaxis	
Supplementary Table 8. Scenario analysis: maternal HIV prevalence and incidence	

<b>Supplementary Table 9.</b> One-way sensitivity analysis: bNAb efficacy against intrapartum and postnatal transmission (base case: 70% reduction)
Supplementary Table 10. One-way sensitivity analysis: bNAb cost (base case: \$20/dose)
Supplementary Table 11. One-way sensitivity analysis: bNAb effect duration (base case: 3 months)
Supplementary Table 12. One-way sensitivity analysis: bNAb uptake
<b>Supplementary Table 13.</b> One-way sensitivity analysis: proportion of mothers on antiretroviral therapy during pregnancy
Supplementary Table 14. One-way sensitivity analysis: breastfeeding duration
Supplementary Table 15. One-way sensitivity analysis: maternal postpartum HIV incidence
Supplementary Table 16. One-way sensitivity analysis: antiretroviral therapy treatment cost
Supplementary Table 17. One-way sensitivity analysis: postpartum vertical transmission risk
<b>Supplementary Table 18.</b> One-way sensitivity analysis: infant oral prophylaxis efficacy (base case: 69% intrapartum efficacy and 71% postpartum efficacy)
Supplementary Table 19. One-way sensitivity analysis: additional cost of identifying high-risk infants
Supplementary Table 20. One-way sensitivity analysis: maternal knowledge of acute HIV infection
Supplementary Table 21. One-way sensitivity analysis: maternal knowledge of chronic HIV infection
Supplementary Table 22. One-way sensitivity analysis: postpartum maternal retention in care
References

# Supplementary Methods

These supplementary methods provide additional details regarding modeling methodology, input specification, and derivation of key parameters. The Cost-Effectiveness of Preventing AIDS Complications – Pediatric (CEPAC-P) model has previously been validated and additional information is available in previously published works.<sup>1–11</sup> For further details regarding the mathematical formulas used in the model, model flowcharts, and opportunities for collaboration, we direct readers to the CEPAC website: <u>https://mpec.massgeneral.org/cepac-model/</u>.

## Cohort weighting

For each country, we simulated four sub-cohorts of infants with varying risks of HIV exposure assessed at the time of birth:

- 1) infants with known, high-risk HIV exposure;
- 2) infants with known, low-risk HIV exposure;
- 3) infants with unrecognized HIV exposure; and
- 4) infants initially unexposed to HIV (but who may become exposed postnatally).

We used World Health Organization (WHO) criteria to define high-risk (i.e., mother was not on antiretroviral therapy [ART] in pregnancy, mother was on ART in pregnancy but had a viral load [VL] >1000 copies/mL near delivery, or mother was on ART for <4 weeks prior to delivery) and low-risk (i.e., mother was on ART and had VL  $\leq$ 1000 copies/mL near delivery) exposure.<sup>12</sup>

Together, these four sub-cohorts include all infants born in a country. To estimate the proportion of infants within each sub-cohort, we used published data on country-specific estimates of maternal HIV prevalence/incidence during pregnancy, knowledge of HIV status, ART uptake, and probability of virologic suppression to populate the following equations:

Known,  
high-risk = 
$$\binom{\% \text{ of mothers known to have}}{\text{chronic HIV who were not}} + \binom{\% \text{ of mothers known to have}}{\text{chronic HIV who were on ART}} + \binom{\% \text{ of mothers known to have}}{\text{been acutely infected with HIV}}$$
  
Known,  
low-risk =  $\binom{\% \text{ of mothers known to have}}{\text{chronic HIV who were on ART}}$   
proportion =  $\binom{\% \text{ of mothers known to have}}{\text{chronic HIV who were on ART}}$   
Unknown  
HIV-exposed =  $\binom{\% \text{ of mothers with unknown}}{\text{chronic HIV during pregnancy}} + \binom{\% \text{ of mothers with unknown}}{\text{acute HIV during pregnancy}}$   
Unexposed =  $1 - \binom{\text{known, high-risk}}{\text{proportion}} - \binom{\text{known, low-risk}}{\text{proportion}} - \binom{\text{unknown}}{\text{HIV-exposed}}$ 

We used the proportion of infants within each of the four sub-cohorts to weight model outcomes and scale results representative of all infants born in a country.

## Additional modeled strategies

To determine the potential impact of broadly neutralizing antibody (bNAb) infant prophylaxis, we modeled the standard-of-care alone and various strategies offering bNAbs, in addition to the standard-of-care, to subsets of infants. A bNAb strategy targeted one of three nested populations of infants: 1) infants with known, high-risk

HIV exposure at birth (*HR-HIVE* strategies); 2) infants with any known HIV exposure at birth (*HIVE* strategies); or 3) all infants regardless of known HIV exposure (*ALL* strategies). Infants in the target population were offered one of three dosing approaches: 1) one bNAbs dose at birth (*1-dose*), 2) one bNAbs dose at birth and one dose at three months (*2-doses*), or 3) one dose of bNAbs at birth and one bNAbs dose every three months thereafter for up to 18 months while breastfeeding (*Extended*). The combination of a target population and a dosing approach comprised a bNAb strategy. For example, *ALL–1-dose* would be the bNAb strategy in which all infants, regardless of known HIV exposure, are offered one dose of bNAbs at birth.

In the primary analysis, we mainly examined strategies in which all infants in the target population received the same dosing approach. However, we also examined hybrid strategies in which subsets of the target population received different dosing approaches. For example, *ALL–1-dose plus HIVE–Extended* would offer one dose of bNAbs to all infants at birth and an additional dose of bNAbs to infants with known HIV exposure every three months for up to 18 months while breastfeeding. With the exception of *ALL–1-dose plus HIVE–Extended* all other hybrid strategies did not hold comparable value to non-hybrid strategies and are, thus, only presented in the appendix (Supplementary Table 5).

## Infant HIV prophylaxis model structure

The infant HIV prophylaxis module (Supplemental Figure 2) is embedded within the CEPAC-P model and allows the user to simulate up to four concurrent and independent lines of HIV prophylaxis. The influence of infant HIV prophylaxis on reducing intrapartum (IP) transmission is reflected as a one-time multiplier on the IP component of the overall intrauterine (IU)/IP transmission risks at birth. For all months after birth, children who are breastfeeding, have not had a prior positive HIV test, and who do not have an active dose of prophylaxis from a prior month face optional user-specified prophylaxis eligibility criteria based on their age, maternal characteristics, and early infant diagnosis (EID) test results.

If the child meets eligibility criteria for that line of prophylaxis, they then face a probability of access and adherence to prophylaxis each month. If the child receives a dose of prophylaxis, an "efficacy multiplier" is applied to reduce postnatal transmission for a user-specified number of months during which the prophylaxis dose is active. Irrespective of efficacy, if a child receives prophylaxis in a given month, they also experience a probability of mild and/or severe drug toxicity in the month the dose was administered. Every toxicity event also carries a toxicity cost; when a severe toxicity is encountered, it also carries a probability of death in that month and triggers the prophylaxis regimen to be permanently stopped.

## Oral infant prophylaxis regimens and efficacy

In the standard-of-care and in all bNAb strategies, infants with known HIV exposure were eligible for oral infant prophylaxis per WHO recommendations (i.e., six weeks of daily nevirapine [NVP] for infants who are low-risk, HIV-exposed and 12 weeks of daily zidovudine [ZDV] plus nevirapine for infants who are high-risk, HIV-exposed).<sup>12</sup> With conflicting data on the efficacy of one vs. multi-drug infant prophylaxis regimens, we modeled the same relative efficacy of both regimens.<sup>13</sup>

Modeled perinatal transmission risks among women on ART in pregnancy were largely derived from studies in which infants received short courses of antiretroviral prophylaxis after birth. Therefore, we did not model additional reductions in perinatal transmission among infants born to mothers on ART in pregnancy. However, among infants born to women who did not receive ART in pregnancy, we modeled a 69% relative reduction in the intrapartum component of perinatal transmission with oral infant prophylaxis based on data from the Post-Exposure Prophylaxis of Infants (PEPI) trial.<sup>14</sup> In the PEPI study, the cumulative HIV acquisition rate at six weeks among breastfeeding infants who received a single NVP dose plus one week of ZDV was  $5 \cdot 10\%$  compared to 1.58% among infants who received control plus extended dual prophylaxis (NVP + ZDV) (relative risk [RR]: 0.31).<sup>14</sup> While transmission by six weeks may include some early postnatal transmission, we applied

this risk reduction to the intrapartum component of vertical transmission risks for high-risk infants in the model, to be conservative with respect to the relative incremental benefits of bNAbs.

We also modeled a 71% decrease in postnatal transmission risk with oral infant prophylaxis based on an analysis of pooled individual data from five randomized trials of infant NVP prophylaxis demonstrating an adjusted hazard ratio (in time-varying analyses) of 0.29 (95% CI: 0.20-0.42) for vertical transmission while NVP was administered.<sup>15</sup>

## BNAb efficacy and duration

Anti-HIV bNAbs, such as VRC01, VRC01-LS, and VRC07-523LS, have demonstrated safety, tolerability, and favorable pharmacokinetics in infants.<sup>16–18</sup> Current bNAbs under investigation for use as infant HIV prophylaxis include:

Study	BNAb(s) investigated	Target site	Trial type	Included populations	Trial status
IMPAACT P1112	VRC01	CD4-binding site	Phase 1 study on safety and	Infants with HIV exposure	Completed
	VRC01LS	CD4-binding site	pharamacokinetics		
	VRC07-523LS	CD4-binding site			
PedMAB	VRC07-523LS plus CAP256V2LS	CD4-binding site V1/V2 loop	Phase 1/2 study on safety, pharamacokinetics,	Newborns with HIV exposure	Enrolling
			and dose finding		
SAMBULEL O	VRC07-523LS	CD4-binding site	Phase 2 study on safety and pharmacokinetics	Newborns with HIV exposure, without HIV exposure, and with HIV	In development
EDCTP Neo bNAb Trial	VRC07-523LS	CD4-binding site	Proof-of-concept on effectiveness, efficacy, and operational feasibility	Newborns with HIV exposure	In development
IMPAACT 2037	PGT121.414.LS with or without VRC07523-LS	V3 glycan CD4-binding site	Phase 1 study on safety and pharmacokinetics	Newborns with HIV exposure	In development

Table adapted from <sup>19</sup>.

Since there are currently no published human infant HIV prophylaxis efficacy studies, base case efficacy was estimated using data from human adult, non-human primate, and *in vitro* studies. In the Antibody Mediated Prevention (AMP) trials, VRC01 did not prevent overall sexual acquisition of HIV among populations of cisgender men and transgender adults in the Americas and Europe, or among women in sub-Saharan Africa.<sup>20</sup> However, acquisition of VRC01-sensitive isolates was 75.4% lower among individuals who received VRC01 compared to individuals who received placebo (IC<sub>80</sub> <1  $\mu$ g/mL).<sup>20</sup> Other bNAbs under investigation, such as 3BNC117-LS, VRC07-523LS, 1-18, and 10-1074-LS are more potent and have greater breadth than VRC01.<sup>21</sup> For example, VRC07-523LS neutralized 91% of primary African isolates in a multiclade panel with an IC<sub>80</sub> of 4.4  $\mu$ g/mL compared to VRC01 neutralizing 66% with an IC<sub>80</sub> of 18.4  $\mu$ g/mL.<sup>21</sup>

By applying the 75% efficacy against acquisition of sensitive isolates found in the AMP trial to the 91% neutralization coverage of VRC07-523LS found in the multiclade panel, we estimate VRC07-523LS could potentially have 68% overall efficacy. Similar to combination ART, a final bNAb infant prophylaxis product will likely be a combination of bNAbs, such as the VRC07-523LS+PGT121+PGDM1400 combination currently being studied as adult prophylaxis (NCT03205917, NCT03928821, NCT04212091, and NCT03721510), to achieve high breadth and potency. As such, we assumed a three-bNAb combination would have 70% efficacy in the base case, only slightly higher than the implied efficacy of VRC07-523LS alone to be conservative of the clinical impact a bNAb combination could have as prophylaxis. Given the uncertainty in final product characteristics, bNAb efficacy was varied widely in sensitivity analyses.

While the AMP studies investigated bNAb efficacy when delivered as pre-exposure prophylaxis, non-human primate studies have also observed efficacy of bNAbs as post-exposure prophylaxis if given within 24-30 hours of exposure.<sup>22,23</sup> Based on these data, we assumed that a bNAb given at birth would reduce the risk of IP HIV transmission as post-exposure prophylaxis, in addition to acting as pre-exposure prophylaxis for postnatal transmission.

Pharmacokinetic data from HIV-exposed infants suggest that with an 80mg dose of VRC07-523LS delivered subcutaneously at birth, concentrations of the bNAb would remain sufficiently high to achieve protective efficacy through at least 12 weeks of life.<sup>16</sup> In the base case, we assumed a three-month effect duration following each bNAb dose, and we also varied this assumption in sensitivity analyses.

## BNAb cost estimates

The base case average bNAb cost was modeled as \$20 per dose, including the estimated costs of production (assuming a 100mg bNAb dose), as well as delivery (including training, personal protective equipment, and cold-chain), personnel, and facility/overhead needed to administer vaccines in low- and middle-income countries. The midpoint of the estimated cost range for all components was rounded to the nearest dollar and summed to reflect the total cost of bNAbs if they were produced, delivered, and administered at scale.

## Itemized costs included in modeled bNAb cost per dose

Cost component	Cost estimate or range*	Rounded midpoint cost*
BNAb production costs per 100mg dose <sup>24</sup>	\$2.00 - \$20.00	\$11
Supply and delivery costs per dose, including: training, social mobilization, hand hygiene, personal protective equipment, waste management, and cold-chain costs <sup>25</sup>	\$1.66	\$2
Service personnel costs <sup>26</sup>	\$0.68 - \$1.45	\$1
Facility overhead and capital costs <sup>27</sup>	\$1·92 - \$4·21	\$3
Total estimated cost	\$6·26 - \$27·32	<b>\$17</b>

\*All costs are reported in 2020 USD.

To conservatively estimate the cost-effectiveness of bNAb infant prophylaxis, the total estimated cost was rounded up to the nearest ten (\$20/dose). The bNAb cost was varied widely in sensitivity analyses (\$5/dose - \$100/dose) to capture the total estimated cost using the lower bound of each cost component and to account for scenarios in which there are additional unforeseen costs or if bNAbs are not produced at scale.

## Determining cost-effectiveness

We calculated incremental cost-effectiveness ratios (ICERs; USD/year of life saved [YLS]) by ordering strategies by increasing discounted life expectancy and dividing the difference in discounted costs by the difference in discounted life expectancy of consecutive, non-dominated strategies. Life expectancy and costs were discounted at 3%/year per standard cost-effectiveness practices.<sup>28</sup> BNAb strategies were dominated if they

resulted in shorter life expectancy than a less costly strategy or resulted in higher costs per YLS (i.e., higher ICER) than the next best-performing, non-dominated strategy. We considered a bNAb strategy cost-saving if it was non-dominated and resulted in the same or greater life expectancy than the standard-of-care at lower lifetime HIV-related costs.

While the WHO-CHOICE 100% GDP per capita-based cost-effectiveness threshold has been widely cited, there is growing concern that spending to this threshold may not offer good value, particularly in resource-limited settings.<sup>29–35</sup> Due to budget constraints, investing in interventions at this GDP-based cost-effectiveness threshold may result in substantial opportunity costs (e.g., forgone health benefits) relative to other investments in health care that offer better value.<sup>29–35</sup> Cost-effectiveness thresholds accounting for these additional considerations have been estimated in the published literature:


	Cost-effectiveness threshold (in % GDP per capita)					
Source	Côte d'Ivoire	South Africa	Zimbabwe			
Woods B, Revill P, Sculpher M,	4-52%	17-69%	1-32%			
Claxton K, 2016 <sup>29</sup>						
Ochalek JM, Lomas J, Claxton KP,	15-19%	43-58%	22-30%			
2018 <sup>33</sup>						
Jit M, 2021 <sup>34</sup>	30-40%	30-40%	30-40%			
Edoka EP, Stacey NK, 2020 <sup>35</sup>	-	53%	-			
Meyer-Rath G, Rensburg C, Larson	-	10-17%	-			
B, Jamieson L, Rosen S, 2017 <sup>31</sup>						

## Cost-effectiveness thresholds for LMICs proposed in published literature

Table adapted from <sup>36</sup>.

As such, we used a more conservative cost-effectiveness threshold of 50% of GDP per capita in our base case analysis. Strategies that resulted in the greatest clinical benefit with an ICER  $\leq$ 50% of a country's GDP per capita (Côte d'Ivoire: \$1163/YLS, South Africa: \$2828/YLS, Zimbabwe: \$607/YLS)<sup>37</sup> were considered cost-effective. Given that a 50% GDP per capita cost-effectiveness threshold may still require donor-support, we also assessed the impact of using a 20% GDP per capita cost-effectiveness threshold in a sensitivity analysis. Since the cost-effective bNAb strategy did not change using the 20% GDP per capita cost-effectiveness threshold in a sensitivity analysis. Since the cost-effective bNAb strategy did not change using the 20% GDP per capita cost-effectiveness threshold in any of the three settings modeled under base case bNAb cost and efficacy assumptions, we chose to only present the 50% GDP per capita cost-effectiveness threshold in the main manuscript.


## **CEPAC-P Infant HIV Prophylaxis Module**



CEPAC-P, Cost-Effectiveness of Preventing AIDS Complications-Pediatrics Model; Y, yes; N, no; ART, antiretroviral therapy; VL, viral load; EID, early infant diagnosis.


\* This process is repeated separately for each line of prophylaxis each month.

<sup>+</sup> Efficacy of prophylaxis against intrapartum transmission is applied directly as a one-time multiplier against the intrapartum component of the intrauterine/intrapartum transmission risk.





ART, antiretroviral therapy; VL, viral load; SOC, standard-of-care.

\* The bNAb effect duration was varied during sensitivity analysis, and the frequency of administration was adjusted accordingly.




US\$, United States dollar; yrs, years; HIVE, bNAb strategy offering bNAbs to infants with known HIV exposure at birth; ALL, bNAb strategy offering bNAbs to all infants regardless of HIV exposure; mo., month.





BNAb, broadly neutralizing antibody; WHO, World Health Organization; HR-HIVE, bNAb strategy targeting infants with known, high-risk HIV exposure at birth; HIVE, bNAb strategy targeting infants regardless of known HIV exposure; mo., month.



SOC, standard-of-care; 1d, one bNAb dose; 2d, two bNAb doses; Ext, extended bNAb dosing (one dose every three months through 18 months of life while breastfeeding); HR-HIVE, bNAb strategy targeting infants with known, high-risk HIV exposure at birth; HIVE, bNAb strategy targeting infants with known HIV exposure at birth; ALL, bNAb strategy targeting all infants regardless of known HIV exposure.

The estimated number of infants at risk of intrauterine/intrapartum HIV acquisition in each exposure group varies by country. In Côte d'Ivoire, an estimated 6900 infants have known, high-risk HIV exposure at birth; and 1400 infants have unrecognized HIV exposure at birth. In South Africa, an estimated 66 200 infants have known, high-risk HIV exposure at birth; 295 700 have known, low-risk HIV exposure at birth; and 11 600 infants have unrecognized HIV exposure at birth; and 2600 infants have unrecognized HIV exposure at birth. In Zimbabwe, an estimated 12 600 infants have known, high-risk HIV exposure at birth; 35 500 infants have known, low-risk HIV exposure at birth; and 2600 infants have unrecognized HIV exposure at birth.

Supplementary Figure 6. Cost-effective bNAb strategy across influential univariate sensitivity analyses, by country

	Côte d'Ivoire Cost-effectivness threshold: ICER <u>&lt;</u> \$1163/YLS		South Africa Cost-effectiveness threshold: ICER <u>&lt;</u> \$2828/YLS		<b>Zimbabwe</b> Cost-effectiveness threshold: ICER $\leq$ \$607/YLS	
Base case	14 (6.3		9814 (2.5%)		3752 (6.9%)	
	Low	High	Low	High	Low	High
BNAb cost \$5/dose - \$100/dose; base case: \$20/dose	1468 (6.3%)	1468 (6.3%)	9814 (2.5%)	13 045 (3.3%)	3507 (6.5%)	4551 (8.4%)
BNAb effect duration 1 - 6 mo.; base case: 3 mo.	1863 (7.9%)	1465 (6.2%)	12 336 (3.1%)	9793 (2.5%)	3757 (6.9%)	3733 (6.9%)
BNAb efficacy 10 - 100%; base case: 70%	1935 (8.3%)	1256 (5.3%)	16 564 (4.2%)	6621 (1.7%)	5013 (9.3%)	3161 (5.8%)
Maternal HIV prevalence and incidence Pregnancy prevalence: varies by country* Incidence postpartum: varies by country*	561 (6.3%)	2794 (6.3%)	4933 (2.7%)	12 551 (2.4%)	1569 (7.1%)	6755 (6.2%)
Maternal knowledge of acute HIV infection During pregnancy: 25 - 95%; base case: varies by country <sup>†</sup> Postpartum: 0 - 15%/mo.; base case: varies by country <sup>†</sup>	1493 (6.4%)	1381 (5.9%)	10 766 (2.8%)	8377 (2.1%)	4157 (7.7%)	3201 (5.9%)
Maternal knowledge of chronic HIV infection Côte d'Ivoire: 56 - 100%; base case: 93% South Africa: 75 - 100%; base case: 99% Zimbabwe: 80 - 100%; base case: 98%	3839 (17.5%)	1039 (4.4%)	23 654 (6.2%)	9548 (2.4%)	5290 (9.9%)	3539 (6.5%)
HIVE - 1 dose	lybrid: ALL - 1 d IIVE - Extended \LL - Extended (	(18 mo.)	#		of pediatric HI\ tical transmissi	

ICER, incremental cost-effectiveness ratio; YLS, year of life saved; bNAbs, broadly neutralizing antibodies; mo., month; HIVE, bNAb strategy targeting infants with known HIV exposure at birth; ALL, bNAb strategy targeting all infants regardless of known HIV exposure.

\* Maternal HIV prevalence at the time of delivery is inclusive of chronic HIV infection and incident infection during pregnancy. Maternal HIV prevalence was varied according to the lowest and highest subnational estimates in each country (Côte d'Ivoire: 1-5%, base case: 3%; South Africa: 15-45%, base case: 33%; and Zimbabwe: 5-25%, base case: 12%). Postpartum maternal HIV incidence was also decreased (Côte d'Ivoire: 0.001%/month, South Africa: 0.107%/month, Zimbabwe: 0.022%/month) or increased (Côte d'Ivoire: 0.005%/month, South Africa: 0.331%/month, Zimbabwe: 0.116%/month) proportional to the change in prevalence.

<sup>†</sup> In the base case, maternal knowledge of acute HIV infection in Côte d'Ivoire is 56% for infection acquired during pregnancy and 2% per month postpartum, in South Africa is 55% during pregnancy and 9% per month postpartum, and in Zimbabwe is 70% during pregnancy and 5% per month postpartum.

#### Supplementary Figure 7. Cost-effective bNAb strategy across non-influential univariate sensitivity analyses, by country

	<b>Côte d'Ivoire</b>	South Africa	Zimbabwe
	Cost-effectivness threshold:	Cost-effectiveness threshold:	Cost-effectiveness threshold:
	ICER ≤ \$1163/YLS	ICER ≤ \$2828/YLS	ICER ≤ \$607/YLS
Base case	1468	9814	3752
	(6.3%)	(2.5%)	(6.9%)
BNAbs have no intrapartum efficacy	1549	11 728	4070
	(6.6%)	(3.0%)	(7.6%)
Infants receive either bNAbs or standard of care oral infant prophylaxis, but not both	1518	10 213	3928
	(6.5%)	(2.6%)	(7.2%)

	Low	High	Low	High	Low	High
ART costs 0.5 - 2.0x; base case: 1.0x	1468 (6.3%)	1468 (6.3%)	9814 (2.5%)	9814 (2.5%)	3752 (6.9%)	3752 (6.9%)
BNAb uptake* Côte d'Ivoire: 56 - 83%; base case: varies by age South Africa: 85 - 96%; base case: varies by age Zimbabwe: 71 - 92%; base case: varies by age	1578 (6.7%)	1392 (5.9%)	10 461 (2.7%)	9655 (2.5%)	3978 (7.3%)	3634 (6.7%)
Breastfeeding duration Duration among women with/without HIV: Côte d'Ivoire: 8/8 - 24/24 mo.; base case: 14/19 mo. South Africa: 2/2 - 18/18 mo.; base case: 6/12 mo. Zimbabwe: 8/15 - 20/20 mo.; base case: 13/18 mo.	1114 (4.8%)	1974 (8.4%)	7957 (2.1%)	14 640 (3.7%)	3265 (6.1%)	4428 (8.1%)
Cost of ascertaining high-risk status 10 - \$31.66; base case: \$31.66	1468 (6.3%)	1468 (6.3%)	9814 (2.5%)	9814 (2.5%)	3752 (6.9%)	3752 (6.9%)
Maternal ART coverage during pregnancy <sup>†</sup> Côte d'Ivoire: 70 - 100%; base case: 95% South Africa: 60 - 100%; base case: 97% Zimbabwe: 65 - 100%; base case: 89%	2140 (9.4%)	1346 (5.7%)	25 351 (6.7%)	8752 (2.2%)	5078 (9.6%)	3112 (5.7%)
Dral infant prophylaxis efficacy Intrapartum efficacy: 40 - 90%; base case: 69% Postnatal efficacy: 58 - 90%; base case: 71%	1491 (6.4%)	1452 (6.2%)	10 002 (2.6%)	9681 (2.5%)	3860 (7.1%)	3676 (6.8%)
Postnatal vertical transmission risk 15 - 2.0x; base case: 1.0x	1119 (4.8%)	2129 (9.1%)	8299 (2.1%)	12 770 (3.3%)	2831 (5.2%)	5431 (10.0%)
Postpartum maternal ART retention 0% - 100% at 6+ mo. among mothers with known status; ase case: varies by month and country	1729 (7.4%)	1359 (5.8%)	10 658 (2.7%)	9 528 (2.4%)	4203 (7.8%)	3574 (6.6%)
Postpartum maternal HIV incidence .5 - 2.0x; base case: 1.0x	1433 (6.2%)	1544 (6.5%)	9293 (2.4%)	10 830 (2.6%)	3435 (6.6%)	4576 (7.9%)

HIVE - 1 dose HIVE - Extended (18 mo.) HIVE - Extended (18 mo.)

ALL - Extended (18 mo.)


Number of pediatric HIV infections Total vertical transmission rate (%)


ICER, incremental cost-effectiveness ratio; YLS, year of life saved; bNAbs, broadly neutralizing antibodies; ART, antiretroviral therapy; mo., month; HIVE, bNAb strategy targeting infants with known HIV exposure at birth; ALL, bNAb strategy targeting all infants regardless of known HIV exposure.


\* In the base case, bNAb uptake varies by age informed by the country-specific percentage of infants delivered in a healthcare facility and uptake of vaccines in the routine infant vaccination schedule. In sensitivity analyses, the lowest and highest of each country's agespecific uptake was used as the uptake at every timepoint for the low and high scenarios, respectively.

† Maternal ART coverage during pregnancy is a proportion of all women known to have HIV during pregnancy.

Supplementary Figure 8. Cost-effectiveness results of a three-way sensitivity analysis assessing bNAb efficacy, cost, and cost-effectiveness threshold, by country









Base case

HR-HIVE - 1 dose


HR-HIVE - 2 doses

HR-HIVE - Extended (18 mo.)





Zimbabwe ICER threshold (50% GDP): \$607




ALL - Extended (18 mo.)

ICER, incremental cost-effectiveness ratio; GDP, gross domestic product; bNAb, broadly neutralizing antibody; HR-HIVE, bNAb strategy targeting infants with known, high-risk HIV exposure at birth; HIVE, bNAb strategy targeting infants with known HIV exposure at birth; ALL, bNAb strategy targeting all infants regardless of known HIV exposure; mo., month.

HIVE - Extended (18 mo.)

F)

Supplementary Figure 9. Cost-effectiveness results of a three-way sensitivity analysis assessing bNAb efficacy, cost, and efficacy duration, by country



mo., month; bNAb, broadly neutralizing antibody; HR-HIVE, bNAb strategy targeting infants with known, high-risk HIV exposure at birth; HIVE, bNAb strategy targeting infants with known HIV exposure at birth; ALL, bNAb strategy targeting all infants regardless of known HIV exposure; ICER, incremental cost-effectiveness ratio; GDP, gross domestic product.

#### Supplementary Table 1. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist

Topic	No.	Item	Location where item is reported
Title			<b>T</b> '4 <b>D</b> 1
Title	1	Identify the study as an economic evaluation and specify the interventions being compared.	Title, Page 1
Abstract			
Abstract	2	Provide a structured summary that highlights context, key methods, results, and alternative analyses.	Abstract, Pages 4-5
Introduction			
Background and objectives	3	Give the context for the study, the study question, and its practical relevance for decision making in policy or practice.	Introduction, Pages 6-7
Methods			
Health economic analysis plan	4	Indicate whether a health economic analysis plan was developed and where available.	n/a
Study population	5	Describe characteristics of the study population (such as age range, demographics, socioeconomic, or clinical characteristics).	Methods, Third Paragraph
Setting and location	6	Provide relevant contextual information that may influence findings.	Methods, First Paragraph
Comparators	7	Describe the interventions or strategies being compared and why chosen.	Methods, Fourth Paragraph
Perspective	8	State the perspective(s) adopted by the study and why chosen.	Methods, Tenth Paragrap
Fime horizon	9	State the time horizon for the study and why appropriate.	Methods, Tenth Paragrap
Discount rate	10	Report the discount rate(s) and reason chosen.	Methods, Tenth Paragrap
Selection of outcomes	11	Describe what outcomes were used as the measure(s) of benefit(s) and harm(s).	Methods, Tenth Paragrap
Measurement of outcomes	12	Describe how outcomes used to capture benefit(s) and harm(s) were measured.	n/a
Valuation of outcomes	13	Describe the population and methods used to measure and value outcomes.	n/a
Measurement and valuation of resources and costs	14	Describe how costs were valued.	Methods, Sixth and Ninth Paragraphs
Currency, price date, and conversion	15	Report the dates of the estimated resource quantities and unit costs, plus the currency and year of conversion.	Methods, Ninth Paragrap
Rationale and description of nodel	onale and description of 16 If modelling is used, describe in detail and why used. Report if the model is publicly		Methods, First paragraph Appendix Supplementary Methods; Supplementary
Analytics and assumptions	17	Describe any methods for analysing or statistically transforming data, any extrapolation methods, and approaches for validating any model used.	Figure 1 Methods, Second Paragraph; Appendix Supplemental Methods; Supplementary Table 2
Characterising heterogeneity	18	Describe any methods used for estimating how the results of the study vary for subgroups.	n/a
Characterising distributional effects	19	Describe how impacts are distributed across different individuals or adjustments made to reflect priority populations.	Methods , Third Paragrap
Characterising uncertainty	20	Describe methods to characterise any sources of uncertainty in the analysis.	Methods, Last Paragraph
Approach to engagement with	20	Describe any approaches to engage patients or service recipients, the general public,	n/a
patients and others affected by the study	21	communities, or stakeholders (such as clinicians or payers) in the design of the study.	ii/a
Results			
Study parameters	22	Report all analytic inputs (such as values, ranges, references) including uncertainty or distributional assumptions.	Table 1; Supplementary Table 2
Summary of main results	23	Report the mean values for the main categories of costs and outcomes of interest and	Results, First and Second
,			Paragraphs; Table 2
Effect of uncertainty	summarise them in the most appropriate overall measure.		Results, Third through Eighth Paragraphs; Figures 4-5; Supplementary Figures 5 7; Supplementary Tables 6-22
Effect of engagement with patients and others affected by the study	25	Report on any difference patient/service recipient, general public, community, or stakeholder involvement made to the approach or findings of the study	n/a
Discussion			
Study findings, limitations, generalisability, and current knowledge	26	Report key findings, limitations, ethical or equity considerations not captured, and how these could affect patients, policy, or practice.	Discussion, First through Ninth Paragraphs
Other relevant information			
Source of funding	27	Describe how the study was funded and any role of the funder in the identification, design, conduct, and reporting of the analysis	Title, Pages 2-3
Conflicts of interest	28	Report authors conflicts of interest according to journal or International Committee of Medical Journal Editors requirements.	Title, Page 3

#### Supplementary Table 2. Extended model input parameters

Parameter	Côte d'Ivoire	South Africa	Zimbabwe	Reference(s)
Maternal characteristics				
Proportion of mothers with chronic infection, %				
High-risk cohort	98	79	62	Derived from <sup>38–55</sup>
Low-risk cohort	100	100	100	Assumption
Unrecognized exposed cohort	94	12	27	Derived from <sup>38–50,53–56</sup>
Unexposed cohort	0	0	0	Assumption
Probability of acute HIV infection in pregnancy, %	0.03	3.30	1.94	55,45-48
Probability of acute HIV infection postnatally, %/mo.	0.003	0.240	0.056	52,55,57-59
Probability of known HIV status in pregnancy, %				Derived from <sup>38–41,49,52,56,60,61</sup>
Among mothers with chronic infection	93	99	98	42,43,49,53,55,62
Among mothers with acute infection	56	55	70	38-44,56
Probability of learning HIV status postnatally, %/mo.	2	9	5	43,53,55
Probability of being on ART during pregnancy, %				
High-risk cohort				
Among those with chronic infection	86	84	41	Derived from <sup>42,43,49–55</sup>
Among those with acute infection	95	97	89	Derived from <sup>38–50,53–56,63</sup>
Low-risk cohort	100	100	100	Assumption
Unrecognized exposed and unexposed cohorts	0	0	0	Assumption
Viral load if on ART at delivery, %			•	1 isosanip uon
Non-high-risk cohort				Derived from 42,43,49-53,60,64
HIV RNA <u>&lt;</u> 50 c/mL	76	76	76	
HIV RNA 50-1,000 c/mL	24	24	24	
HIV RNA 50-1,000 c/mL	0	0	0	
High-risk and unrecognized exposed cohorts	0	0	0	Assumption
HIV RNA >1,000 c/mL	100	100	100	Assumption
Probability of delivering in a healthcare facility, %	70	96	86	42-44
HIV RNA <1,000 c/mL among postpartum women on ART, by month postpartum	77-92	77-92	77-92	65–74
Retention in HIV care, %	11-92	11-92	11-92	75
· · · · · · · · · · · · · · · · · · ·				
High-risk and low-risk cohorts	07	00	00	
6 mo. postpartum	87	88	88	
12 mo. postpartum	87	87	87	
24 mo. postpartum	79	79	79	
Unrecognized exposed and unexposed cohorts				
6 mo. postpartum	9	37	19	
12 mo. postpartum	17	57	33	
24 mo. postpartum	27	69	47	
Infant cohort characteristics and transmission risks				
Total number of live births (thousands)	907	1153	425	76
Age, mean (SD), mo.	0 (0)	0 (0)	0 (0)	Assumption
Proportion female, %	52	52	52	77
Initial CD4% at infection, mean (SD), %	45 (9)	45 (9)	45 (9)	1
Breastfed infants, %				43,53,55,78
Unexposed or Unrecognized HIV-exposed infants	99	84	99	
Infants with known HIV exposure	99	66	94	
Breastfeeding duration, mean (SD) mo.				42-44,68,79
Unexposed or Unrecognized HIV-exposed infants	19 (7)	12 (6)	18 (7)	
Infants with known HIV exposure	14 (7)	6 (6)	13 (7)	
Intrauterine infections as a share of all perinatal infections, %	67	67	67	80
Perinatal transmission, one-time %				
Chronic maternal HIV infection in pregnancy				
On ART, HIV RNA <u>&lt;</u> 50 c/mL at delivery	0.24	0.24	0.24	81
On ART, HIV RNA 50-1,000 c/mL at delivery	1.45	1.45	1.45	81

Parameter	Côte d'Ivoire	South Africa	Zimbabwe	Reference(s)
On ART, HIV RNA >1,000 c/mL at delivery	4.14	4.14	4.14	81
Not on ART at delivery	19.70	19.70	19.70	82
Acute maternal HIV infection in pregnancy				
On ART at delivery	8.79	8.79	8.79	81,82
Not on ART at delivery	18.10	18.10	18.10	82
Postnatal transmission rate, %/mo. <sup>†, ø</sup>				
On ART, HIV RNA $\leq 50 \text{ c/mL}$	0.06	0.06	0.06	81
On ART, HIV RNA 50-1,000 c/mL	0.39	0.39	0.39	81
On ART, HIV RNA >1,000 c/mL	0.78	0.78	0.78	81
Not on ART	0.89	0.89	0.89	82
Early infant diagnosis				
Probability of uptake, % by age				
Birth	0	93	9	83,84
6-8 weeks	69	64	54	53,61,68,85-89
6/9 months (country-specific timepoint)	25	25	26	53,90
18 months	22	22	22	91
Nucleic acid amplification test characteristics				
Sensitivity, 0 months after infection, %	0	0	0	Assumption
Sensitivity, >1 month after infection, %	99.4	99.4	99.4	92
Specificity, %	99.6	99.6	99.6	92
Probability of result return, %	84	96	83	61,93,94
Delay between primary test and result return, mean mo. (SD)	2(1)	2 (1)	2 (1)	61,93
Probability of linkage to care upon detection, %	59.8	80.7	59.8	95,96
Antibody test characteristics	55.8	80 /	59.8	
Sensitivity, 0 months after infection, %	0	0	0	Assumption
Sensitivity, $\geq 1$ month after infection, %	100	100	100	97,98
Sensitivity, <u>&gt;1</u> month and meetion, <u>%</u> Specificity, %	100	100	100	
Before seroconversion	0.01	0.01	0.01	Assumption
After seroconversion	99	99	99	Assumption 98
Probability of result return, %	99	99	99	93,95
2 · · ·				<sup>93</sup> /Assumption
Delay between primary test and result return, mean mo. (SD) Probability of linkage to care upon detection, %	0 (0) 92.6	0 (0) 92·6	0 (0) 92.6	95
	100	92.0	92.6	A
Probability of HIV detection after presenting to care with a severe OI, %	100	100	100	Assumption
Infant HIV prophylaxis				
Probability of receiving scheduled prophylaxis, %	86	97	86	99
Standard-of-care oral infant prophylaxis (NVP +/- ZDV) <sup>+</sup>		86		42-44,100
bNAb prophylaxis (varies by age) <sup>§</sup>	56-83	85-96	71-92	
Efficacy of standard-of-care oral infant prophylaxis (NVP +/- ZDV) <sup>#,1</sup> %				14,15
Against intrapartum transmission	69	69	69	
Against postnatal transmission	71	71	71	
Efficacy of bNAb prophylaxis against intrapartum and postnatal transmission (in addition to efficacy of standard-of-care), %	70	70	70	Assumption based on <sup>20,21</sup>
Duration of bNAb effect, mo.	3	3	3	16,17
Probability of infant standard-of-care oral prophylaxis major toxicity, one-time %	0	0	0	Assumption based on <sup>101–103</sup>
Probability of infant bNAb prophylaxis minor toxicity, one-time %	50	50	50	Assumption
Probability of infant bNAb prophylaxis major toxicity, one-time %	0	0	0	Assumption
Natural history	· · · · · · · · · · · · · · · · · · ·		, , , , , , , , , , , , , , , , , , ,	
Monthly CD4% or CD4 decline in absence of ART, by age				
Syears (range by age and time of transmission), %	0.5 - 4.0	0.2-4.0	0.5 - 4.0	1
$\geq$ 5 years, mean (SD) (range by viral load and CD4), cells/mm <sup>3</sup>	$3 \cdot 0 (0 \cdot 3) - 6 \cdot 4 (0 \cdot 3)$	$3 \cdot 0 (0 \cdot 3) - 6 \cdot 4 (0 \cdot 3)$	$3 \cdot 0 (0 \cdot 3) - 6 \cdot 4 (0 \cdot 3)$	1,104
Monthly risk of clinical events, by age, %	5 0 (0 5) - 0 4 (0 5)	5 0 (0 5) - 0 4 (0 5)	5 0 (0 5) - 0 4 (0 5)	
0-5 years (range by age and CD4%)				77

Parameter	Côte d'Ivoire	South Africa	Zimbabwe	Reference(s)
WHO stage 3 event (except tuberculosis)	$3 \cdot 3 - 11 \cdot 6$	3.3-11.6	3.3 - 11.6	
WHO stage 4 event (except tuberculosis)	$1 \cdot 4 - 6 \cdot 4$	1.4 - 6.4	$1 \cdot 4 - 6 \cdot 4$	
Tuberculosis (any body site)	0.5 - 3.8	0.5 - 3.8	0.5 - 3.8	
≥5 years (range by CD4)				105,106
Mild fungal infection	0.75 - 9.42	1.76 - 3.14	$1 \cdot 8 - 3 \cdot 1$	
Mild bacterial infection	0.93 - 2.01	0	0	
Bacterial gastroenteritis	0.18 - 1.33	0	0	
Malaria	0.85 - 2.97	0	0	
Visceral bacterial infection	0.15 - 1.70	0.04 - 0.71	0.04 - 0.21	
WHO stage 3 or 4 visceral disease	0.03 - 2.92	0.03 - 1.43	0.03 - 1.43	
WHO stage 3 or 4 mucocutaneous disease	0.01 - 2.74	0.03 - 2.56	0.03 - 2.26	
Other WHO stage 3 or 4 disease	0.04 - 2.08	0.02 - 0.73	0.02 - 0.73	
Other severe disease	0.75 - 3.79	0.19 - 1.62	0.19 - 1.62	
Other mild infection	0.72 - 4.16	2.39	2.39	
Tuberculosis (any body site)	0.06 - 0.66	0.03 - 1.74	0.03 - 1.74	
Risk of death within 30 days of clinical event, by age, %				
0-5 years				1,77
WHO stage 3 or 4 event	13.5	13.5	13.5	
Tuberculosis	11.1	11.1	11.1	
≥5 years (range by CD4)	11 1			105,106
Mild fungal infection	0	0	0	
Mild bacterial infection	0			
Bacterial gastroenteritis	0			
Malaria	0-16.7			
Visceral bacterial infection	0 - 16.7 0 - 16.7	0	0	
WHO stage 3 or 4 visceral disease	6.7 - 12.3	0.5	0.5	
WHO stage 3 or 4 viscenar disease WHO stage 3 or 4 mucocutaneous disease	0	0	0 5	
Other WHO stage 3 or 4 disease	6.7 - 12.3	0	0	
Other severe disease	0.7 - 12.5 0 - 16.7	0.4	0.4	
Other mild infection	0 - 10' /	2.4	2.4	
Tuberculosis (any body site)	$\frac{0}{6.5 - 50.0}$	9.2	9.2	
Monthly risk of HIV-related mortality, by age, % (range by CD4 and OI history)	0.3 - 30.0	9.2	9.2	1,77,105,106
0-5 months	5.3 - 40.8	5.2 40.8	5.3 - 40.8	
		$5 \cdot 3 - 40 \cdot 8$		
6-11 months	$2 \cdot 2 - 16 \cdot 8$	$2 \cdot 2 - 16 \cdot 8$ $0 \cdot 9 - 7 \cdot 2$	$2 \cdot 2 - 16 \cdot 8$	
12-23 months	$\frac{0.9 - 7.2}{0.5 - 2.6}$		0.9 - 7.2	
24-35 months	$\frac{0.5 - 3.6}{0.4 - 2.0}$	0.5 - 3.6	$\frac{0.5 - 3.6}{0.4 - 2.0}$	
36-47 months	0.4 - 2.9	0.4 - 2.9	0.4 - 2.9	
48-59 months	0.1 - 1.0	0.1 - 1.0	0.1 - 1.0	
5-13 years	0.1 - 1.0	0.1 - 1.0	0.1 - 1.0	
≥13 years	0.04 - 5.4	0.2 - 9.5	0.2 - 9.5	
Monthly risk of non-HIV related mortality, %				107,108
HIV-exposed, uninfected children, born to mothers not on ART, by age	1.01	1.01	1.01	107,108
0-2 months	1.01	1.01	1.01	
3-5 months	0.41	0.41	0.41	
6-11 months	0.28	0.28	0.28	
12-17 months	0.14	0.14	0.14	
18-23 months	0.07	0.07	0.07	
≥24 months	See below	See below	See below	100.110
All others, by age				109,110
0-11 months (range by age and sex)	0.50 - 0.66	0.24 - 0.31	0.30 - 0.38	
12-23 months (range by sex)	0.05 - 0.06	0.02	0.03	
24-59 months (range by sex)	0.05 - 0.06	0.02	0.03	
5-13 years (range by age and sex)	0.02 - 0.03	0.003 - 0.006	0.01 - 0.05	

Parameter	Côte d'Ivoire	South Africa	Zimbabwe	Reference(s)
13-99 years	0.02 - 2.40	0.004 - 1.930	0.01 - 1.89	
100 years	100	100	100	
Freatment				
Efficacy of adult OI prophylaxis (co-trimoxazole) (range by OI type), %	18 - 88	18 - 50	18 - 88	106,111
Probability of adult OI prophylaxis (co-trimoxazole) minor toxicity, one-time %	17	17	17	106,111
Probability of adult OI prophylaxis (co-trimoxazole) major toxicity, one-time %	6	6	6	106,111
Probability of virologic suppression (<1,000 c/mL for children, <50 c/mL for adults) at 48 weeks while on ART, one-time %				
Pediatric 1 <sup>st</sup> line ART (LPV/r or EFV-based)	76	76	76	112-118
Pediatric 2 <sup>nd</sup> and subsequent lines of ART (DTG-based)	87	87	87	119
Adult 1 <sup>st</sup> line ART (DTG-based)	90	90	90	120,121
Adult 2 <sup>nd</sup> and subsequent lines of ART (PI-based)	83	83	83	122
Probability of virologic failure after initial suppression, %/mo.				
Pediatric 1 <sup>st</sup> line ART	0.52	0.52	0.52	113,116
Pediatric 2 <sup>nd</sup> and subsequent lines of ART	0.37	0.37	0.37	119
Adult 1 <sup>st</sup> line ART	0.60	0.60	0.60	120,121,123,124
Adult 2 <sup>nd</sup> and subsequent lines of ART	0.50	0.50	0.50	125
Probability of resuppression when reinitiating ART, one-time %	. 20	. 20	. 20	
Pediatric ART lines	31	31	31	126
Adult ART lines	67	67	67	127,128
Effect of ART on CD4 when suppressed, by age	07	01	57	
0-4 years, absolute CD4% gain/mo., mean (SD)				
0-6 months after ART initiation	2.2 (0.6)	2.2 (0.6)	2.2 (0.6)	129,130
≥6 months after ART initiation	0.7 (0.2)	0.7 (0.2)	0.7 (0.2)	129,130
≥5 years, absolute CD4 gain/mo., mean (SD)	07(02)	07(02)	07(02)	
0-2 months after ART initiation, cells/mm <sup>3</sup>	83.2 (38.2)	83.2 (38.2)	83.2 (38.2)	131
$\geq 2$ months after ART initiation, cells/mm <sup>3</sup>	4.2 (1.9)	4.2 (1.9)	4.2 (1.9)	131
Relative risk reduction of HIV-related mortality for patients on ART, by age, %	4.2 (1.9)	4-2 (1-9)	4-2 (1-9)	
	90	90	90	1
0-5 years	90	90	90	1
5-13 years	55 - 96	90 55 – 96		132
≥13 years (range by viral load and CD4)	55 - 96	55 - 96	55 - 96	
Relative risk reduction of clinical events for patients on ART, by age, %	95	95	95	1
0-5 years	85	85	85	1
5-13 years (range by OI type)	0-85	0-85	0-85	132
$\geq$ 13 years (range by OI type)	0-32	0-32	0-32	
Loss to follow-up probability after ART initiation, by age, %/mo.	1.4	0.0	0.1	133–142
0-13 years	1.6	0.8	0.4	133-142
$\geq$ 13 years	1.0	2.1	1.1	143-147
Return to care probability after 6 months of loss to follow-up, %/mo.				
With presentation of a severe OI	100	100	100	Assumption
Without presentation of a severe OI	1.3	1.3	1.3	
Frequency of CD4 monitoring while in care, test interval, mo.				80
First 12 months post-ART initiation	6	6	6	
After 12 months post-ART initiation	12	12	12	
CD4 threshold to stop CD4 monitoring, cells/mm <sup>3</sup>	>350	>350	>350	
Frequency of viral load monitoring while in care, mo.				80
First 12 months post-ART initiation	6	6	6	
After 12 months post-ART initiation	12	12	12	
Costs (in 2020 USD)				
Early infant diagnosis program, \$/test				
Nucleic acid amplification test	26.06	26.06	26.06	149
Antibody test	4.06	4.06	4.06	150
Negative result return	2.09	2.09	2.09	151

Parameter	Côte d'Ivoire	South Africa	Zimbabwe	Reference(s)
Positive result return	3.48	3.48	3.48	
Pediatric ART (range by age and weight, per mo.)				
1 <sup>st</sup> line	5.65 - 11.70	5.65 - 11.70	5.65 - 11.70	152,153
2 <sup>nd</sup> line	12.43 - 25.99	12.43 - 25.99	12.43 - 25.99	152,153
Adult ART (per mo.)				
1 <sup>st</sup> line	5.50	5.50	5.50	154
2 <sup>nd</sup> line	23.00	23.00	23.00	154
Infant oral prophylaxis (NVP +/- ZDV), per mo.	0.91 - 1.74	0.91 - 1.74	0.91 - 1.74	152,153
bNAb prophylaxis, per dose	20.00	20.00	20.00	24–27
Routine HIV care, by age, \$/mo. (range by CD4%/CD4 and ART status)				
0-18 years	4.59 - 181.90	3.73 - 148.88	7.04 - 35.18	105,155-158
≥18 years	4.16 - 28.48	3.73 - 148.88	7.04 - 35.18	105,106,156-158
Routine CD4 monitoring test, \$/test	3.98	3.98	3.98	159,160
Routine HIV viral load test, \$/test	24.05	24.05	24.05	149
Adult OI prophylaxis (co-trimoxazole), \$/mo.	1.04	1.04	1.04	161
Acute OI care (range by OI type), \$/mo.				
0-5 years	128.96 - 456.65	867.99 - 1525.15	0	155,162,163
≥5 years	$82 \cdot 51 - 574 \cdot 89$	$230 \cdot 20 - 780 \cdot 51$	0	105,106,158
Toxicity, \$/event				
Standard-of-care oral infant prophylaxis, minor (outpatient visit)	0	0	0	106,158,164
Infant bNAb prophylaxis, minor/major (outpatient visit)	2.72	22.03	1.93	106,158,164
Adult OI oral prophylaxis (co-trimoxazole), minor (outpatient visit)	2.72	22.03	1.93	106,158,164
Adult OI oral prophylaxis (co-trimoxazole), major (hospitalization)	83.60	1611.45	52.61	106,158,164
Death-related costs, \$/death	90.49	586.16	0	106,111,158,164
Cost of identifying high-risk HIV-exposed infant	31.66	31.66	31.66	26,27,149,151

*ART*, antiretroviral therapy; mo, month; SD, standard deviation; WHO, World Health Organization; OI, opportunistic infection; NVP, nevirapine; ZDV, zidovudine; bNAb, broadly neutralizing antibody; LPV/r, lopinavir/ritonavir; EFV, efavirenz; DTG, dolutegravir; PI, protease inhibitor.

<sup>+</sup> All women included in this analysis are known to have HIV infection by delivery. Therefore, we did not model acute HIV infection during breastfeeding.

<sup>•</sup> Postnatal transmission risks among infants whose mothers are on ART while breastfeeding account for the potential impact of antiretrovirals transferred through breastmilk.

<sup>\*</sup> Infants with known, high-risk HIV exposure received dual oral infant prophylaxis with nevirapine (NVP) + zidovudine (ZDV) for 12 weeks. Infants with known, low-risk HIV exposure received NVP alone for 6 weeks.

<sup>§</sup> The probability of receiving broadly neutralizing antibody (bNAb) prophylaxis was based on the probability of receiving World Health Organization (WHO) Expanded Program on Immunization vaccines, by age at recommended immunization.

<sup>1</sup> A reduction in the risk of intrapartum transmission with use of oral infant prophylaxis was only applied to infants born to mothers who were known to have HIV infection, but who were not on antiretroviral therapy (ART) at delivery. The impact of oral infant prophylaxis on intrapartum transmission among mothers on ART at delivery is already captured in the on ART perinatal transmission estimates.

Supplementary Table 3. Justification of sensitivity analysis ra
---

Model input parameter	Base case value	Sensitivity analysis range	Justification
Antiretroviral therapy (ART) costs (per mo.)	Pediatric ART: $I^{st} Line: \$5.65 - \$11.70$	0.5x - 2.0x	By halving and doubling all base case ART costs, we aim to capture a plausible range of potential cost changes due to reasons such as new
	2 <sup>nd</sup> Line: \$12.43 - \$25.99 Adult ART: 1 <sup>st</sup> Line: \$5.50 2 <sup>nd</sup> Line: \$23.00		formulations coming to market or price adjustments of existing formulations.
Broadly neutralizing antibody (bNAb) cost (per dose)	\$20	\$5 - \$100	This range was chosen to capture the lower and upper bounds of projected bNAb costs: \$6.26 and \$27.32, respectively (see appendix pp 5-6). Given that our bNAb efficacy estimate assumes a three-bNAb product, we also wanted to capture the price if production cost for each bNAb was separate and equal to the upper bound (i.e., 3 x \$20 for production alone).
BNAb effect duration	3 mo.	1 mo 6 mo.	A single, subcutaneous 20 mg/kg dose of VRC01—an older generation, single bNAb product—achieved the mean serum concentration target in infants of >50 ug/mL for 28 days following administration. <sup>18</sup> VRC01's pharmacokinetic data informed the lower bound of the sensitivity analysis range, while the upper bound was 2x the suggested efficacy duration of newer generation antibodies, such as VRC07-523LS, from similar pharmacokinetic studies. <sup>16</sup>
BNAb efficacy	70%	10% - 100%	We varied bNAb efficacy widely in increments of 10% from 10% to 100% to capture all potential efficacies of a bNAb product used for infant HIV prophylaxis.
BNAb uptake (varying by age)	Côte d'Ivoire: 56% - 83% South Africa: 85% - 96%	Côte d'Ivoire: 56% at all time points – 83% at all time points South Africa: 85% at all time points – 92% at all time points	The lower bound of bNAb uptake was informed by a linear regression model of average uptake of all country-specific recommended vaccinations through 18 months. <sup>100</sup> The upper bound was informed by the average uptake of recommended vaccines at birth for South Africa or the proportion of infants delivered in a health facility for Côte d'Ivoire and Zimbabwe reported by UNICEF. <sup>42,44</sup>
	Zimbabwe: 71% - 92%	Zimbabwe: 71% at all time points – 92% at all time points	
Mean breastfeeding duration	Côte d'Ivoire: Women with HIV: 14 mo. Women w/o HIV: 19 mo. South Africa: Women with HIV: 6 mo. Women w/o HIV: 12 mo.	Côte d'Ivoire: Women with HIV: 8 mo 24 mo. Women w/o HIV: 8 mo 24 mo. South Africa: Women with HIV: 2 mo 18 mo. Women w/o HIV: 2 mo 18 mo.	In Côte d'Ivoire, we varied the range of mean breastfeeding duration to capture all plausible scenarios in a clinical setting. The same range was used for all women, irrespective of HIV status. We chose a lower bound of 8 months based on clinical assumptions. The upper bound was partially informed by subnational Multiple Indicator Cluster Survey (MICS) estimates: Nord-Est region has the longest duration of breastfeeding (21.5 months). <sup>42</sup>
	Zimbabwe: Women with HIV: 13 mo. Women w/o HIV: 18 mo.	Zimbabwe: Women with HIV: 8 mo 20 mo. Women w/o HIV: 15 mo 20 mo.	In South Africa, the range for women without HIV was informed by published literature and survey estimates. In the Mother-Infant Health Study, women without HIV predominantly breastfed for 2 months, informing the lower bound. <sup>166</sup> Demographic Health Survey (DHS) data reported that the longest median duration of breastfeeding among any subgroup was 16.5 months among women in the lowest wealth quintile, which was used to inform the upper bound. <sup>43</sup>
			In Zimbabwe, the range for women without HIV was informed by provincial MICS data: Harare had the shortest breastfeeding duration (15·9 months) and Mashonaland Central had the longest breastfeeding duration (19·4 months). <sup>44</sup> The range for women with HIV was informed by the IQR of a nationally representative sample of mother and HIV-exposed infant pairs between 2013 and 2014. <sup>79</sup>

Model input parameter	Base case value	Sensitivity analysis range	Justification
Cost of ascertaining high-risk status	\$31.66	\$0 - \$31.66	The cost of ascertaining whether an infant has low- or high-risk HIV exposure was assumed to include the cost of a maternal viral load test. The cost components included the cost of a viral load test (\$24.05), result return with counseling (\$3.48), and personnel/overhead (\$4.13), reported in 2020 USD. <sup>26,27,149,151</sup> In sensitivity analyses, we wanted to assess whether assuming zero additional cost would make the <i>HR-HIVE</i> strategies cost-effective relative to other bNAb strategies. We chose not to increase the cost of a ascertaining risk status because, compared to the base case results, it would only make the <i>HR-HIVE</i> strategies even more costly and less clinically beneficial than other strategies (i.e., dominated).
Maternal ART coverage during pregnancy	Côte d'Ivoire: 95% South Africa: 97%	Côte d'Ivoire: 70% - 100% South Africa: 60% - 100%	We chose the ranges for maternal ART coverage during pregnancy based on the 95% confidence intervals from UNAIDS 2021 data (Côte d'Ivoire: 70 - >98%; South Africa: 60 - >98%; Zimbabwe: 68 - >98%). <sup>54</sup>
	Zimbabwe: 89%	Zimbabwe: 65% - 100%	
Maternal HIV prevalence and incidence	Côte d'Ivoire: Prevalence at delivery: 2.6% Incidence postpartum: 0.003%/mo. South Africa:	Côte d'Ivoire: Prevalence at delivery: 1.0% - 5.0% Incidence postpartum: 0.001%/mo. – 0.005%/mo. South Africa:	We chose the ranges for maternal HIV prevalence and incidence based on subnational estimates among women ages 15-49 years old from Population- Based HIV Impact Assessments (PHIA) data for Côte d'Ivoire and Zimbabwe and National Antenatal Sentinel HIV Survey data for South Africa. In our analysis, maternal HIV prevalence at delivery is inclusive of prevalence and incidence during pregnancy. We applied a multiplier to the base case estimate
	Prevalence at delivery: 33.0% Incidence postpartum: 0.240%/mo.	Prevalence at delivery: 15·0% - 45·0% Incidence postpartum: 0·107%/mo. – 0·331%/mo.	of HIV prevalence at delivery such that it captured the range of subnational estimates. We assumed the same multiplier applies to incidence postpartum. In Côte d'Ivoire, Woroba had the lowest prevalence (1.5%) and Montagnes
	Zimbabwe: Prevalence at delivery: 12·3% Incidence postpartum: 0·056%/mo.	Zimbabwe: Prevalence at delivery: 5.0% - 25.0% Incidence postpartum: 0.022%/mo 0.116%/mo.	had the highest prevalence $(5.0\%)$ . <sup>55</sup> In South Africa, Western Cape province had the lowest prevalence $(15.9\%)$ KwaZulu-Natal province had the highest prevalence $(41.1\%)$ . <sup>49</sup> In Zimbabwe, the lower bound of maternal HIV prevalence was informed by the lower 95% confidence interval estimate of maternal HIV prevalence (9.9%). The HIV prevalence for women in Matabeleland South (24.2%) informs the upper bound. <sup>53</sup>
Maternal knowledge of acute HIV infection	Côte d'Ivoire: During pregnancy: 56% Postpartum: 2%/mo. South Africa: During pregnancy: 55% Postpartum: 9%/mo. Zimbabwe: During pregnancy: 70% Postpartum: 5%/mo.	All countries: During pregnancy: 25% - 95% Postpartum: 0%/mo. – 15%/mo.	The lower bound of maternal knowledge of acute HIV infection during pregnancy was informed by published literature. In a study from Kenya, 26.7% of women who initially tested HIV-negative in antenatal care and returned to antenatal care to retest prior to delivery. <sup>39</sup> We aimed to capture all plausible scenarios of maternal knowledge of acute HIV infection by setting the upper bound of obtaining knowledge during pregnancy at 95% and during the postpartum period at 15%/mo.
Maternal knowledge of chronic HIV infection	Côte d'Ivoire: 93% South Africa:	Côte d'Ivoire: 56-100% South Africa:	The ranges for maternal knowledge of chronic HIV infection were informed by the upper and lower bounds of 95% confidence intervals for knowledge of HIV status as reported in South Africa DHS 2016 and UNAIDS 2020 data. <sup>43,60</sup>
	2 Zimbabwe: 98%	Zimbabwe: 80-100%	
Oral infant prophylaxis efficacy	Against intrapartum transmission: 69% Against postnatal transmission: 71%	Against intrapartum transmission: 40% - 90%	We chose the range of oral infant prophylaxis efficacy against intrapartum transmission based on ranges reported in the PEPI, HPTN 040, and PHT-5 studies. <sup>14,167,168</sup>
		Against postnatal transmission: 58% - 80%	

Model input parameter	Base case value	Sensitivity analysis range	Justification
Oral infant prophylaxis efficacy			The range for oral infant prophylaxis efficacy against intrapartum
(continued)			transmission was informed by the 95% confidence interval of relative risk
()			reduction for infants given a short course of nevirapine (NVP) + zidovudine
			(ZDV) compared to a single dose of NVP. <sup>14</sup> The range for oral infant
			prophylaxis efficacy against postnatal transmission was informed by the 95%
			confidence interval of infant HIV infection for infants given 6 weeks of NVP
			compared to no oral infant prophylaxis. <sup>15</sup>
Postnatal vertical transmission risk	On ART	0.5x - 2.0x	By halving and doubling all base case postnatal vertical transmission risks,
1 Ostnatar verticar transmission risk	Acute HIV: 4.0%	0 5x - 2 0x	we aim to capture a plausible range of potential transmission risks due to
	Chronic HIV, suppressed: 0.06%		reasons such as adherence to ART regimens or varying HIV viral loads.
	Chronic HIV, not suppressed:		reasons such as adherence to ART regimens of varying III v vital loads.
	0.39% - 0.78%		
	Off ART		
	Acute HIV: 4.6%		
	Chronic HIV: 0.89%		
Postpartum maternal ART retention	Côte d'Ivoire:	All countries:	We varied postpartum maternal ART retention for the known, high-risk and
<u> </u>	Known, high-risk / low-risk:	Known, high-risk and low-risk	low-risk cohorts from 50% to 100% after 6 months to capture all plausible
	0 mo.: 86% / 100%	6 + mo.: 50% - 100%	scenarios in a clinical setting. For the unrecognized as HIV exposed and
	6 mo.: 87%		unexposed cohorts, we calculated the ranges based on receiving ART during
	12 mo.: 87%	Côte d'Ivoire:	pregnancy if HIV status is known and maternal knowledge of HIV during
	24 mo.: 79%	Unrecognized exposed and unexposed:	breastfeeding. <sup>43,53–55</sup>
		0 mo.: 0%	
	Unrecognized exposed and unexposed:	6 mo.: 5% - 10%	
	0 mo.: 0%	12 mo.: 10% - 19%	
	6 mo.: 9%	24 mo.: 17% - 35%	
	12 mo.: 17%		
	24 mo.: 27%	South Africa:	
		Unrecognized exposed and unexposed:	
	South Africa:	0 mo.: 0%	
	Known, high-risk / low-risk:	6 mo.: 21% - 42%	
	0 mo.: 87% / 100%	12 mo.: 33% - 66%	
	6 mo.: 88%	24 mo.: 44% - 87%	
	12 mo.: 87%	27 mo.: 1170 0770	
	24 mo.: 79%	Zimbabwe:	
	24 mo.: 1970	Unrecognized exposed and unexposed:	
	Unrecognized exposed and unexposed:	0 mo.: 0%	
	0 mo.: 0%	6 mo.: 11% - 21%	
	6 mo.: 37%	12 mo.: 19% - 38%	
	12 mo.: 57%	24 mo.: 30% - 59%	
	24 mo.: 69%	24 mo. 5070 5570	
	Zimbabwe:		
	Known, high-risk / low-risk:		
	0 mo.: 59% / 100%		
	6 mo.: 88%		
	<i>12 mo.:</i> 87%		
	24 mo.: 79%		
	Unrecognized exposed and unexposed:		
	0 mo.: 0%		
	6 mo.: 19%		
	<i>12 mo.:</i> 33%		
	24 mo.: 47%		

Model input parameter	Base case value	Sensitivity analysis range	Justification
Postpartum maternal HIV incidence	Côte d'Ivoire: 0·003%/mo. South Africa: 0·240%/mo. Zimbabwe: 0·056%/mo.	0.5x - 2.0x	By halving and doubling all base case postpartum maternal HIV incidence, we aim to capture a plausible range of postpartum incidence changes due to reasons such as subnational incidence rates and missing cases in survey data.

mo.: month; w/o: without; IQR: interquartile range.

#### Supplementary Table 4. Validation of CEPAC-P infant HIV vertical transmission projections

Country	CEPAC-P projected vertical transmission rate in the standard of care (SOC) strategy, %	UNAIDS 2021 estimates, % (95% CI) <sup>62</sup>
Côte d'Ivoire	8.4	8 (4-12)
South Africa	4.4	4 (3-8)
Zimbabwe	9.5	9 (6-12)

SOC: standard-of-care; CI: confidence interval. Model-projected estimates of vertical transmission are often higher than those observed in clinical studies since they capture infants who may have acquired HIV infection, but be undiagnosed due to loss to follow up from EID programs or death prior to diagnosis.

	Clinical outcomes			Lifetime efficacy and costs			
Country/strategy	IU/IP cumulative HIV incidence (%)	Postnatal cumulative HIV incidence (%)	Total cumulative HIV incidence (%)	Undiscounted life expectancy (yrs)	Discounted life expectancy (yrs)	Discounted costs (\$)	ICER (\$/YLS)
Côte d'Ivoire [CET: ICER ≤ \$465/YLS (20%	% GDP per capita), ICER	R≤\$1163/YLS (50% C	GDP per capita)]				
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference
HR-HIVE – 1 dose	3.3	4.8	8.0	60.133	26.375	15	dominated
HR-HIVE – 2 doses	3.3	4.7	7.8	60.134	26.375	15	dominated
HIVE – 1 dose	3.3	4.7	7.8	60.134	26.375	14	dominated
HIVE – 1 dose plus HR-HIVE – 2 doses	3.3	4.6	7.6	60.136	26.376	15	dominated
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	14	dominated
HIVE – 2 doses	3.3	4.3	7.4	60.138	26.377	14	dominated
HIVE – 1 dose plus HR-HIVE Extended	3.3	4.2	7.3	60.138	26.377	14	dominated
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	27	dominated
ALL – 1 dose plus HR-HIVE – 2 doses	3.0	4.5	7.3	60.140	26.378	28	dominated
ALL – 2 doses	3.0	4.2	7.0	60.140	26.378	43	dominated
ALL – 1 dose plus HIVE – 2 doses	3.0	4.3	7.1	60.143	26.379	27	dominated
ALL - 1 dose plus HR-HIVE - Extended	3.0	4.1	7.0	60.143	26.379	28	dominated
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	13	cost-saving*"
ALL - 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.150	26.382	26	6242
ALL - Extended	3.0	2.7	5.5	60.156	26.383	91	57 860
outh Africa [CET: ICER ≤ \$1131/YLS (20	% GDP per capita), ICEI	R≤\$2828/YLS (50%)	GDP per capita)]				
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference
HR-HIVE – 1 dose	2.1	2.1	4.0	68·979	28.518	115	dominated
HR-HIVE – 2 doses	2.1	2.1	4.0	68.986	28.521	115	dominated
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	114	dominated
HIVE – 1 dose	2.0	2.0	3.8	69·011	28.529	105	dominated
HIVE – 1 dose plus HR-HIVE – 2 doses	2.0	1.9	3.8	69·018	28.532	115	dominated
HIVE – 1 dose plus HR-HIVE - Extended	2.0	1.9	3.7	69.027	28.534	114	dominated
HIVE – 2 doses	2.0	1.8	3.6	69.045	28.541	104	dominated
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	116	dominated
ALL – 1 dose plus HR-HIVE – 2 doses	1.8	1.7	3.4	69.070	28.550	126	dominated
ALL – 1 dose plus HR-HIVE - Extended	1.8	1.7	3.4	69.079	28.553	125	dominated
HIVE – Extended	2.0	1.5	3.3	69.095	28.557	100	cost-saving
ALL – 1 dose plus HIVE – 2 doses	1.8	1.6	3.3	69.097	28.559	115	dominated
ALL – 2 doses	1.8	1.5	3.2	69.122	28.568	122	dominated
ALL – 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	111	606
ALL - Extended	1.8	0.8	2.5	69.228	28.602	135	882*.†

#### Supplementary Table 5. Clinical and economic outcomes of all modeled bNAb infant prophylaxis programs, by country

		<b>Clinical outcomes</b>			Lifetime effi	cacy and costs	
		Postnatal					
Country/strategy	IU/IP cumulative HIV incidence (%)	cumulative HIV incidence (%)	Total cumulative HIV incidence (%)	Undiscounted life expectancy (yrs)	Discounted life expectancy (yrs)	Discounted costs (\$)	ICER (\$/YLS)
Zimbabwe [CET: ICER ≤ \$243/YLS (20% C	GDP per capita), ICER ≤	\$607/YLS (50% GDP	per capita)]				
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	71	dominated
HR-HIVE – 2 doses	3.7	5.2	8.5	68.373	28.053	70	dominated
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	67	dominated
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	69	dominated
HIVE – 1 dose plus HR-HIVE – 2 doses	3.7	5.0	8.3	68.387	28.057	70	dominated
HIVE – 1 dose plus HR-HIVE - Extended	3.7	4.7	8.0	68.401	28.062	69	dominated
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	79	dominated
HIVE - 2 doses	3.7	4.8	8.0	68.402	28.063	66	dominated
ALL – 1 dose plus HR-HIVE – 2 doses	3.4	4.7	7.8	$68 \cdot 408$	28.065	83	dominated
ALL - 1 dose plus HR-HIVE - Extended	3.4	4.5	7.5	68.422	28.069	82	dominated
ALL – 1 dose plus HIVE – 2 doses	3.4	4.5	7.5	68.423	28.070	79	dominated
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	93	dominated
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	61	cost-saving*,†
ALL - 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	74	1731
ALL - Extended	3.4	2.6	5.7	68.517	28.101	134	4516

Supplemental Table 5. Clinical and economic outcomes of all modeled bNAb infant prophylaxis programs, by country (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \*Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. †Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs			
	IU/IP cumulative Postnatal cumulative Total cumulative		Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)
Côte d'Ivoire [CET: ICER ≤ \$465/YL§	6 (20% GDP per capita)	), ICER ≤ \$1163/YLS (50	% GDP per capita)]				
Standard-of-care	3.6	$5 \cdot 0$	8.4	60.129	26.373	15	Reference
HR-HIVE – 1 dose	3.6	4.9	8.3	60.130	26.374	15	dominated
HR-HIVE – 2 doses	3.6	4.7	8.1	60.131	26.374	15.	dominated
HIVE – 1 dose	3.6	4.7	8.1	60.131	26.374	15	dominated
HR-HIVE – Extended	3.6	4.4	7.8	60.134	26.375	15	dominated
HIVE – 2 doses	3.6	4.3	7.8	60.135	26.375	14	dominated
ALL – 1 dose	3.6	4.7	8.1	60.134	26.375	28	dominated
ALL - 2 doses	3.6	4.2	7.6	60.135	26.376	43	dominated
HIVE – Extended	3.6	3.2	6.6	60.142	26.378	13	cost-saving*,†
ALL - 1 dose plus HIVE - Extended	3.6	3.1	6.6	60.145	26.380	27	10 008
ALL - Extended	3.6	2.7	6.1	60.151	26.381	92	59 542
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]				
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference
HR-HIVE – 1 dose	2.3	2.1	4.3	68.938	28.504	121	dominated
HR-HIVE – 2 doses	2.3	2.1	4.2	68.945	28.506	121	dominated
HR-HIVE – Extended	2.3	2.0	4.2	68.953	28.509	120	dominated
HIVE – 1 dose	2.3	2.0	4.2	68.955	28.510	113	dominated
ALL – 1 dose	2.3	1.8	4.0	68.986	28.521	127	dominated
HIVE – 2 doses	2.3	1.8	$4 \cdot 0$	68.989	28.522	112	dominated
HIVE – Extended	2.3	1.5	3.7	69.038	28.538	109	cost-saving
ALL - 2 doses	2.3	1.5	3.7	69.044	28.541	133	dominated
ALL – 1 dose plus HIVE - Extended	2.3	1.3	3.5	69.069	28.549	122	dominated
ALL - Extended	2.3	0.8	3.0	69.150	28.575	146	998* <sup>,</sup> †
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita). I	CER < \$607/YLS (50% C	<b>JDP</b> per capita)]				
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference
HR-HIVE – 1 dose	4.3	5.4	9.2	68.337	28.040	74	dominated
HR-HIVE – 2 doses	4.3	5.2	9.1	68.344	28.042	74	dominated
HIVE – 1 dose	4.3	5.2	9.0	68.346	28.043	71	dominated
HR-HIVE – Extended	4.3	4.9	8.8	68.358	28.046	73	dominated
ALL - 1 dose	4.3	4.9	8.8	68.357	28.046	85	dominated
HIVE - 2  doses	4.3	4.8	8.6	68.369	28.051	70	dominated
ALL - 2 doses	4.3	4.4	8.2	68.395	28.058	98	dominated
HIVE – Extended	4.3	3.7	7.6	68.424	28.068	65	cost-saving**†
ALL – 1 dose plus HIVE - Extended	4.3	3.4	7.3	68.434	28.072	79	3855
ALL - Extended	4.3	2.6	6.5	68.472	28.085	139	4584

#### Supplementary Table 6. Scenario analysis: bNAbs do not reduce intrapartum transmission (base case: 70% reduction)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \*Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. <sup>†</sup>Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		<b>Clinical outcomes</b>		Lifetime efficacy and costs			
	IU/IP cumulative Postnatal cumulative		Total cumulative	Undiscounted life	Discounted life	Discounted costs	
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)
Côte d'Ivoire [CET: ICER ≤ \$465/YL8	(20% GDP per capita	), ICER ≤ \$1163/YLS (50	% GDP per capita)]				
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference
HR-HIVE – 1 dose	3.3	5.0	8.1	60.131	26.374	15	dominated
HR-HIVE - 2  doses	3.3	4.9	8.0	60.132	26.374	15	dominated
HIVE – 1 dose	3.3	4.9	8.0	60.132	26.374	14	dominated
HR-HIVE – Extended	3.3	4.5	7.6	60.135	26.375	15	dominated
ALL – 1 dose	3.0	4.9	7.7	60.134	26.375	28	dominated
HIVE – 2 doses	3.3	4.5	7.6	60.136	26.376	14	dominated
ALL - 2 doses	3.0	4.4	7.2	60.144	26.378	43	dominated
HIVE - Extended	3.3	3.4	6.5	60.143	26.379	13	cost-saving*,†
ALL - 1 dose plus HIVE - Extended	3.0	3.3	6.2	60.145	26.379	26	15 769
ALL - Extended	3.0	2.9	5.8	60.156	26.383	91	21 344
South Africa [CET: ICER≤\$1131/YL	8 (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	0% GDP per capita)]				
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference
HR-HIVE – 1 dose	2.1	2.2	4.1	68.969	28.514	116	dominated
HR-HIVE - 2 doses	2.1	2.1	4.0	68.975	28.517	116	dominated
HR-HIVE – Extended	2.1	2.1	4.0	68.984	28.519	115	dominated
HIVE – 1 dose	2.0	2.1	3.9	69.000	28.525	106	dominated
HIVE – 2 doses	2.0	1.9	3.7	69.032	28.536	105	dominated
ALL – 1 dose	1.8	1.9	3.6	69.058	28.544	118	dominated
HIVE – Extended	2.0	1.6	3.4	69.080	28.552	102	cost-saving
ALL - 2 doses	1.8	1.5	3.2	69.107	28.562	123	dominated
ALL – 1 dose plus HIVE - Extended	1.8	1.4	3.1	69.138	28.571	113	587
ALL - Extended	1.8	0.9	2.6	69.211	28.596	136	941* <sup>,</sup> †
Zimbabwe [CET: ICER ≤ \$243/YLS (2	0% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]				
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference
HR-HIVE – 1 dose	3.7	5.6	8.9	68.349	28.044	72	dominated
HR-HIVE $-2$ doses	3.7	5.5	8.8	68.356	28.046	72	dominated
HIVE – 1 dose	3.7	5.5	8.7	68.361	28.048	69	dominated
HR-HIVE – Extended	3.7	5.2	8.5	68.370	28.051	71	dominated
ALL – 1 dose	3.4	5.2	8.3	68.381	28.056	81	dominated
HIVE – 2 doses	3.7	5.1	8.3	68.383	28.056	68	dominated
ALL - 2 doses	3.4	4.7	7.7	68.411	28.066	95	dominated
HIVE – Extended	3.7	4.0	7.2	68.438	28.074	63	cost-saving*,*
ALL - 1 dose plus HIVE - Extended	3.4	3.7	6.8	68.457	28.081	76	1696
ALL - Extended	3.4	2.9	6.0	68.497	28.093	136	5020

#### Supplementary Table 7. Scenario analysis: bNAbs replace WHO-recommended standard-of-care oral infant prophylaxis

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

In this scenario, infants receive either bNAbs or WHO-recommended standard-of-care oral prophylaxis, but not both; sub-populations not eligible to receive bNAbs in a strategy continue to be eligible for WHO-recommended standard-of-care oral prophylaxis. For example, in the HR-HIVE strategy, infants who are known, high-risk, HIV-exposed could only receive bNAbs but not oral prophylaxis while all other sub-populations would still be eligible to receive WHO-recommended standard-of-care oral prophylaxis. Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest tent housandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \*Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. \*Indicates the cost-effective strategy using a cos

	-	Clinical outcomes		Lifetime efficacy and costs			
	IU/IP cumulative	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs	
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	5 (20% GDP per capita)	), ICER ≤ \$1163/YLS (50	% GDP per capita)]				
Low maternal HIV prevalence/inciden							
Standard-of-care	3.6	5.0	8.4	60.177	26.392	5	Reference
HR-HIVE – 1 dose	3.3	4.9	8.0	60.178	26.393	5	dominated
HR-HIVE – 2 doses	3.3	4.7	7.8	60.179	26.393	5	dominated
HIVE – 1 dose	3.3	4.7	7.8	60.179	26.393	5	dominated
HR-HIVE – Extended	3.3	4.4	7.5	60.180	26.393	5	dominated
HIVE – 2 doses	3.3	4.3	7.4	60.180	26.393	5	dominated
ALL – 2 doses	3.0	4.2	7.0	60.181	26.394	35	dominated
ALL – 1 dose	3.0	4.7	7.5	60.183	26.394	20	dominated
HIVE – Extended	3.3	3.2	6.3	60.183	26.395	4	cost-saving*'
ALL - 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.187	26.396	19	9521
ALL - Extended	3.0	2.7	5.6	60.190	26.396	85	213 006
High maternal HIV prevalence/inciden	ıce						
Standard-of-care	3.6	5.0	8.4	60.059	26.345	27	Reference
HR-HIVE – 1 dose	3.3	$4 \cdot 8$	7.9	60.065	26.348	27	dominated
HR-HIVE – 2 doses	3.3	4.7	7.8	60.067	26.349	27	dominated
HIVE – 1 dose	3.3	4.7	7.8	60.069	26.349	26	dominated
HR-HIVE – Extended	3.3	4.3	7.5	60.072	26.351	27	dominated
HIVE - 2 doses	3.3	4.3	7.4	60.075	26.352	25	dominated
ALL – 1 dose	3.0	4.6	7.5	60.077	26.353	40	dominated
ALL – 2 doses	3.0	4.1	7.0	60.081	26.355	54	dominated
HIVE – Extended	3.3	3.1	6.3	60.090	26.357	23	cost-saving*,†
ALL - 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.098	26.361	37	4158
ALL - Extended	3.0	2.7	5.5	60.106	26.363	99	32 843
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]				
Low maternal HIV prevalence/inciden		~	• • •				
Standard-of-care	2.5	2.5	$4 \cdot 8$	69.322	28.639	56	Reference
HR-HIVE – 1 dose	2.2	2.3	4.4	69.349	28.648	57	dominated
HR-HIVE – 2 doses	2.2	2.3	4.4	69.352	28.649	57	dominated
HR-HIVE – Extended	2.2	2.2	4.3	69.356	28.650	56	dominated
HIVE – 1 dose	2.1	2.2	4.2	69.363	28.653	52	dominated
HIVE - 2 doses	2.1	2.0	4.0	69.378	28.658	52	dominated
ALL – 1 dose	2.0	2.0	3.8	69.389	28.661	70	dominated
HIVE – Extended	2.1	1.7	3.7	69.401	28.665	50	cost-saving*
ALL - 2 doses	2.0	1.6	3.4	69.423	28.673	81	dominated
ALL – 1 dose plus HIVE - Extended	2.0	1.5	3.3	69.427	28.674	68	2065
ALL - Extended	2.0	0.9	2.7	69.477	28.690	104	2262†

#### Supplementary Table 8. Scenario analysis: maternal HIV prevalence and incidence

Country/strategy	Clinical outcomes			Lifetime efficacy and costs			
	IU/IP cumulative	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs	
	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]				
High maternal HIV prevalence/inciden	ice						
Standard-of-care	2.2	2.0	4.1	68.714	28.426	144	Reference
HR-HIVE – 1 dose	1.9	1.9	3.7	68.786	28.450	149	dominated
HR-HIVE - 2 doses	1.9	1.9	3.7	68.795	28.453	149	dominated
HR-HIVE – Extended	1.9	1.8	3.7	68.807	28.457	148	dominated
HIVE – 1 dose	1.8	1.8	3.5	68.830	28.466	135	dominated
HIVE – 2 doses	1.8	1.6	3.3	68.876	28.482	134	dominated
ALL – 1 dose	1.7	1.6	3.2	68.888	28.487	142	dominated
HIVE - Extended	1.8	1.3	3.0	68.945	28.504	129	cost-saving
ALL - 2 doses	1.7	1.3	2.9	68.963	28.512	145	dominated
ALL - 1 dose plus HIVE - Extended	1.7	1.1	2.8	69.003	28.525	135	298
ALL - Extended	1.7	0.7	2.4	69.094	28.555	152	548*.†
Zimbabwe [CET: ICER ≤ \$243/YLS (2	0% GDP per capita), I	CER≤\$607/YLS (50% C	<b>GDP per capita</b> ]				
Low maternal HIV prevalence/incident	· · · · ·		1 1 //				
Standard-of-care	4.4	5.8	9.6	68·675	28.160	29	Reference
HR-HIVE – 1 dose	3.8	5.4	8.8	68.694	28.166	29	dominated
HR-HIVE – 2 doses	3.8	5.3	8.7	68.697	28.167	29	dominated
HIVE – 1 dose	3.7	5.3	8.6	68.699	28.168	27	dominated
HR-HIVE – Extended	3.8	5.0	8.4	68.703	28.169	28	dominated
ALL – 1 dose	3.5	5.0	8.1	68.708	28.170	43	dominated
HIVE – 2 doses	3.7	4.9	8.2	68.708	28.171	27	dominated
ALL - 2 doses	3.5	4.4	7.5	68.728	28.176	59	dominated
HIVE – Extended	3.7	3.8	7.1	68.731	28.179	25	cost-saving*"
ALL – 1 dose plus HIVE - Extended	3.5	3.5	6.6	68.739	28.181	41	7410
ALL - Extended	3.5	2.6	5.8	68.756	28.187	109	10 687
High maternal HIV prevalence/inciden							
Standard-of-care	4.2	5.4	9.1	67.742	27.829	139	Reference
HR-HIVE – 1 dose	3.6	5.1	8.3	67.829	27.860	137	dominated
HR-HIVE – 2 doses	3.6	5.0	8.2	67.843	27.865	137	dominated
HIVE – 1 dose	3.5	4.9	8.1	67.857	27.870	130	dominated
HR-HIVE – Extended	3.6	4.7	7.9	67.871	27.874	134	dominated
HIVE - 2  doses	3.5	4.5	7.7	67.903	27.886	128	dominated
ALL - 1 dose	3.3	4.7	7.7	67.903	27.886	138	dominated
ALL - 2  doses	3.3	4.2	7.1	67.973	27.909	148	dominated
HIVE – Extended	3.5	3.4	6.6	68·016	27.922	119	cost-saving*
ALL – 1 dose plus HIVE - Extended	3.3	3.2	6.2	68.062	27.938	126	494†
ALL - Extended	3.3	2.4	5.5	68.134	27.963	173	1894

#### Supplementary Table 8. Scenario analysis: maternal HIV prevalence and incidence (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

The setting-specific maternal HIV prevalence and incidence are specified in Supplementary Table 2 (base case) and Supplementary Table 3 (low/high scenarios). Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

· · ·		Clinical outcomes		Lifetime efficacy and costs			
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs	
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	6 (20% GDP per capita	), ICER ≤ \$1163/YLS (50	% GDP per capita)]				
bNAb efficacy: 10%							
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference*
HR-HIVE – 1 dose	3.6	5.0	8.3	60.130	26.373	15	dominated
HR-HIVE - 2 doses	3.6	4.9	8.3	60.130	26.373	15	dominated
HIVE – 1 dose	3.6	4.9	8.3	60.130	26.374	15	706†
HR-HIVE – Extended	3.6	4.9	8.2	60.130	26.374	16	dominated
HIVE - 2 doses	3.6	4.9	8.2	60.131	26.374	15	dominated
ALL – 2 doses	3.5	4.9	8.2	60.130	26.374	45	dominated
HIVE – Extended	3.6	4.7	8.1	60.132	26.374	16	1593
ALL – 1 dose	3.5	4.9	8.2	60.133	26.375	28	dominated
ALL - 1 dose plus HIVE - Extended	3.5	4.7	8.0	60.134	26.375	29	11 561
ALL - Extended	3.5	4.7	8.0	60.137	26.375	95	615 409
bNAb efficacy: 100%							
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference
HR-HIVE - 1 dose	3.2	4.8	7.8	60.134	26.375	15	dominated
HR-HIVE – 2 doses	3.2	4.6	7.6	60.136	26.376	14	dominated
HIVE – 1 dose	3.1	4.6	7.5	60.137	26.376	14	dominated
HR-HIVE – Extended	3.2	4.1	7.1	60.139	26.377	14	dominated
HIVE - 2 doses	3.1	$4 \cdot 0$	7.0	60.141	26.378	13	dominated
ALL – 1 dose	2.8	4.5	7.1	60.143	26.379	27	dominated
ALL - 2 doses	2.8	3.8	6.4	60.146	26.380	42	dominated
HIVE – Extended	3.1	2.4	5.3	60.153	26.382	11	cost-saving*,†
ALL – 1 dose plus HIVE - Extended	2.8	2.3	4.9	60.159	26.385	24	5017
ALL - Extended	2.8	1.6	4.3	60.166	26.387	89	38 627
South Africa [CET: ICER ≤ \$1131/YL		), ICER < \$2828/YLS (50	)% GDP per capita)]				
bNAb efficacy: 10%	. (		·····				
Standard-of-care	2.3	2.2	$4 \cdot 4$	68.924	28.499	112	Reference
HR-HIVE – 1 dose	2.3	2.2	4.3	68.931	28.502	122	dominated
HR-HIVE – 2 doses	2.3	2.2	4.3	68.933	28.502	122	dominated
HR-HIVE – Extended	2.3	2.2	4.3	68.934	28.503	122	dominated
HIVE – 1 dose	2.3	2.2	4.3	68.934	28.503	115	1009
ALL – 1 dose	2.3	2.2	4.2	68.938	28.504	132	dominated
HIVE – 2 doses	2.3	2.1	4.3	68.940	28.505	118	dominated
HIVE – Extended	2.3	2.1	4.2	68.947	28.507	120	1118*.†
ALL - 2  doses	2.3	2.1	4.2	68.950	28.508	143	dominated
ALL – 1 dose plus HIVE - Extended	2.3	2.1	4.2	68.951	28.509	136	dominated
ALL - Extended	2.3	2.0	4.1	68.967	28.513	169	7902

#### Supplementary Table 9. One-way sensitivity analysis: bNAb efficacy against intrapartum and postnatal transmission (base case: 70% reduction)

	Clinical outcomes			Lifetime efficacy and costs			
Country/strategy	IU/IP cumulative HIV incidence (%)	Postnatal cumulative HIV incidence (%)	Total cumulative HIV incidence (%)	Undiscounted life expectancy (yrs)	Discounted life expectancy (yrs)	Discounted costs (\$)	ICER (\$/YLS)
South Africa [CET: ICER ≤ \$1131/YL							
bNAb efficacy: 100%	r ( · · · · · · · · · · · · · · · · · ·		F F I				
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference
HR-HIVE – 1 dose	1.9	2.1	3.9	69.004	28.527	112	dominated
HR-HIVE – 2 doses	1.9	2.0	3.8	69.013	28.530	111	dominated
HR-HIVE – Extended	1.9	1.9	3.7	69.026	28.534	110	dominated
HIVE – 1 dose	1.8	1.9	3.6	69.050	28.543	100	dominated
HIVE - 2 doses	1.8	1.6	3.3	69.098	28.559	97	dominated
ALL – 1 dose	1.6	1.6	3.1	69.127	28.570	108	dominated
HIVE – Extended	1.8	1.2	2.9	69.169	28.582	90	cost-saving
ALL – 2 doses	1.6	1.1	2.6	69.210	28.599	111	dominated
ALL – 1 dose plus HIVE - Extended	1.6	0.9	2.4	69.246	28.609	98	295
ALL - Extended	1.6	0.2	1.7	69.363	28.648	117	476*,†
Zimbabwe [CET: ICER ≤ \$243/YLS (2		CER < \$607/YLS (50% C	<b>JDP per capita</b> ]				
bNAb efficacy: 10%	·····		[····/				
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference*
ALL – 1 dose	4.2	5.5	9.2	68·328	28.036	87	dominated
HR-HIVE – 1 dose	4.3	5.6	9.3	68.327	28.036	75	dominated
HR-HIVE $-2$ doses	4.3	5.6	9.3	68·328	28.037	75	dominated
HIVE – 1 dose	4.2	5.6	9.3	68·330	28.037	72	dominated
HR-HIVE – Extended	4.3	5.5	9.3	68·330	28.037	76	276†
HIVE – 2 doses	4.2	5.5	9.3	68·333	28.038	74	dominated
ALL - 2 doses	4.2	5.5	9.2	68·339	28.039	104	dominated
ALL - 1 dose plus HIVE - Extended	4.2	5.3	9.0	68.338	28.039	92	1379
HIVE – Extended	4.2	5.4	9.1	68.340	28.040	77	dominated
ALL - Extended	4.2	5.2	8.9	68.342	28.041	157	82 283
bNAb efficacy: 100%							
Standard-of-care	4.3	5.6	9.5	68·321	28.034	72	Reference
HR-HIVE – 1 dose	3.5	5.2	8.3	68.386	28.057	68	dominated
HR-HIVE – 2 doses	3.5	5.0	8.1	68.396	28.061	67	dominated
HIVE – 1 dose	3.4	4.9	7.9	68.405	28.064	64	dominated
HR-HIVE – Extended	3.5	4.6	7.7	68.417	28.067	65	dominated
HIVE – 2 doses	3.4	4.4	7.4	68.437	28.075	62	dominated
ALL - 1 dose	3.1	4.5	7.3	68.437	28.076	75	dominated
ALL - 2 doses	3.1	3.7	6.5	68.490	28.093	87	dominated
HIVE – Extended	3.4	2.7	5.8	68.518	28.101	53	cost-saving*,†
ALL – 1 dose plus HIVE - Extended	3.1	2.4	5.1	68.550	28.113	65	995
ALL - Extended	3.1	1.2	4.0	68.609	28.132	121	2849

Supplementary Table 9. One-way sensitivity analysis: bNAb efficacy against intrapartum and postnatal transmission (base case: 70% reduction) (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. <sup>†</sup> Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs			
	IU/IP cumulative	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs	
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	S (20% GDP per capita	), ICER≤\$1163/YLS (50	% GDP per capita)]				
bNAb cost: \$5/dose	• •			<i></i>			<b>D</b> 0
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference
HR-HIVE – 1 dose	3.3	4.8	8.0	60.133	26.375	15	dominated
HR-HIVE – 2 doses	3.3	4.7	7.8	60.134	26.375	15	dominated
HIVE – 1 dose	3.3	4.7	7.8	60.135	26.375	14	dominated
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	14	dominated
HIVE – 2 doses	3.3	4.3	7.4	60.138	26.377	13	dominated
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	17	dominated
ALL – 2 doses	3.0	4.2	$7 \cdot 0$	60.140	26.378	21	dominated
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	11	cost-saving*.
ALL – 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.151	26.382	15	1673
ALL - Extended	3.0	2.7	5.5	60.156	26.383	31	14 322
bNAb cost: \$100/dose							
Standard-of-care	3.6	$5 \cdot 0$	8.4	60.129	26.373	15	Reference
HR-HIVE - 1 dose	3.3	4.8	8.0	60.133	26.375	15	dominated
HR-HIVE - 2  doses	3.3	4.7	7.8	60.134	26.375	16	dominated
HIVE – 1 dose	3.3	4.7	7.8	60.135	26.375	15	400*
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	16	dominated
HIVE - 2 doses	3.3	4.3	7.4	60.138	26.377	17	dominated
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	82	dominated
ALL – 2 doses	3.0	4.2	$7 \cdot 0$	60.140	26.378	162	dominated
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	19	874†
ALL - 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.151	26.382	86	31 377
ALL - Extended	3.0	2.7	5.5	60.156	26.383	410	289 474
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	% GDP per capita)]				
bNAb cost: \$5/dose							
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference
HR-HIVE – 1 dose	2.1	2.1	4.0	68.979	28.518	114	dominated
HR-HIVE – 2 doses	2.1	2.1	4.0	68.986	28.521	114	dominated
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	113	dominated
HIVE – 1 dose	2.0	2.0	3.8	69.011	28.529	103	dominated
HIVE – 2 doses	2.0	1.8	3.6	69.045	28.541	99	dominated
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	105	dominated
HIVE – Extended	2.0	1.5	3.3	69.095	28.557	93	cost-saving
ALL - 2 doses	1.8	1.5	3.2	69.122	28.568	102	dominated
ALL – 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	96	dominated
ALL - Extended	1.8	0.8	2.5	69.228	28.602	94	24*.†

#### Supplementary Table 10. One-way sensitivity analysis: bNAb cost (base case: \$20/dose)

		<b>Clinical outcomes</b>			Lifetime efficacy	and costs	
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs	
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER $\leq$ \$2828/YLS (50	)% GDP per capita)]				
bNAb cost: \$100/dose							
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference
HR-HIVE - 1 dose	2.1	2.1	4.0	68.979	28.518	117	dominated
HR-HIVE – 2 doses	2.1	2.1	4.0	68.986	28.521	119	dominated
HR-HIVE – Extended	2.1	$2 \cdot 0$	3.9	68.995	28.523	121	dominated
HIVE – 1 dose	2.0	2.0	3.8	69.011	28.529	118	214
HIVE - 2 doses	2.0	1.8	3.6	69.045	28.541	127	dominated
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	172	dominated
HIVE – Extended	2.0	1.5	3.3	69.095	28.557	138	723*,†
ALL – 2 doses	1.8	1.5	3.2	69.122	28.568	228	dominated
ALL - 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	192	2918
ALL - Extended	1.8	0.8	2.5	69.228	28.602	350	5977
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]				
bNAb cost: \$5/dose	• • * *	,	• • •				
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	70	dominated
HR-HIVE – 2 doses	3.7	5.2	8.5	68.373	28.053	69	dominated
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	65	dominated
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	67	dominated
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	67	dominated
HIVE - 2 doses	3.7	$4 \cdot 8$	8.0	68.402	28.063	63	dominated
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	67	dominated
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	55	cost-saving
ALL – 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	56	160* <sup>,</sup> †
ALL - Extended	3.4	2.6	5.7	68.517	28.101	67	791
bNAb cost: \$100/dose			·				
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	72	54*
HR-HIVE $-2$ doses	3.7	5.2	8.5	68.373	28.053	74	dominated
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	74	295†
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	78	dominated
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	146	dominated
HIVE - 2 doses	3.7	4.8	8.0	68.402	28.063	80	dominated
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	228	dominated
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	93	756
ALL – 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	165	9833
ALL - Extended	3.4	2.6	5.7	68.517	28.101	488	24 338

#### Supplementary Table 10. One-way sensitivity analysis: bNAb cost (base case: \$20/dose) (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	<b>Discounted life</b>	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	5 (20% GDP per capita	), ICER ≤ \$1163/YLS (50	% GDP per capita)]					
bNAb effect duration: 1 month								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference	
HR-HIVE – 1 dose	3.3	4.9	8.0	60.132	26.374	15	dominated	
HR-HIVE - 2 doses	3.3	4.9	8.0	60.133	26.375	15	dominated	
HIVE – 1 dose	3.3	4.9	7.9	60.133	26.375	14	cost-saving	
HIVE – 2 doses	3.3	4.8	7.8	60.134	26.375	15	dominated	
HR-HIVE – Extended	3.3	4.4	7.5	60.136	26.376	15	dominated	
ALL – 1 dose	3.0	4.9	7.7	60.137	26.377	28	dominated	
ALL – 2 doses	3.0	4.7	7.6	60.140	26.378	45	dominated	
HIVE – Extended	3.3	3.2	6.3	60.145	26.379	16	267* <sup>,</sup> †	
ALL - 1 dose plus HIVE - Extended	3.0	3.2	6.1	60.150	26.381	29	7052	
ALL - Extended	3.0	2.7	5.6	60.158	26.384	235	81 484	
bNAb effect duration: 6 months								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference	
HR-HIVE – 1 dose	3.3	4.7	7.8	60.134	26.375	15	dominated	
HR-HIVE – 2 doses	3.3	4.5	7.6	60.135	26.376	14	dominated	
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	14	dominated	
HIVE – 1 dose	3.3	4.4	7.4	60.137	26.376	14	dominated	
HIVE - 2 doses	3.3	3.7	6.7	60.142	26.378	13	dominated	
ALL – 1 dose	3.0	4.2	7.1	60.143	26.379	27	dominated	
HIVE – Extended	3.3	3.1	6.2	60.146	26.379	12	cost-saving*.*	
ALL - 2 doses	3.0	3.3	6.2	60.145	26.381	40	dominated	
ALL – 1 dose plus HIVE - Extended	3.0	3.0	5.9	60.151	26.382	25	5467	
ALL - Extended	3.0	2.6	5.5	60.158	26.383	55	19 636	
South Africa [CET: ICER ≤ \$1131/YL				00 100	20 000	00	17 000	
bNAb effect duration: 1 month	5 (2070 ODT per cupit	.), ICHK <u>-</u> 02020/ IHS (30	, to GD1 per cupitu)					
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference	
HR-HIVE – 1 dose	2.5	2.2	4.1	68.970	28.515	112	dominated	
HR-HIVE $-2$ doses	2.1	2.1	4.0	68.976	28.517	116	dominated	
HIVE - 1  dose	$2 \cdot 0$	2.1	4.0	68.985	28.520	108	cost-saving	
HR-HIVE – Extended	2.0	2.0	3.9	68.995	28.523	117	dominated	
HIVE - 2  doses	$2 \cdot 1$ $2 \cdot 0$	2.0	3.9	68.997	28.525	110	dominated	
ALL - 1 dose	1.8	2.1	3.8	69.011	28.523	121	dominated	
ALL - 1  dose ALL - 2  doses	1.8	1.9	3.6	69.038	28.529	133	dominated	
HIVE – Extended	2.0	1.9	3.3	69.093	28.559	116	222*	
ALL - 1 dose plus HIVE - Extended	1.8	1.3	3.1	69.119	28.557	130	1462†	
ALL – I dose plus HIVE - Extended ALL - Extended	1.8	0.8				227		
ALL - Extended	1.9	0.9	2.5	69.221	28.600	221	2861	

# Supplementary Table 11. One-way sensitivity analysis: bNAb effect duration (base case: 3 months)

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	<b>Discounted life</b>	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER $\leq$ \$2828/YLS (50)	)% GDP per capita)]					
bNAb effect duration: 6 months								
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.0	68.986	28.520	114	dominated	
HR-HIVE - 2 doses	2.1	2.0	3.9	68.994	28.523	113	dominated	
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	113	dominated	
HIVE – 1 dose	2.0	1.8	3.6	69.044	28.541	101	dominated	
HIVE – 2 doses	2.0	1.5	3.4	69.086	28.554	97	dominated	
HIVE – Extended	2.0	1.5	3.3	69.097	28.558	96	cost-saving	
ALL – 1 dose	1.8	1.5	3.2	69.119	28.567	109	dominated	
ALL – 1 dose plus HIVE - Extended	1.8	1.1	2.8	69.171	28.584	105	dominated	
ALL - 2 doses	1.8	1.0	2.7	69.200	28.593	110	dominated	
ALL - Extended	1.8	0.8	2.5	69.231	28.603	111	322* <sup>,</sup> †	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	0% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
bNAb effect duration: 1 month	• • //	,	• • •					
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference	
HR-HIVE – 1 dose	3.7	5.5	8.8	68·356	28.046	72	dominated	
HR-HIVE $-2$ doses	3.7	5.4	8.7	68.361	28.048	72	dominated	
HIVE – 1 dose	3.7	5.5	8.7	68.361	28.048	69	cost-saving	
ALL – 1 dose	3.4	5.4	8.4	68·370	28.051	82	dominated	
HIVE – 2 doses	3.7	5.3	8.6	68.370	28.051	70	dominated	
HR-HIVE – Extended	3.7	4.9	8.2	68.388	28.057	73	dominated	
ALL - 2 doses	3.4	5.1	8.2	68.392	28.058	99	dominated	
HIVE – Extended	3.7	3.6	6.9	68.457	28.080	76	223*.†	
ALL – 1 dose plus HIVE - Extended	3.4	3.6	6.7	68.466	28.083	89	4366	
ALL - Extended	3.4	2.6	5.7	68.511	28.101	294	11 905	
bNAb effect duration: 6 months								
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference	
HR-HIVE – 1 dose	3.7	5.2	8.5	68.373	28.052	70	dominated	
HR-HIVE $-2$ doses	3.7	5.0	8.3	68.382	28.055	69	dominated	
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	68	dominated	
HIVE – 1 dose	3.7	4.8	8.0	68.401	28.062	64	dominated	
ALL - 1 dose	3.4	4.4	7.4	68.430	28.002	76	dominated	
HIVE – 2 doses	3.7	4.1	7.4	68.436	28.072	60	dominated	
HIVE – Extended	3.7	3.6	6.9	68.459	28.081	58	cost-saving*.	
ALL - 2 doses	3.4	3.3	6.4	68.487	28.090	83	dominated	
ALL = 2 doses ALL = 1 dose plus HIVE - Extended	3.4	3.2	6.3	68.488	28.090	69	1108	
ALL - Extended	3.4	2.5	5.6	68.520	28.102	94	2223	

#### Supplementary Table 11. One-way sensitivity analysis: bNAb effect duration (base case: 3 months) (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	5 (20% GDP per capita	), ICER $\leq$ \$1163/YLS (50	% GDP per capita)]					
56% uptake at all time points								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference	
HR-HIVE – 1 dose	3.4	4.9	8.0	60.132	26.374	15	dominated	
HR-HIVE – 2 doses	3.4	4.8	7.9	60.133	26.375	15	dominated	
HIVE – 1 dose	3.3	4.8	7.9	60.133	26.375	14	dominated	
HR-HIVE – Extended	3.4	4.5	7.7	60.135	26.375	15	dominated	
HIVE – 2 doses	3.3	4.5	7.6	60.136	26.376	14	dominated	
ALL – 1 dose	3.1	4.7	7.7	60.138	26.376	25	dominated	
ALL - 2 doses	3.1	4.4	7.3	60.142	26.378	35	dominated	
HIVE – Extended	3.3	3.6	6.7	60.142	26.378	13	cost-saving*'	
ALL – 1 dose plus HIVE - Extended	3.1	3.5	6.5	60.146	26.380	24	6745	
ALL - Extended	3.1	3.2	6.2	60.153	26.381	75	38 825	
83% uptake at all time points								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference	
HR-HIVE – 1 dose	3.3	$4 \cdot 8$	7.9	60.134	26.375	15	dominated	
HR-HIVE – 2 doses	3.3	4.7	7.7	60.135	26.375	15	dominated	
HIVE – 1 dose	3.2	4.7	7.7	60.136	26.376	14	dominated	
HR-HIVE – Extended	3.3	4.2	7.3	60.137	26.376	14	dominated	
HIVE – 2 doses	3.2	4.3	7.3	60.139	26.377	14	dominated	
ALL – 1 dose	2.9	4.6	7.3	60.141	26.378	30	dominated	
ALL - 2  doses	2.9	4.1	6.8	60.143	26.379	45	dominated	
HIVE – Extended	3.2	2.9	5.9	60.148	26.380	12	cost-saving*,†	
ALL – 1 dose plus HIVE - Extended	2.9	2.8	5.6	60.154	26.383	28	6494	
ALL - Extended	2.9	2.3	5.1	60.158	26.384	103	65 508	
outh Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	), ICER < \$2828/YLS (50	)% GDP per capita)]					
85% uptake at all time points	~ (	.,, (	,,, ,,, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.1	68.973	28.516	116	dominated	
HR-HIVE – 2 doses	2.1	2.1	4.0	68.980	28.518	115	dominated	
HR-HIVE – Extended	2.1	2.0	4.0	68.987	28.521	115	dominated	
HIVE – 1 dose	2.0	2.0	3.9	69.002	28.526	106	dominated	
HIVE - 2  doses	2.0 2.0	1.8	3.7	69·032	28.537	105	dominated	
ALL – 1 dose	1.9	1.8	3.6	69·050	28.543	115	dominated	
HIVE – Extended	2.0	1.5	3.4	69.078	28.552	102	cost-saving	
ALL - 2  doses	1.9	1.5	3.3	69.098	28.560	102	dominated	
ALL – 2 doses ALL – 1 dose plus HIVE - Extended	1.9	1.4	3.1	69.126	28.568	111	589	
ALL - Extended	1.9	0.9	2.7	69.201	28.592	134	930* <sup>,</sup> †	

### Supplementary Table 12. One-way sensitivity analysis: bNAb uptake

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER $\leq$ \$2828/YLS (50	)% GDP per capita)]					
96% uptake at all time points								
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.0	68.979	28.518	115	dominated	
HR-HIVE - 2 doses	2.1	2.1	4.0	68.986	28.521	115	dominated	
HR-HIVE – Extended	2.1	$2 \cdot 0$	3.9	68.996	28.524	114	dominated	
HIVE – 1 dose	2.0	2.0	3.8	69.011	28.529	105	dominated	
HIVE - 2 doses	2.0	1.8	3.6	69.045	28.541	104	dominated	
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	116	dominated	
HIVE – Extended	$2 \cdot 0$	1.5	3.3	69.098	28.558	100	cost-saving	
ALL – 2 doses	1.8	1.4	3.1	69.122	28.568	122	dominated	
ALL - 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.150	28.576	111	606	
ALL - Extended	1.8	0.8	2.5	69.235	28.604	136	891* <sup>,</sup> †	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
71% uptake at all time points	•••	,						
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference	
HR-HIVE – 1 dose	3.8	5.4	8.8	68.358	28.047	71	dominated	
HR-HIVE - 2 doses	3.8	5.3	8.7	68.363	28.049	71	dominated	
HIVE – 1 dose	3.8	5.2	8.6	68.370	28.051	68	dominated	
HR-HIVE – Extended	3.8	$5 \cdot 0$	8.4	68.375	28.053	70	dominated	
ALL - 1 dose	3.6	$5 \cdot 0$	8.2	68.381	28.056	78	dominated	
HIVE – 2 doses	3.8	4.9	8.3	68.387	28.057	67	dominated	
ALL – 2 doses	3.6	4.6	7.8	68.419	28.067	89	dominated	
HIVE – Extended	3.8	$4 \cdot 0$	7.3	68.433	28.072	63	cost-saving*,†	
ALL – 1 dose plus HIVE - Extended	3.6	3.7	7.0	68.445	28.077	73	2444	
ALL - Extended	3.6	3.1	6.3	68.488	28.090	124	3706	
92% uptake at all time points								
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference	
HR-HIVE – 1 dose	3.7	5.3	8.6	68.369	28.051	70	dominated	
HR-HIVE – 2 doses	3.7	5.2	8.4	68.377	28.054	70	dominated	
HIVE – 1 dose	3.6	5.1	8.3	68.384	28.056	66	dominated	
HR-HIVE – Extended	3.7	4.8	8.1	68.392	28.059	68	dominated	
HIVE - 2 doses	3.6	4.7	7.9	68.406	28.064	65	dominated	
ALL – 1 dose	3.4	4.8	7.8	68.409	28.065	80	dominated	
ALL - 2 doses	3.4	4.3	7.3	68.441	28.076	93	dominated	
HIVE – Extended	3.6	3.4	6.7	68.469	28.084	60	cost-saving*"	
ALL – 1 dose plus HIVE - Extended	3.4	3.2	6.2	68.494	28.093	74	1545	
ALL - Extended	3.4	2.3	5.3	68·535	28.107	140	4822	

# Supplementary Table 12. One-way sensitivity analysis: bNAb uptake (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

The setting-specific base case uptake is specified in Supplementary Table 2. Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	<b>Discounted life</b>	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
Côte d'Ivoire [CET: ICER≤\$465/YLS		), ICER $\leq$ \$1163/YLS (50)	% GDP per capita)]					
Proportion of mothers on ART during	pregnancy: 70%							
Standard-of-care	7.3	5.4	12.2	60.081	26.353	42	Reference	
HR-HIVE – 1 dose	6.4	5.2	11.1	60.090	26.357	39	dominated	
HIVE – 1 dose	6.3	5.1	11.0	60.091	26.357	38	dominated	
HR-HIVE - 2 doses	6.4	4.9	10.8	60.092	26.357	39	dominated	
HIVE – 2 doses	6.3	4.6	10.5	60.094	26.359	37	dominated	
HR-HIVE – Extended	6.4	4.3	10.3	60.095	26.359	37	dominated	
ALL – 1 dose	6.1	5.0	10.6	60.096	26.359	52	dominated	
ALL - 2 doses	6.1	4.4	10.1	60.097	26.360	66	dominated	
HIVE – Extended	6.3	3.4	9.4	60.102	26.361	33	cost-saving*"	
ALL - 1 dose plus HIVE - Extended	6.1	3.3	9.1	60.107	26.363	47	6244	
ALL - Extended	6.1	2.9	8.6	60.113	26.365	112	57 665	
Proportion of mothers on ART during	pregnancy: 100%							
Standard-of-care	3.0	4.9	7.7	60.138	26.377	14	Reference	
HR-HIVE – 1 dose	2.8	4.8	7.4	60.141	26.378	14	dominated	
HR-HIVE $-2$ doses	2.8	4.7	7.3	60.142	26.378	14	dominated	
HIVE – 1 dose	2.7	4.7	7.2	60.143	26.379	13	dominated	
HR-HIVE – Extended	2.8	4.3	$7 \cdot 0$	60.144	26.379	14	dominated	
HIVE – 2 doses	2.7	4.3	6.8	60.146	26.380	13	dominated	
ALL – 1 dose	2.5	4.6	6.9	60.148	26.381	27	dominated	
ALL - 2 doses	2.5	4.1	6.5	60.148	26.381	42	dominated	
HIVE – Extended	2.7	3.1	5.7	60.154	26.383	12	cost-saving*.	
ALL – 1 dose plus HIVE - Extended	2.5	3.1	5.4	60.159	26.385	25	6242	
ALL - Extended	2.5	2.6	5.0	60.164	26.386	90	57 888	
South Africa [CET: ICER≤\$1131/YLS								
Proportion of mothers on ART during		,,, 10211 <u> </u>	/o obi per euprus)					
Standard-of-care	8.1	2.6	10.1	67.590	28.013	232	Reference	
HR-HIVE – 1 dose	6.4	2.3	8.3	67.824	28.091	209	dominated	
HIVE - 1 dose	6.3	2.3	8.1	67.844	28.098	199	dominated	
HR-HIVE $-2$ doses	6.4	2.2	8.1	67.848	28.099	207	dominated	
HR-HIVE – Extended	6.4	2.0	8.0	67.869	28.106	206	dominated	
HIVE – 2 doses	6.3	2.0	7.9	67.884	28.100	196	dominated	
ALL - 1 dose	6.2	2.0	7.8	67.895	28.112	209	dominated	
HIVE – Extended	6.3	1.7	7.6	67.931	28.110	193	cost-saving	
ALL - 2 doses	6.2	1.6	7.4	67.961	28.139	214	dominated	
ALL = 2 doses ALL = 1 dose plus HIVE - Extended	6.2	1.5	7.2	67.982	28.139	204	575	
ALL - Extended	6.2	0.9	6.7	68.066	28.143	204	850* <sup>,</sup> †	

# Supplementary Table 13. One-way sensitivity analysis: proportion of mothers on antiretroviral therapy during pregnancy

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	<b>Discounted life</b>	<b>Discounted costs</b>		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER≤\$1131/YL		a), ICER $\leq$ \$2828/YLS (50)	)% GDP per capita)]					
Proportion of mothers on ART during								
Standard-of-care	2.0	2.2	4.0	69.018	28.534	104	Reference	
HR-HIVE – 1 dose	1.8	2.1	3.7	69.061	28.548	109	dominated	
HR-HIVE - 2 doses	1.8	2.0	3.7	69.067	28.550	108	dominated	
HR-HIVE – Extended	1.8	2.0	3.7	69.075	28.553	108	dominated	
HIVE –1 dose	1.7	2.0	3.5	69.094	28.560	99	dominated	
HIVE – 2 doses	1.7	1.8	3.3	69.127	28.571	98	dominated	
ALL – 1 dose	1.5	1.8	3.2	69.145	28.578	110	dominated	
HIVE - Extended	1.7	1.5	3.0	69.177	28.588	94	cost-saving	
ALL - 2 doses	1.5	1.4	2.9	69.204	28.598	116	dominated	
ALL – 1 dose plus HIVE - Extended	1.5	1.3	2.7	69.229	28.606	105	606	
ALL - Extended	1.5	0.8	2.2	69.310	28.632	129	884* <sup>,</sup> †	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
Proportion of mothers on ART during			• • •					
Standard-of-care	7.8	6.1	12.9	68.038	27.928	93	Reference	
HR-HIVE – 1 dose	6.5	5.6	11.3	68.119	27.957	88	dominated	
HIVE – 1 dose	6.4	5.5	11.1	68.130	27.960	84	dominated	
HR-HIVE $-2$ doses	6.5	5.3	11.0	68.133	27.961	87	dominated	
ALL-1 dose	6.2	5.2	10.6	68.150	27.967	97	dominated	
HR-HIVE – Extended	6.5	4.8	10.6	68.156	27.969	85	dominated	
HIVE – 2 doses	6.4	5.0	10.7	68.154	27.969	83	dominated	
ALL - 2 doses	6.2	4.6	10.0	68.191	27.980	110	dominated	
HIVE – Extended	6.4	3.9	9.6	68.208	27.986	78	cost-saving*,†	
ALL - 1 dose plus HIVE - Extended	6.2	3.6	9.1	68.228	27.993	91	1739	
ALL - Extended	6.2	2.7	8.3	68.267	28.007	151	4466	
Proportion of mothers on ART during								
Standard-of-care	2.7	5.4	7.8	68.461	28.087	61	Reference	
HR-HIVE – 1 dose	2.5	5.2	7.4	68.488	28.096	62	dominated	
HR-HIVE – 2 doses	2.5	5.1	7.3	68.492	28.098	62	dominated	
HR-HIVE – Extended	2.5	4.9	7.1	68.502	28.101	61	dominated	
HIVE – 1 dose	2.3	5.0	7.1	68.504	28.102	58	dominated	
HIVE - 2  dose	2.4	4.6	6.8	68.525	28.102	58	dominated	
ALL - 1 dose	2.2	4.7	6.7	68.524	28.109	71	dominated	
ALL - 2  dose	2.2	4.2	6.2	68.561	28.107	85	dominated	
HIVE – Extended	2.2	3.5	5.7	68.581	28.121	53	cost-saving*'	
ALL – 1 dose plus HIVE - Extended	2.4	3.3	5.2	68.602	28.135	66	1729	
ALL - Extended	2.2	2.5	4.5	68.640	28.148	126	4533	

#### Supplementary Table 13. One-way sensitivity analysis: proportion of mothers on antiretroviral therapy during pregnancy (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER ≤ \$465/YL\$	8 (20% GDP per capita	), ICER $\leq$ \$1163/YLS (50	% GDP per capita)]					
Mean breastfeeding duration: 8 month	is for all women							
Standard-of-care	3.6	2.7	6.2	60.155	26.381	10	Reference	
HR-HIVE – 1 dose	3.3	2.6	5.8	60.158	26.383	10	dominated	
HR-HIVE $-2$ doses	3.3	2.5	5.7	60.159	26.383	10	dominated	
HIVE – 1 dose	3.3	2.5	5.7	60.160	26.383	9	dominated	
HR-HIVE – Extended	3.3	2.3	5.5	60.160	26.384	10	dominated	
HIVE – 2 doses	3.3	2.2	5.4	60.162	26.384	9	dominated	
ALL – 1 dose	3.0	2.4	5.4	60.161	26.385	22	dominated	
HIVE – Extended	3.3	1.6	4.8	60.166	26.386	9	cost-saving*,†	
ALL - 2 doses	3.0	2.1	5.0	60.167	26.386	33	dominated	
ALL - 1 dose plus HIVE - Extended	3.0	1.5	4.5	60.168	26.387	21	10 463	
ALL - Extended	3.0	1.3	4.3	60.168	26.388	52	51 570	
Mean breastfeeding duration: 24 mont	ths for all women							
Standard-of-care	3.6	7.9	11.2	60.121	26.369	20	Reference	
ALL – 1 dose	3.0	7.6	10.3	60.120	26.370	34	dominated	
HR-HIVE – 1 dose	3.3	7.8	10.8	60.125	26.371	20	dominated	
HR-HIVE - 2 doses	3.3	7.7	10.7	60.126	26.371	20	dominated	
HIVE – 1 dose	3.3	7.7	10.6	60.127	26.372	19	dominated	
ALL - 2 doses	3.0	7.1	9.8	60.127	26.372	49	dominated	
HR-HIVE – Extended	3.3	7.1	10.1	60.130	26.373	20	dominated	
HIVE – 2 doses	3.3	7.2	10.2	60.130	26.373	19	dominated	
ALL - 1 dose plus HIVE - Extended	3.0	5.3	8.1	60.136	26.376	31	dominated	
HIVE - Extended	3.3	5.4	8.4	60.142	26.378	17	cost-saving*,†	
ALL - Extended	3.0	$4 \cdot 8$	7.6	60.146	26.380	103	40 559	
outh Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]					
Mean breastfeeding duration: 2 month	is for all women							
Standard-of-care	2.3	0.9	3.2	69.125	28.566	84	Reference	
HR-HIVE – 1 dose	2.1	0.9	2.9	69.178	28.583	87	dominated	
HR-HIVE - 2 doses	2.1	0.8	2.9	69.181	28.585	87	dominated	
HR-HIVE – Extended	2.1	0.8	2.8	69.185	28.586	87	dominated	
HIVE – 1 dose	2.0	0.8	2.7	69.205	28.593	77	dominated	
HIVE – 2 doses	2.0	0.7	2.6	69.225	28.600	76	dominated	
HIVE – Extended	2.0	0.6	2.5	69.244	28.606	75	cost-saving	
ALL – 1 dose	1.8	0.7	2.4	69.252	28.610	83	dominated	
ALL - 2 doses	1.8	0.5	2.3	69.280	28.619	85	dominated	
ALL - 1 dose plus HIVE - Extended	1.8	0.4	2.2	69.291	28.622	81	364*	
ALL - Extended	1.8	0.3	2.1	69.306	28.628	87	1145†	

#### Supplementary Table 14. One-way sensitivity analysis: breastfeeding duration

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
South Africa [CET: ICER ≤ \$1131/YL	· • •	a), ICER $\leq$ \$2828/YLS (50)	<b>)% GDP per capita)]</b>					
Mean breastfeeding duration: 18 month	hs for all women							
Standard-of-care	2.3	4.9	6.9	68.494	28.361	175	Reference	
HR-HIVE – 1 dose	2.1	4.7	6.6	68.553	28.381	178	dominated	
HR-HIVE - 2 doses	2.1	4.7	6.5	68.563	28.385	178	dominated	
HIVE – 1 dose	2.0	4.6	6.3	68.591	28.394	168	dominated	
HR-HIVE – Extended	2.1	4.4	6.3	68.602	28.397	174	dominated	
HIVE – 2 doses	2.0	4.3	6.0	68.645	28.413	166	dominated	
ALL – 1 dose	1.8	4.4	6.0	68.645	28.413	180	dominated	
ALL - 2 doses	1.8	3.9	5.6	68.717	28.439	186	dominated	
HIVE – Extended	2.0	2.9	4.7	68.860	28.482	148	cost-saving	
ALL - 1 dose plus HIVE - Extended	1.8	2.7	4.4	68.914	28.501	159	607	
ALL - Extended	1.8	2.0	3.7	69.031	28.539	192	847* <sup>,</sup> †	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
Mean breastfeeding duration: 8 month	s for women with HIV a	and 15 months for women	without HIV					
Standard-of-care	4.3	4.1	8.0	68.397	28.058	59	Reference	
HR-HIVE – 1 dose	3.7	3.8	7.2	68.440	28.074	58	dominated	
HR-HIVE – 2 doses	3.7	3.7	7.1	68.446	28.076	57	dominated	
HIVE – 1 dose	3.7	3.7	7.0	68.453	28.078	54	dominated	
HR-HIVE – Extended	3.7	3.5	7.0	68.454	28.078	57	dominated	
HIVE – 2 doses	3.7	3.3	6.7	68.470	28.084	53	dominated	
ALL – 1 dose	3.4	3.4	6.5	68.480	28.087	67	dominated	
HIVE – Extended	3.7	2.7	6.1	68.500	28.094	51	cost-saving*,†	
ALL - 2 doses	3.4	2.9	6.1	68.502	28.096	80	dominated	
ALL – 1 dose plus HIVE - Extended	3.4	2.5	5.6	68.527	28.103	64	1348	
ALL - Extended	3.4	1.8	5.0	68.554	28.113	116	5362	
Mean breastfeeding duration: 20 month	hs for all women							
Standard-of-care	4.3	7.6	11.3	68.226	28.004	87	Reference	
HR-HIVE – 1 dose	3.7	7.3	10.5	68.271	28.020	86	dominated	
HR-HIVE – 2 doses	3.7	7.1	10.4	68.279	28.023	86	dominated	
HIVE – 1 dose	3.7	7.1	10.3	68.285	28.025	82	dominated	
HR-HIVE – Extended	3.7	6.7	9.9	68.301	28.030	84	dominated	
ALL – 1 dose	3.4	6.8	9.8	68.298	28.031	95	dominated	
HIVE – 2 doses	3.7	6.7	9.8	68.311	28.034	81	dominated	
ALL - 2 doses	3.4	6.3	9.2	68.340	28.044	109	dominated	
HIVE – Extended	3.7	4.9	8.1	68·398	28.062	74	cost-saving*'†	
ALL – 1 dose plus HIVE - Extended	3.4	4.6	7.7	68.411	28.068	86	2140	
ALL - Extended	3.4	3.8	6.8	68.467	28.086	151	3624	

### Supplementary Table 14. One-way sensitivity analysis: breastfeeding duration (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER≤\$465/YLS	(20% GDP per capita)	, ICER $\leq$ \$1163/YLS (50)	% GDP per capita)]					
Postpartum incidence: 0.5x base case								
Standard-of-care	3.6	4.9	8.3	60.130	26.374	14	Reference	
HR-HIVE – 1 dose	3.3	4.7	7.9	60.134	26.375	14	dominated	
HR-HIVE – 2 doses	3.3	4.6	7.7	60.135	26.375	14	dominated	
HIVE - 1 dose	3.3	4.6	7.7	60.135	26.376	13	dominated	
HR-HIVE – Extended	3.3	4.2	7.4	60.137	26.376	13	dominated	
HIVE – 2 doses	3.3	4.2	7.3	60.138	26.377	13	dominated	
ALL – 1 dose	3.0	4.5	7.4	60.141	26.378	27	dominated	
ALL – 2 doses	3.0	$4 \cdot 0$	6.9	60.141	26.378	43	dominated	
HIVE – Extended	3.3	3.0	6.2	60.146	26.380	12	cost-saving*,†	
ALL - 1 dose plus HIVE - Extended	3.0	3.0	5.9	60.152	26.382	26	6337	
ALL - Extended	3.0	2.6	5.5	60.156	26.383	91	75 319	
Postpartum incidence: 2.0x base case								
Standard-of-care	3.6	5.2	8.5	60.126	26.372	15	Reference	
HR-HIVE – 1 dose	3.3	5.1	8.1	60.130	26.374	15	dominated	
HR-HIVE $-2$ doses	3.3	5.0	8.0	60.131	26.374	15	dominated	
HIVE – 1 dose	3.3	5.0	8.0	60.131	26.374	14	dominated	
HR-HIVE - Extended	3.3	4.6	7.7	60.133	26.375	14	dominated	
HIVE – 2 doses	3.3	4.6	7.6	60.135	26.376	14	dominated	
ALL – 1 dose	3.0	4.9	7.6	60.137	26.377	28	dominated	
ALL - 2 doses	3.0	4.4	7.2	60.138	26.377	44	dominated	
HIVE – Extended	3.3	3.4	6.5	60.143	26.378	13	cost-saving*,*	
ALL – 1 dose plus HIVE - Extended	3.0	3.3	6.2	60.149	26.381	27	5993	
ALL - Extended	3.0	2.8	5.6	60.154	26.382	91	58 257	
South Africa [CET: ICER ≤ \$1131/YLS		), ICER < \$2828/YLS (50	% GDP per capita)]					
Postpartum incidence: 0.5x base case	· ( pp	,,, <u>-</u> (	, hh)!					
Standard-of-care	2.3	1.9	4.1	68.984	28.519	104	Reference	
HR-HIVE – 1 dose	2.1	1.8	3.7	69.039	28.538	108	dominated	
HR-HIVE – 2 doses	2.1	1.7	3.7	69.046	28.541	107	dominated	
HR-HIVE – Extended	2.1	1.7	3.6	69.055	28.543	107	dominated	
HIVE – 1 dose	2.0	1.7	3.5	69.071	28.549	98	dominated	
HIVE - 2 doses	2.0	1.5	3.3	69.105	28.561	96	dominated	
ALL - 1 dose	1.8	1.5	3.2	69.116	28.565	109	dominated	
HIVE – Extended	2.0	1.1	3.0	69.155	28.577	93	cost-saving	
ALL - 2  doses	1.8	1.2	2.9	69.169	28.583	116	dominated	
ALL – 1 dose plus HIVE - Extended	1.8	1.0	2.7	69.200	28.593	104	700*	
ALL - Extended	1.8	0.7	2.4	69.251	28.609	131	1,675†	

# Supplementary Table 15. One-way sensitivity analysis: maternal postpartum HIV incidence

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER≤\$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	0% GDP per capita)]					
Postpartum incidence: 2.0x base case								
Standard-of-care	2.3	2.8	4.8	68.813	28.462	127	Reference	
HR-HIVE – 1 dose	2.1	2.7	4.5	68.868	28.481	130	dominated	
HR-HIVE - 2 doses	2.1	2.6	4.5	68.875	28.483	130	dominated	
HR-HIVE – Extended	2.1	2.6	4.4	68.884	28.486	129	dominated	
HIVE – 1 dose	2.0	2.6	4.3	68.900	28.492	121	dominated	
HIVE – 2 doses	2.0	2.4	4.1	68.934	28.504	119	dominated	
ALL – 1 dose	1.8	2.3	3.9	68.960	28.513	130	dominated	
HIVE – Extended	2.0	2.1	3.8	68.984	28.520	116	cost-saving	
ALL - 2 doses	1.8	1.9	3.5	69.034	28.540	135	dominated	
ALL - 1 dose plus HIVE - Extended	1.8	1.8	3.5	69.043	28.541	125	dominated	
ALL - Extended	1.8	1.0	2.6	69.183	28.588	140	359* <sup>,</sup> †	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
Postpartum incidence: 0.5x base case	• • //	,	• • •					
Standard-of-care	4.3	5.2	9.2	68.351	28.044	66	Reference	
HR-HIVE – 1 dose	3.7	4.9	8.3	68.396	28.060	65	dominated	
HR-HIVE - 2 doses	3.7	4.7	8.2	68.403	28.062	65	dominated	
HIVE – 1 dose	3.7	4.7	8.1	68.410	28.065	61	dominated	
HR-HIVE – Extended	3.7	4.4	7.9	68.417	28.067	64	dominated	
ALL – 1 dose	3.4	4.4	7.6	68.430	28.072	75	dominated	
HIVE – 2 doses	3.7	4.3	7.7	68.432	28.073	61	dominated	
ALL - 2 doses	3.4	3.9	7.1	68.466	28.083	89	dominated	
HIVE – Extended	3.7	3.1	6.6	68.488	28.090	56	cost-saving*.*	
ALL – 1 dose plus HIVE - Extended	3.4	2.9	6.1	68.508	28.097	70	1976	
ALL - Extended	3.4	2.3	5.6	68.534	28.107	131	6572	
Postpartum incidence: 2.0x base case								
Standard-of-care	4.3	6.4	10.0	68.258	28.014	68	Reference	
HR-HIVE – 1 dose	3.7	6.1	9.2	68.303	28.030	68	dominated	
HR-HIVE - 2 doses	3.7	6.0	9.1	68.310	28.032	68	dominated	
HIVE – 1 dose	3.7	6.0	9.0	68.317	28.035	68	dominated	
HR-HIVE – Extended	3.7	5.7	8.8	68.325	28.037	68	dominated	
HIVE – 2 doses	3.7	5.6	8.6	68.339	28.042	68	dominated	
ALL – 1 dose	3.4	5.7	8.5	68.342	28.043	68	dominated	
ALL - 2 doses	3.4	5.0	7.9	68.387	28.058	68	dominated	
HIVE – Extended	3.7	4.5	7.6	68.395	28.060	68	cost-saving*"	
ALL - 1 dose plus HIVE - Extended	3.4	4.2	7.1	68.420	28.069	68	1503	
ALL - Extended	3.4	3.0	5.9	68.486	28.092	68	2414	

## Supplementary Table 15. One-way sensitivity analysis: maternal postpartum HIV incidence (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	IU/IP cumulative	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	6 (20% GDP per capita	), ICER ≤ \$1163/YLS (50	% GDP per capita)]					
ART treatment cost: 0.5x base case								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	12	Reference	
HR-HIVE - 1 dose	3.3	4.8	8.0	60.133	26.375	12	dominated	
HR-HIVE – 2 doses	3.3	4.7	7.8	60.134	26.375	12	dominated	
HIVE – 1 dose	3.3	4.7	7.8	60.134	26.375	11	dominated	
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	12	dominated	
HIVE – 2 doses	3.3	4.3	7.4	60.138	26.377	11	dominated	
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	26	dominated	
ALL - 2 doses	3.0	4.2	7.0	60.140	26.378	41	dominated	
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	10	cost-saving*"	
ALL - 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.150	26.382	25	6722	
ALL - Extended	3.0	2.7	5.5	60.156	26.383	89	57 928	
ART treatment cost: 2.0x base case								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	18	Reference	
HR-HIVE – 1 dose	3.3	$4 \cdot 8$	8.0	60.133	26.375	19	dominated	
HR-HIVE – 2 doses	3.3	4.7	7.8	60.134	26.375	18	dominated	
HIVE – 1 dose	3.3	4.7	7.8	60.134	26.375	18	dominated	
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	18	dominated	
HIVE – 2 doses	3.3	4.3	7.4	60.138	26.377	17	dominated	
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	31	dominated	
ALL - 2 doses	3.0	4.2	7.0	60.140	26.378	47	dominated	
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	15	cost-saving*,*	
ALL – 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.150	26.382	29	6197	
ALL - Extended	3.0	2.7	5.5	60.156	26.383	93	57 720	
South Africa [CET: ICER ≤ \$1131/YLS								
ART treatment cost: 0.5x base case	• (-• <i>,</i> • • p•- ••p••	,,, <u>-</u> + (+ -	/· · · · · · · · · · · · · · · /					
Standard-of-care	2.3	2.2	4.4	68.924	28.499	103	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.0	68.979	28.518	108	dominated	
HR-HIVE $-2$ doses	2.1	2.1	4.0	68.986	28.521	107	dominated	
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	107	dominated	
HIVE – 1 dose	2.0	2.0	3.8	69.011	28.529	98	dominated	
HIVE - 2 doses	2.0	1.8	3.6	69.045	28.541	97	dominated	
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	109	dominated	
HIVE – Extended	2.0	1.5	3.3	69.095	28.557	94	cost-saving	
ALL - 2 doses	1.8	1.5	3.2	69.122	28.568	116	dominated	
ALL = 2 doses ALL = 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	105	596	
ALL - Fusice prus III v L - Extended ALL - Extended	1.8	0.8	2.5	69.228	28.602	105	913* <sup>,</sup> †	

# Supplementary Table 16. One-way sensitivity analysis: antiretroviral therapy treatment cost

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER $\leq$ \$2828/YLS (50	0% GDP per capita)]					
ART treatment cost: 2.0x base case								
Standard-of-care	2.3	2.2	4.4	68.924	28.499	130	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.0	68.979	28.518	131	dominated	
HR-HIVE – 2 doses	2.1	2.1	$4 \cdot 0$	68.986	28.521	131	dominated	
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	130	dominated	
HIVE – 1 dose	2.0	$2 \cdot 0$	3.8	69.011	28.529	120	dominated	
HIVE – 2 doses	2.0	1.8	3.6	69.045	28.541	119	dominated	
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	130	dominated	
HIVE – Extended	$2 \cdot 0$	1.5	3.3	69.095	28.557	114	cost-saving	
ALL – 2 doses	1.8	1.5	3.2	69.122	28.568	135	dominated	
ALL - 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	124	518	
ALL - Extended	1.8	0.8	2.5	69.228	28.602	145	819* <sup>,</sup> †	
Cimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
ART treatment cost: 0.5x base case	•••	,	//					
Standard-of-care	4.3	5.6	9.5	68.321	28.034	62	Reference	
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	61	dominated	
HR-HIVE - 2  doses	3.7	5.2	8.5	68.373	28.053	61	dominated	
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	58	dominated	
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	60	dominated	
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	71	dominated	
HIVE – 2 doses	3.7	4.8	8.0	68.402	28.063	57	dominated	
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	85	dominated	
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	54	cost-saving*,	
ALL – 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	67	1777	
ALL - Extended	3.4	2.6	5.7	68.517	28.101	128	4601	
ART treatment cost: 2.0x base case								
Standard-of-care	4.3	5.6	9.5	68.321	28.034	91	Reference	
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	88	dominated	
HR-HIVE – 2 doses	3.7	5.2	8.5	68.373	28.053	87	dominated	
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	84	dominated	
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	86	dominated	
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	95	dominated	
HIVE – 2 doses	3.7	4.8	8.0	68.402	28.063	82	dominated	
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	108	dominated	
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	75	cost-saving*.	
ALL – 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	86	1522	
ALL - Extended	3.4	2.6	5.7	68.517	28.101	145	4411	

## Supplementary Table 16. One-way sensitivity analysis: antiretroviral therapy treatment cost (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	IU/IP cumulative	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER≤\$465/YLS	6 (20% GDP per capita	), ICER $\leq$ \$1163/YLS (50)	% GDP per capita)]					
Postpartum vertical transmission risk:	0·5x base case							
Standard-of-care	3.6	2.5	6.0	60.147	26.380	10	Reference	
HR-HIVE - 1 dose	3.3	2.5	5.7	60.150	26.381	10	dominated	
HR-HIVE – 2 doses	3.3	2.4	5.6	60.150	26.381	10	dominated	
HIVE – 1 dose	3.3	2.4	5.5	60.151	26.382	9	dominated	
HR-HIVE – Extended	3.3	2.2	5.4	60.152	26.382	10	dominated	
HIVE – 2 doses	3.3	$2 \cdot 2$	5.3	60.153	26.382	9	dominated	
ALL - 2 doses	3.0	2.1	5.0	60.155	26.383	39	dominated	
ALL – 1 dose	3.0	2.4	5.3	60.156	26.384	24	dominated	
HIVE – Extended	3.3	1.6	4.8	60.157	26.384	9	cost-saving*"	
ALL – 1 dose plus HIVE - Extended	3.0	1.6	4.5	60.161	26.386	24	7038	
ALL - Extended	3.0	1.3	4.3	60.166	26.386	89	112 676	
Postpartum vertical transmission risk:	2·0x base case							
Standard-of-care	3.6	9.6	12.8	60.096	26.361	22	Reference	
HR-HIVE – 1 dose	3.3	9.3	12.3	60.101	26.362	22	dominated	
HR-HIVE $-2$ doses	3.3	9.1	12.0	60.103	26.363	22	dominated	
HIVE – 1 dose	3.3	9.1	12.0	60.103	26.364	21	dominated	
HR-HIVE – Extended	3.3	8.4	11.3	60.107	26.365	21	dominated	
ALL – 1 dose	3.0	8.9	11.6	60.109	26.366	35	dominated	
HIVE – 2 doses	3.3	8.3	11.2	60.110	26.366	20	dominated	
ALL - 2 doses	3.0	8.0	10.7	60.113	26.368	50	dominated	
HIVE – Extended	3.3	6.1	9.1	60.125	26.372	17	cost-saving*,†	
ALL – 1 dose plus HIVE - Extended	3.0	5.9	8.7	60.130	26.374	31	6027	
ALL - Extended	3.0	5.2	8.0	60.138	26.376	95	32 149	
South Africa [CET: ICER ≤ \$1131/YL		), ICER < \$2828/YLS (50	)% GDP per capita)]					
Postpartum vertical transmission risk:		.,, (						
Standard-of-care	2.3	1.1	3.3	69·097	28.558	90	Reference	
HR-HIVE – 1 dose	2.1	1.1	3.0	69.146	28.574	94	dominated	
HR-HIVE – 2 doses	2.1	1.1	3.0	69.149	28.576	94	dominated	
HR-HIVE – Extended	2.1	1.0	3.0	69.154	28.577	94	dominated	
HIVE – 1 dose	2.0	1.0	2.9	69.169	28.582	85	cost-saving	
HIVE – 2 doses	2.0	0.9	2.8	69.187	28.589	85	103	
ALL - 1 dose	1.8	0.9	2.6	69.205	28.595	97	dominated	
HIVE – Extended	2.0	0.8	2.6	69·212	28.595	85	dominated	
ALL - 2 doses	1.8	0.7	2.5	69.237	28.606	107	dominated	
ALL – 1 dose plus HIVE - Extended	1.8	0.7	2.4	69.248	28.609	98	590*	
ALL - Extended	1.8	0.4	2.4	69.291	28.623	126	2023†	

# Supplementary Table 17. One-way sensitivity analysis: postpartum vertical transmission risk

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	IU/IP cumulative	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER≤\$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]					
Postpartum vertical transmission risk:	2·0x base case							
Standard-of-care	2.3	4.2	6.3	68.599	28.390	154	Reference	
HR-HIVE – 1 dose	2.1	$4 \cdot 0$	5.9	68.668	28.413	156	dominated	
HR-HIVE – 2 doses	2.1	3.9	5.8	68.681	28.418	155	dominated	
HR-HIVE – Extended	2.1	3.8	5.7	68.698	28.423	153	dominated	
HIVE – 1 dose	2.0	3.8	5.6	68.719	28.431	143	dominated	
HIVE – 2 doses	2.0	3.4	5.2	68.784	28.453	139	dominated	
ALL – 1 dose	1.8	3.4	5.1	68.797	28.459	151	dominated	
HIVE – Extended	2.0	2.8	4.6	68.880	28.484	129	cost-saving	
ALL - 2 doses	1.8	2.8	4.5	68.904	28.496	151	dominated	
ALL – 1 dose plus HIVE - Extended	1.8	2.4	4.1	68·958	28.512	136	260	
ALL - Extended	1.8	1.6	3.3	69.103	28.560	151	315*.†	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita). I	CER < \$607/YLS (50% C	DP per capita)					
Postpartum vertical transmission risk:								
Standard-of-care	4.3	2.9	6.8	68.461	28.081	52	Reference	
HR-HIVE – 1 dose	3.7	2.7	6.1	68.499	28.094	52	dominated	
HR-HIVE – 2 doses	3.7	2.7	6.1	68.502	28.095	52	dominated	
HIVE – 1 dose	3.7	2.6	6.0	68.508	28.097	48	cost-saving	
HR-HIVE – Extended	3.7	2.5	5.9	68.510	28.098	52	dominated	
HIVE – 2 doses	3.7	2.4	5.8	68.519	28.101	49	dominated	
ALL – 1 dose	3.4	2.5	5.6	68.522	28.102	61	dominated	
ALL - 2 doses	3.4	2.2	5.3	68.546	28.109	77	dominated	
HIVE – Extended	3.7	1.9	5.2	68.548	28.110	49	18*.†	
ALL – 1 dose plus HIVE - Extended	3.4	1.7	4.9	68.562	28.115	62	2656	
ALL - Extended	3.4	1.3	4.5	68.582	28.123	124	8712	
Postpartum vertical transmission risk:	2.0x base case							
Standard-of-care	4.3	10.7	14.3	68·060	27.946	107	Reference	
HR-HIVE – 1 dose	3.7	10.1	13.2	68.118	27.967	105	dominated	
HR-HIVE – 2 doses	3.7	9.9	13.0	68.132	27.972	104	dominated	
HIVE – 1 dose	3.7	9.8	12.9	68.141	27.976	100	dominated	
HR-HIVE – Extended	3.7	9.3	12.5	68.159	27.981	100	dominated	
ALL - 1 dose	3.4	9.3	12.2	68.173	27.987	112	dominated	
HIVE – 2 doses	3.7	9.0	12.2	68.185	27.991	97	dominated	
ALL - 2 doses	3.4	8.3	11.2	68.239	28.009	122	dominated	
HIVE – Extended	3.7	6.8	10.0	68·292	28.009	84	cost-saving*'	
ALL – 1 dose plus HIVE - Extended	3.4	6.4	9.4	68.323	28.036	96	1061	
ALL - Extended	3.4	5.0	8.0	68.393	28.060	152	2370	

## Supplementary Table 17. One-way sensitivity analysis: postpartum vertical transmission risk (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER ≤ \$465/YLS								
Low infant oral prophylaxis efficacy (in	ntrapartum efficacy: 40	%; postpartum efficacy: 58	3%)					
Standard-of-care	3.7	5.1	8.5	60.128	26.373	15	Reference	
HR-HIVE – 1 dose	3.4	4.9	8.1	60.132	26.374	15	dominated	
HR-HIVE – 2 doses	3.4	4.8	7.9	60.133	26.375	15	dominated	
HIVE – 1 dose	3.3	4.8	7.9	60.134	26.375	14	dominated	
HR-HIVE – Extended	3.4	4.4	7.6	60.135	26.376	15	dominated	
HIVE – 2 doses	3.3	4.4	7.5	60.137	26.376	14	dominated	
ALL – 1 dose	3.1	4.7	7.6	60.139	26.377	28	dominated	
ALL - 2 doses	3.1	4.2	$7 \cdot 1$	60.139	26.378	43	dominated	
HIVE – Extended	3.3	3.2	6.4	60.145	26.379	13	cost-saving*"	
ALL - 1 dose plus HIVE - Extended	3.1	3.1	6.1	60.150	26.381	26	6240	
ALL - Extended	3.1	2.7	5.6	60.155	26.382	91	57 858	
High infant oral prophylaxis efficacy (i	intrapartum efficacy: 90	%; postpartum efficacy: 8	0%)					
Standard-of-care	3.6	4.9	8.3	60.130	26.374	14	Reference	
HR-HIVE – 1 dose	3.3	4.8	7.9	60.133	26.375	15	dominated	
HR-HIVE – 2 doses	3.3	4.7	7.7	60.135	26.375	15	dominated	
HIVE – 1 dose	3.2	4.7	7.7	60.135	26.376	14	dominated	
HR-HIVE – Extended	3.3	4.3	7.4	60.137	26.376	14	dominated	
HIVE - 2 doses	3.2	4.3	7.3	60.138	26.377	14	dominated	
ALL – 1 dose	3.0	4.6	7.4	60.140	26.378	27	dominated	
ALL - 2 doses	3.0	4.1	6.9	60.141	26.378	43	dominated	
HIVE – Extended	3.2	3.1	6.2	60.146	26.380	13	cost-saving*,	
ALL – 1 dose plus HIVE - Extended	3.0	3.1	5.9	60.151	26.382	26	6246	
ALL - Extended	3.0	2.6	5.5	60.157	26.383	91	57 856	
South Africa [CET: ICER ≤ \$1131/YLS								
Low infant oral prophylaxis efficacy (in								
Standard-of-care	2.4	2.2	4.5	68·909	28.494	114	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.1	68.970	28.515	116	dominated	
HR-HIVE $-2$ doses	2.1	2.1	4.0	68.977	28.517	116	dominated	
HR-HIVE – Extended	2.1	2.0	4.0	68.985	28.520	115	dominated	
HIVE – 1 dose	2.0	2.0	3.9	69.003	28.526	106	dominated	
HIVE - 2  doses	2.0	1.8	3.7	69.037	28.538	105	dominated	
ALL - 1 dose	1.8	1.8	3.5	69.055	28.545	105	dominated	
HIVE – Extended	2.0	1.5	3.4	69.086	28.554	101	cost-saving	
ALL - 2 doses	1.8	1.5	3.2	69.114	28.565	123	dominated	
ALL = 2 doses ALL = 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.139	28.573	112	596	
ALL - Fusice plus III v E - Extended ALL - Extended	1.8	0.8	2.6	69.220	28.599	136	882*,†	

Supplementary Table 18. One-way sensitivity analysis: infant oral prophylaxis efficacy (base case: 69% intrapartum efficacy and 71% postpartum efficacy)

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
South Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]					
High infant oral prophylaxis efficacy (	intrapartum efficacy: 9	0%; postpartum efficacy: 8	30%)					
Standard-of-care	2.3	2.2	4.3	68.934	28.503	110	Reference	
HR-HIVE – 1 dose	2.0	2.1	4.0	68.986	28.521	114	dominated	
HR-HIVE – 2 doses	2.0	2.0	3.9	68.993	28.523	114	dominated	
HR-HIVE – Extended	2.0	2.0	3.9	69.002	28.526	113	dominated	
HIVE – 1 dose	1.9	2.0	3.8	69.017	28.531	104	dominated	
HIVE – 2 doses	1.9	1.8	3.6	69.051	28.543	103	dominated	
ALL – 1 dose	1.8	1.8	3.4	69.069	28.550	115	dominated	
HIVE – Extended	1.9	1.5	3.3	69.101	28.559	100	cost-saving	
ALL - 2 doses	1.8	1.4	3.1	69.127	28.570	122	dominated	
ALL - 1 dose plus HIVE - Extended	1.8	1.3	2.9	69.152	28.577	111	613	
ALL - Extended	1.8	0.8	2.5	69.233	28.604	134	882*.†	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
Low infant oral prophylaxis efficacy (i.								
Standard-of-care	4.5	5.8	9.8	68.303	28.027	74	Reference	
HR-HIVE – 1 dose	3.9	5.4	8.8	68.354	28.046	72	dominated	
HR-HIVE $-2$ doses	3.9	5.3	8.7	68.361	28.048	71	dominated	
HIVE – 1 dose	3.8	5.2	8.6	68.369	28.051	68	dominated	
HR-HIVE – Extended	3.9	5.0	8.4	68.375	28.053	70	dominated	
ALL – 1 dose	3.6	4.9	8.1	68.389	28.058	81	dominated	
HIVE – 2 doses	3.8	4.8	8.2	68.391	28.059	67	dominated	
ALL - 2 doses	3.6	4.4	7.6	68.427	28.070	94	dominated	
HIVE – Extended	3.8	3.7	7.1	68.446	28.076	63	cost-saving*.	
ALL – 1 dose plus HIVE - Extended	3.6	3.4	6.7	68.467	28.084	75	1715	
ALL - Extended	3.6	2.6	5.9	68.506	28.097	135	4520	
High infant oral prophylaxis efficacy (	intrapartum efficacy: 9	0%; postpartum efficacy: 8	30%)					
Standard-of-care	4.2	5.5	9.2	68.334	28.038	70	Reference	
HR-HIVE – 1 dose	3.6	5.3	8.5	68.374	28.053	70	dominated	
HR-HIVE – 2 doses	3.6	5.1	8.3	68.382	28.056	69	dominated	
HIVE – 1 dose	3.6	5.1	8.3	68.388	28.058	66	dominated	
HR-HIVE – Extended	3.6	4.8	8.1	68.396	28.060	68	dominated	
ALL - 1 dose	3.3	4.8	7.8	68.408	28.065	78	dominated	
HIVE – 2 doses	3.6	4.7	7.9	68.410	28.066	65	dominated	
ALL - 2 doses	3.3	4.3	7.3	68.446	28.000	92	dominated	
HIVE – Extended	3.6	3.6	6.8	68·466	28.083	60	cost-saving*"	
ALL – 1 dose plus HIVE - Extended	3.3	3.3	6.3	68.486	28.091	73	1738	
ALL - Extended	3.3	2.5	5.5	68.525	28.104	133	4516	

Supplementary Table 18. One-way sensitivity analysis: infant oral prophylaxis efficacy (base case: 69% intrapartum efficacy and 71% postpartum efficacy) (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest tent thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
Côte d'Ivoire [CET: ICER ≤ \$465/YLS	· · ·	), ICER ≤ \$1163/YLS (50	% GDP per capita)]					
Cost of identifying high-risk infants: \$0								
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference	
HR-HIVE – 1 dose	3.3	4.8	8.0	60.133	26.375	14	dominated	
HR-HIVE $-2$ doses	3.3	4.7	7.8	60.134	26.375	14	dominated	
HIVE – 1 dose	3.3	4.7	7.8	60.134	26.375	14	dominated	
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	14	dominated	
HIVE - 2 doses	3.3	4.3	7.4	60.138	26.377	14	dominated	
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	27	dominated	
ALL - 2 doses	3.0	4.2	7.0	60.140	26.378	43	dominated	
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	13	cost-saving*,†	
ALL - 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.150	26.382	26	6242	
ALL - Extended	3.0	2.7	5.5	60.156	26.383	91	57 860	
Cost of identifying high-risk infants: \$3	32							
Standard-of-care	3.6	5.0	8.4	60.129	26.373	15	Reference	
HR-HIVE – 1 dose	3.3	4.8	8.0	60.133	26.375	15	dominated	
HR-HIVE $-2$ doses	3.3	4.7	7.8	60.134	26.375	15	dominated	
HIVE – 1 dose	3.3	4.7	7.8	60.134	26.375	14	dominated	
HR-HIVE – Extended	3.3	4.3	7.5	60.136	26.376	14	dominated	
HIVE - 2 doses	3.3	4.3	7.4	60.138	26.377	14	dominated	
ALL – 1 dose	3.0	4.6	7.5	60.139	26.377	27	dominated	
ALL - 2 doses	3.0	4.2	7.0	60.140	26.378	43	dominated	
HIVE – Extended	3.3	3.2	6.3	60.146	26.379	13	cost-saving*,*	
ALL – 1 dose plus HIVE - Extended	3.0	3.1	6.0	60.150	26.382	26	6242	
ALL - Extended	3.0	2.7	5.5	60.156	26.383	91	57 860	
South Africa [CET: ICER ≤ \$1131/YLS							.,	
Cost of identifying high-risk infants: \$0		,,, ielit <u>-</u> 02020, i 115 (et	, , , o o o o o o o o o o o o o o o o o					
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.0	68.979	28.518	105	dominated	
HR-HIVE $-2$ doses	2.1	2.1	4.0	68.986	28.521	105	dominated	
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	104	dominated	
HIVE – 1 dose	$2 \cdot 0$	2.0	3.8	69.011	28.529	105	dominated	
HIVE - 2  dose	2.0	1.8	3.6	69.045	28.541	103	dominated	
ALL - 1 dose	1.8	1.8	3.5	69.063	28.548	116	dominated	
HIVE – Extended	2.0	1.5	3.3	69.095	28.557	100	cost-saving	
ALL - 2 doses	1.8	1.5	3.2	69.122	28.568	100	dominated	
ALL – 2 doses ALL – 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	111	606	
1								
ALL - Extended	1.8	0.8	2.5	69.228	28.602	135	882*	

# Supplementary Table 19. One-way sensitivity analysis: additional cost of identifying high-risk infants

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER≤\$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]					
Cost of identifying high-risk infants: \$.	32							
Standard-of-care	2.3	2.2	4.4	68.924	28.499	112	Reference	
HR-HIVE – 1 dose	2.1	2.1	4.0	68.979	28.518	115	dominated	
HR-HIVE – 2 doses	2.1	2.1	4.0	68.986	28.521	115	dominated	
HR-HIVE – Extended	2.1	2.0	3.9	68.995	28.523	114	dominated	
HIVE – 1 dose	2.0	2.0	3.8	69.011	28.529	105	dominated	
HIVE – 2 doses	$2 \cdot 0$	1.8	3.6	69.045	28.541	104	dominated	
ALL – 1 dose	1.8	1.8	3.5	69.063	28.548	116	dominated	
HIVE – Extended	2.0	1.5	3.3	69.095	28.557	100	cost-saving	
ALL - 2 doses	1.8	1.5	3.2	69.122	28.568	122	dominated	
ALL - 1 dose plus HIVE - Extended	1.8	1.3	3.0	69.147	28.575	111	606	
ALL - Extended	1.8	0.8	2.5	69.228	28.602	135	882*.†	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	<b>GDP per capita</b> ]					
Cost of identifying high-risk infants: \$			• • •					
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference	
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	67	dominated	
HR-HIVE – 2 doses	3.7	5.2	8.5	68.373	28.053	66	dominated	
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	67	dominated	
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	65	dominated	
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	79	dominated	
HIVE – 2 doses	3.7	4.8	8.0	68.402	28.063	66	dominated	
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	93	dominated	
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	61	cost-saving*,	
ALL – 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	74	1731	
ALL - Extended	3.4	2.6	5.7	68.517	28.101	134	4516	
Cost of identifying high-risk infants: \$.	32							
Standard-of-care	4.3	5.6	9.5	68.321	28.034	72	Reference	
HR-HIVE – 1 dose	3.7	5.3	8.6	68.366	28.050	71	dominated	
HR-HIVE - 2  doses	3.7	5.2	8.5	68.373	28.053	70	dominated	
HIVE – 1 dose	3.7	5.2	8.4	68.380	28.055	67	dominated	
HR-HIVE – Extended	3.7	4.9	8.2	68.387	28.057	69	dominated	
ALL – 1 dose	3.4	4.9	7.9	68.400	28.062	79	dominated	
HIVE – 2 doses	3.7	4.8	8.0	68.402	28.063	66	dominated	
ALL - 2 doses	3.4	4.3	7.4	68.438	28.074	93	dominated	
HIVE – Extended	3.7	3.6	6.9	68.458	28.081	61	cost-saving*"	
ALL – 1 dose plus HIVE - Extended	3.4	3.4	6.5	68.478	28.088	74	1731	
ALL - Extended	3.4	2.6	5.7	68.517	28.101	134	4516	

## Supplementary Table 19. One-way sensitivity analysis: additional cost of identifying high-risk infants (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

The cost of ascertaining an infant's HIV exposure risk status includes a maternal viral load test (\$24.05), result return (\$3.48), and personnel/overhead costs (\$4.13).<sup>26,27,149,151</sup> Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

ative te (%)Postnatal cumulative HIV incidence (%)capita), ICER $\leq$ \$1163/YLS (50 egnancy: 25%; retesting postparts $5 \cdot 0$ $4 \cdot 9$ $4 \cdot 8$ $4 \cdot 8$ $4 \cdot 4$ $4 \cdot 4$ $4 \cdot 4$ $4 \cdot 4$ $4 \cdot 2$ $3 \cdot 2$ $3 \cdot 2$ $2 \cdot 7$ regnancy: 95%; retesting postparts		Undiscounted life expectancy (yrs) 60·128 60·132 60·133 60·133 60·135 60·136 60·136 60·138 60·139	Discounted life expectancy (yrs) 26·373 26·374 26·375 26·375 26·375 26·375 26·376 26·377	Discounted costs (\$) 15 15 15 15 14 14 14 14	ICER (\$/YLS) Reference dominated dominated dominated dominated
• capita), ICER ≤ \$1163/YLS (50         egnancy: 25%; retesting postparts $5 \cdot 0$ $4 \cdot 9$ $4 \cdot 8$ $4 \cdot 8$ $4 \cdot 4$ $4 \cdot 4$ $4 \cdot 7$ $4 \cdot 2$ $3 \cdot 2$ $2 \cdot 7$	% GDP per capita)]           um: 0%/month)           8·4           8·1           7·9           7·6           7·5           7·6           7·1           6·4	60·128 60·132 60·133 60·133 60·135 60·136 60·138	26·373 26·374 26·375 26·375 26·375 26·375 26·376	15 15 15 14 14	Reference dominated dominated dominated dominated
egnancy: 25%; retesting postparts $5 \cdot 0$ $4 \cdot 9$ $4 \cdot 8$ $4 \cdot 8$ $4 \cdot 4$ $4 \cdot 4$ $4 \cdot 4$ $4 \cdot 7$ $4 \cdot 2$ $3 \cdot 2$ $3 \cdot 2$ $2 \cdot 7$	<i>am: 0%/month)</i> 8·4 8·1 7·9 7·9 7·6 7·5 7·6 7·1 6·4	60·132 60·133 60·133 60·135 60·136 60·138	26·374 26·375 26·375 26·375 26·375 26·376	15 15 14 14	dominated dominated dominated dominated
$ \begin{array}{c} 5 \cdot 0 \\ 4 \cdot 9 \\ 4 \cdot 8 \\ 4 \cdot 8 \\ 4 \cdot 4 \\ 4 \cdot 4 \\ 4 \cdot 4 \\ 4 \cdot 7 \\ 4 \cdot 2 \\ 3 \cdot 2 \\ 3 \cdot 2 \\ 3 \cdot 2 \\ 2 \cdot 7 \\ \end{array} $	$ \begin{array}{c} 8 \cdot 4 \\ 8 \cdot 1 \\ 7 \cdot 9 \\ 7 \cdot 9 \\ 7 \cdot 6 \\ 7 \cdot 5 \\ 7 \cdot 6 \\ 7 \cdot 1 \\ 6 \cdot 4 \end{array} $	60·132 60·133 60·133 60·135 60·136 60·138	26·374 26·375 26·375 26·375 26·375 26·376	15 15 14 14	dominated dominated dominated dominated
$ \begin{array}{r} 4 \cdot 9 \\ 4 \cdot 8 \\ 4 \cdot 8 \\ 4 \cdot 4 \\ 4 \cdot 4 \\ 4 \cdot 4 \\ 4 \cdot 7 \\ 4 \cdot 2 \\ 3 \cdot 2 \\ 3 \cdot 2 \\ 3 \cdot 2 \\ 2 \cdot 7 \\ \end{array} $	$     \begin{array}{r}       8 \cdot 1 \\       7 \cdot 9 \\       7 \cdot 9 \\       7 \cdot 6 \\       7 \cdot 5 \\       7 \cdot 6 \\       7 \cdot 1 \\       6 \cdot 4 \\     \end{array} $	60·132 60·133 60·133 60·135 60·136 60·138	26·374 26·375 26·375 26·375 26·375 26·376	15 15 14 14	dominated dominated dominated dominated
$ \begin{array}{r} 4.8\\ 4.8\\ 4.4\\ 4.4\\ 4.7\\ 4.2\\ 3.2\\ 3.2\\ 3.2\\ 2.7\\ \end{array} $	$7.9 \\ 7.9 \\ 7.6 \\ 7.5 \\ 7.6 \\ 7.1 \\ 6.4$	60·133 60·133 60·135 60·136 60·138	26·375 26·375 26·375 26·376	15 14 14	dominated dominated dominated
$ \begin{array}{r} 4.8 \\ 4.4 \\ 4.4 \\ 4.7 \\ 4.2 \\ 3.2 \\ 3.2 \\ 2.7 \\ \end{array} $	$7 \cdot 9  7 \cdot 6  7 \cdot 5  7 \cdot 6  7 \cdot 1  6 \cdot 4$	60·133 60·135 60·136 60·138	26·375 26·375 26·376	14 14	dominated dominated
$ \begin{array}{r} 4 \cdot 4 \\ 4 \cdot 4 \\ 4 \cdot 7 \\ 4 \cdot 2 \\ 3 \cdot 2 \\ 3 \cdot 2 \\ 2 \cdot 7 \\ \end{array} $	$   \begin{array}{r}     7 \cdot 6 \\     7 \cdot 5 \\     7 \cdot 6 \\     7 \cdot 1 \\     6 \cdot 4   \end{array} $	60·135 60·136 60·138	26·375 26·376	14	dominated
4·4 4·7 4·2 3·2 3·2 2·7	7.5 7.6 7.1 6.4	60·136 60·138	26.376		
4·7 4·2 3·2 3·2 2·7	7.6 7.1 6.4	60.138		14	
4·2 3·2 3·2 2·7	7·1 6·4		26.377		dominated
3·2 3·2 2·7	6.4	60.139		27	dominated
3·2 2·7			26.378	44	dominated
2.7	6.1	60.144	26.379	13	cost-saving*'†
	-	60.149	26.381	26	6012
regnancy: 95%; retesting postpart	5.6	60.155	26.382	91	55 092
	tum: 15%/month)				
4.6	8.0	60.133	26.375	14	Reference
4.5	7.6	60.136	26.376	14	dominated
4.4	7.5	60.137	26.377	14	dominated
4.4	7.4	60.138	26.377	14	dominated
4.0	7.1	60.140	26.377	14	dominated
4.0	7.0	60.141	26.378	13	dominated
4.3	7.1	60.143	26.379	27	dominated
3.8	6.7	60.143	26.379	42	dominated
2.8	5.9	60.149	26.381	12	cost-saving*.*
	5.6	60.154			6779
2.4	5.3	60.159		91	79 100
	0% GDP per capita)]				
• // = · · · · ·	I I /1				
	,	68.851	28.472	118	Reference
					dominated
	4.3				dominated
	-				dominated
					cost-saving
					dominated
					405
					875*,†
	r capita), ICER ≤ \$2828/YLS (5	$2 \cdot 4$ $5 \cdot 3$ r capita), ICER ≤ \$2828/YLS (50% GDP per capita)]         egnancy: 25%; retesting postpartum: 0%/month) $2 \cdot 2$ $4 \cdot 7$ $2 \cdot 1$ $4 \cdot 3$ $2 \cdot 1$ $4 \cdot 3$ $2 \cdot 1$ $4 \cdot 3$ $2 \cdot 0$ $4 \cdot 1$ $1 \cdot 8$ $4 \cdot 0$ $1 \cdot 8$ $3 \cdot 7$ $1 \cdot 5$ $3 \cdot 7$ $1 \cdot 5$ $3 \cdot 4$ $1 \cdot 3$ $3 \cdot 2$	$2\cdot4$ $5\cdot3$ $60\cdot159$ capita), ICER ≤ \$2828/YLS (50% GDP per capita)]           egnancy: 25%; retesting postpartum: 0%/month) $2\cdot2$ $4\cdot7$ $68\cdot851$ $2\cdot1$ $4\cdot3$ $68\cdot905$ $2\cdot1$ $4\cdot3$ $68\cdot911$ $2\cdot0$ $4\cdot1$ $68\cdot937$ $1\cdot8$ $4\cdot0$ $68\cdot970$ $1\cdot8$ $3\cdot7$ $69\cdot000$ $1\cdot5$ $3\cdot4$ $69\cdot060$ $1\cdot3$ $3\cdot2$ $69\cdot082$	$2\cdot4$ $5\cdot3$ $60\cdot159$ $26\cdot384$ capita), ICER $\leq$ \$2828/YLS (50% GDP per capita)]egnancy: 25%; retesting postpartum: 0%/month) $2\cdot2$ $4\cdot7$ $68\cdot851$ $28\cdot472$ $2\cdot1$ $4\cdot3$ $68\cdot905$ $28\cdot491$ $2\cdot1$ $4\cdot3$ $68\cdot911$ $28\cdot493$ $2\cdot0$ $4\cdot3$ $68\cdot919$ $28\cdot495$ $2\cdot0$ $4\cdot1$ $68\cdot937$ $28\cdot502$ $1\cdot8$ $4\cdot0$ $68\cdot970$ $28\cdot513$ $1\cdot8$ $3\cdot7$ $69\cdot000$ $28\cdot524$ $1\cdot5$ $3\cdot4$ $69\cdot060$ $28\cdot545$ $1\cdot3$ $3\cdot2$ $69\cdot082$ $28\cdot551$	$2\cdot4$ $5\cdot3$ $60\cdot159$ $26\cdot384$ $91$ capita), ICER ≤ \$2828/YLS (50% GDP per capita)]egnancy: 25%; retesting postpartum: 0%/month) $2\cdot2$ $4\cdot7$ $68\cdot851$ $28\cdot472$ $118$ $2\cdot1$ $4\cdot3$ $68\cdot905$ $28\cdot491$ $121$ $2\cdot1$ $4\cdot3$ $68\cdot911$ $28\cdot493$ $121$ $2\cdot0$ $4\cdot3$ $68\cdot919$ $28\cdot495$ $120$ $2\cdot0$ $4\cdot1$ $68\cdot937$ $28\cdot502$ $111$ $1\cdot8$ $4\cdot0$ $68\cdot970$ $28\cdot513$ $110$ $1\cdot8$ $3\cdot7$ $69\cdot000$ $28\cdot524$ $120$ $1\cdot5$ $3\cdot4$ $69\cdot060$ $28\cdot545$ $127$ $1\cdot3$ $3\cdot2$ $69\cdot082$ $28\cdot551$ $116$

## Supplementary Table 20. One-way sensitivity analysis: maternal knowledge of acute HIV infection

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS	
South Africa [CET: ICER≤\$1131/YL	S (20% GDP per capita	a), ICER ≤ \$2828/YLS (50	)% GDP per capita)]					
High maternal knowledge of acute HI	V infection (in pregnand	y: 95%; retesting postpart	um: 15%/month)					
Standard-of-care	1.9	2.0	3.8	69.051	28.546	101	Reference	
HR-HIVE – 1 dose	1.6	1.9	3.4	69.109	28.566	104	dominated	
HR-HIVE - 2  doses	1.6	1.8	3.4	69.117	28.568	104	dominated	
HR-HIVE – Extended	1.6	1.8	3.3	69.127	28.571	104	dominated	
HIVE – 1 dose	1.5	1.8	3.2	69.140	28.577	94	dominated	
ALL – 1 dose	1.5	1.7	3.1	69.161	28.584	109	dominated	
HIVE – 2 doses	1.5	1.6	3.0	69.175	28.589	93	dominated	
ALL - 2 doses	1.5	1.4	2.8	69.217	28.603	115	dominated	
HIVE – Extended	1.5	1.3	2.7	69.226	28.605	90	cost-saving*	
ALL - 1 dose plus HIVE - Extended	1.5	1.1	2.6	69.247	28.612	104	dominated	
ALL - Extended	1.5	0.7	2.1	69.320	28.636	128	1221†	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
Low maternal knowledge of acute HIV								
Standard-of-care	4.9	6.6	10.9	68.213	27.994	79	Reference	
HR-HIVE – 1 dose	4.5	6.4	10.3	68.244	28.005	79	dominated	
HR-HIVE – 2 doses	4.5	6.3	10.2	68.249	28.007	79	dominated	
HIVE – 1 dose	4.4	6.3	10.1	68.258	28.010	76	dominated	
HR-HIVE – Extended	4.5	6.1	10.0	68.260	28.010	78	dominated	
HIVE – 2 doses	4.4	5.9	9.7	68.278	28.017	75	dominated	
ALL – 1 dose	3.9	5.6	9.1	68.310	28.029	85	dominated	
HIVE – Extended	4.4	4.8	8.7	68.330	28.034	70	cost-saving*	
ALL - 2 doses	3.9	5.0	8.5	68.351	28.042	99	dominated	
ALL – 1 dose plus HIVE - Extended	3.9	4.2	7.7	68.383	28.053	80	520†	
ALL - Extended	3.9	3.1	6.6	68.438	28.072	138	3081	
High maternal knowledge of acute HI	V infection (in pregnand	v: 95%; retesting postpart	um: 15%/month)					
Standard-of-care	4.0	5.0	8.6	68.383	28.056	67	Reference	
HR-HIVE – 1 dose	3.4	4.6	7.6	68.436	28.075	65	dominated	
HR-HIVE – 2 doses	3.4	4.5	7.5	68.444	28.078	64	dominated	
HIVE – 1 dose	3.3	4.5	7.4	68.449	28.080	61	dominated	
ALL - 1 dose	3.2	4.4	7.2	68.454	28.082	75	dominated	
HR-HIVE – Extended	3.4	4.2	7.2	68.460	28.083	63	dominated	
HIVE – 2 doses	3.3	4.1	7.0	68.473	28.088	60	dominated	
ALL - 2 doses	3.2	3.9	6.7	68.490	28.093	89	dominated	
HIVE – Extended	3.3	2.9	5.9	68.530	28.107	55	cost-saving*'	
ALL – 1 dose plus HIVE - Extended	3.2	2.8	5.7	68.534	28.107	70	dominated	
ALL - Extended	3.2	2.8	5.2	68.561	28.103	130	7013	

### Supplementary Table 20. One-way sensitivity analysis: HIV knowledge of acute infection (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest tent thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \* Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita. † Indicates the cost-effective strategy using a cost-effectiveness threshold of 50% GDP per capita.

		Clinical outcomes		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER ≤ \$465/YL§	6 (20% GDP per capita)	), ICER $\leq$ \$1163/YLS (50)	% GDP per capita)]					
Low maternal knowledge of chronic H	IV infection: 56%							
Standard-of-care	11.0	8.1	18.9	60.020	26.329	27	Reference	
HR-HIVE – 1 dose	10.8	8.1	18.6	60.022	26.329	27	dominated	
HR-HIVE – 2 doses	10.8	8.0	18.5	60.023	26.330	27	dominated	
HIVE - 1 dose	10.7	8.0	18.5	60.023	26.330	27	dominated	
HR-HIVE – Extended	10.8	7.7	18.3	60.025	26.330	27	dominated	
HIVE – 2 doses	10.7	7.7	18.3	60.025	26.331	27	dominated	
HIVE – Extended	10.7	$7 \cdot 0$	17.5	60.030	26.332	26	cost-saving*,†	
ALL – 1 dose	9.0	7.6	16.5	60.041	26.337	39	dominated	
ALL - 2 doses	9.0	6.9	15.7	60.044	26.339	54	dominated	
ALL - 1 dose plus HIVE - Extended	9.0	6.7	15.5	60.048	26.340	38	1587	
ALL - Extended	9.0	4.5	13.4	60.065	26.345	100	11 429	
High maternal knowledge of chronic H	IIV infection: 100%							
Standard-of-care	2.4	4.2	6.6	60.149	26.381	12	Reference	
HR-HIVE – 1 dose	2.1	4.1	6.2	60.153	26.383	13	dominated	
HR-HIVE – 2 doses	2.1	$4 \cdot 0$	6.0	60.154	26.383	13	dominated	
HIVE – 1 dose	2.0	$4 \cdot 0$	6.0	60.155	26.384	12	dominated	
HR-HIVE – Extended	2.1	3.6	5.7	60.157	26.384	12	dominated	
ALL – 1 dose	2.0	$4 \cdot 0$	5.9	60.157	26.385	25	dominated	
HIVE – 2 doses	2.0	3.6	5.6	60.158	26.385	12	dominated	
ALL - 2 doses	2.0	3.6	5.5	60.158	26.385	41	dominated	
HIVE – Extended	2.0	2.4	4.4	60.166	26.388	10	cost-saving*,†	
ALL - 1 dose plus HIVE - Extended	2.0	2.4	4.3	60.169	26.389	24	11 617	
ALL - Extended	2.0	2.2	4.2	60.173	26.390	89	197 506	
South Africa [CET: ICER≤\$1131/YL	S (20% GDP per capita	), ICER ≤ \$2828/YLS (50	% GDP per capita)]					
Low maternal knowledge of chronic H			• • •					
Standard-of-care	6.9	3.3	9.8	67.760	28.071	207	Reference	
HR-HIVE – 1 dose	6.7	3.2	9.5	67.807	28.087	209	dominated	
HR-HIVE – 2 doses	6.7	3.1	9.5	67.812	28.089	209	dominated	
HR-HIVE – Extended	6.7	3.1	9.4	67.819	28.091	208	dominated	
HIVE – 1 dose	6.6	3.1	9.3	67.831	28.095	201	dominated	
HIVE – 2 doses	6.6	2.9	9.2	67.857	28.104	200	dominated	
HIVE – Extended	6.6	2.7	8.9	67.895	28.117	198	dominated	
ALL – 1 dose	5.3	2.7	7.7	68.064	28.178	193	dominated	
ALL – 1 dose plus HIVE - Extended	5.3	2.3	7.3	68.128	28.199	189	cost-saving	
ALL – 2 doses	5.3	2.2	7.2	68.149	28.207	196	dominated	
ALL - Extended	5.3	1.2	6.2	68.302	28.257	203	239*.†	

# Supplementary Table 21. One-way sensitivity analysis: maternal knowledge of chronic HIV infection

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
South Africa [CET: ICER ≤ \$1131/YL	· · ·	a), ICER $\leq$ \$2828/YLS (50)	)% GDP per capita)]					
High maternal knowledge of chronic H	5							
Standard-of-care	2.3	2.1	4.3	68.946	28.507	110	Reference	
HR-HIVE – 1 dose	2.0	2.0	3.9	69·000	28.526	114	dominated	
HR-HIVE - 2 doses	2.0	2.0	3.9	69.007	28.528	113	dominated	
HR-HIVE – Extended	2.0	1.9	3.8	69.016	28.531	113	dominated	
HIVE – 1 dose	1.9	1.9	3.7	69.034	28.538	103	dominated	
HIVE – 2 doses	1.9	1.7	3.5	69.068	28.549	102	dominated	
ALL – 1 dose	1.7	1.7	3.4	69.082	28.555	115	dominated	
HIVE – Extended	1.9	1.4	3.2	69.118	28.566	99	cost-saving	
ALL – 2 doses	1.7	1.4	3.1	69.140	28.575	121	dominated	
ALL - 1 dose plus HIVE - Extended	1.7	1.2	2.9	69.166	28.583	110	674	
ALL - Extended	1.7	0.8	2.4	69.245	28.608	134	909* <sup>,</sup> †	
Zimbabwe [CET: ICER ≤ \$243/YLS (2	0% GDP per capita), I	CER≤\$607/YLS (50% C	GDP per capita)]					
Low maternal knowledge of chronic H			• • •					
Standard-of-care	7.3	6.6	13.4	68.047	27.933	94	Reference	
HR-HIVE – 1 dose	6.8	6.3	12.6	68.088	27.947	93	dominated	
HR-HIVE $-2$ doses	6.8	6.2	12.5	68.094	27.950	93	dominated	
HIVE – 1 dose	6.7	6.2	12.5	68.099	27.951	90	dominated	
HR-HIVE – Extended	6.8	6.0	12.3	68.106	27.954	92	dominated	
HIVE – 2 doses	6.7	5.9	12.1	68.117	27.958	89	dominated	
HIVE – Extended	6.7	4.9	11.2	68.164	27.973	85	cost-saving*	
ALL – 1 dose	5.8	5.8	11.2	68.159	27.973	99	dominated	
ALL - 2 doses	5.8	5.1	10.5	68·203	27.987	112	dominated	
ALL – 1 dose plus HIVE - Extended	5.8	4.6	9.9	68·224	27.994	94	410†	
ALL - Extended	5.8	3.1	8.5	68.298	28.019	150	2238	
High maternal knowledge of chronic H								
Standard-of-care	4.0	5.3	9.1	68.348	28.044	69	Reference	
HR-HIVE – 1 dose	3.4	5.0	8.2	68.397	28.062	68	dominated	
HR-HIVE – 2 doses	3.4	4.9	8.1	68.404	28.064	68	dominated	
HIVE – 1 dose	3.4	4.9	8.0	68.408	28.065	64	dominated	
HR-HIVE – Extended	3.4	4.6	7.8	68.418	28.069	67	dominated	
ALL - 1 dose	3.2	4.6	7.6	68.424	28.071	77	dominated	
HIVE – 2 doses	3.4	4.5	7.6	68.430	28.073	64	dominated	
ALL - 2 doses	3.2	4.1	7.0	68.462	28.083	91	dominated	
HIVE – Extended	3.4	3.4	6.5	68.487	28.091	59	cost-saving*'†	
ALL – 1 dose plus HIVE - Extended	3.2	3.1	6.1	68.503	28.091	72	2215	
ALL - Extended	3.2	2.4	5.4	68.539	28.109	132	4077	

#### Supplementary Table 21. One-way sensitivity analysis: maternal knowledge of chronic HIV infection (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest ten thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \*Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

		<b>Clinical outcomes</b>		Lifetime efficacy and costs				
	<b>IU/IP cumulative</b>	Postnatal cumulative	Total cumulative	Undiscounted life	Discounted life	Discounted costs		
Country/strategy	HIV incidence (%)	HIV incidence (%)	HIV incidence (%)	expectancy (yrs)	expectancy (yrs)	(\$)	ICER (\$/YLS)	
Côte d'Ivoire [CET: ICER≤\$465/YLS	· · ·		1 1 /					
Low postpartum maternal retention in	care (50% of mothers w	vith known HIV status in o	care at 6+ months)					
Standard-of-care	3.6	7.1	10.4	60.114	26.368	18	Reference	
HR-HIVE – 1 dose	3.3	7.0	10.0	60.118	26.369	19	dominated	
HR-HIVE – 2 doses	3.3	6.8	9.8	60.119	26.370	18	dominated	
HIVE – 1 dose	3.3	6.8	9.8	60.120	26.370	18	dominated	
HR-HIVE – Extended	3.3	6.2	9.2	60.123	26.371	18	dominated	
HIVE – 2 doses	3.3	6.2	9.2	60.125	26.372	17	dominated	
ALL – 1 dose	3.0	6.8	9.5	60.125	26.372	31	dominated	
ALL – 2 doses	3.0	6.0	8.8	60.127	26.373	47	dominated	
HIVE – Extended	3.3	4.3	7.4	60.138	26.377	15	cost-saving*"	
ALL - 1 dose plus HIVE - Extended	3.0	4.2	7.1	60.143	26.379	28	6245	
ALL - Extended	3.0	3.8	6.7	60.148	26.380	93	57 575	
High postpartum maternal retention in	care (100% of mothers	with known HIV status in	care at 6+ months)					
Standard-of-care	3.6	4.1	7.5	60.135	26.375	13	Reference	
HR-HIVE – 1 dose	3.3	$4 \cdot 0$	7.1	60.139	26.377	13	dominated	
HR-HIVE – 2 doses	3.3	3.9	7.0	60.140	26.377	13	dominated	
HIVE – 1 dose	3.3	3.9	6.9	60.140	26.378	13	dominated	
HR-HIVE – Extended	3.3	3.6	6.7	60.142	26.378	13	dominated	
HIVE – 2 doses	3.3	3.5	6.6	60.143	26.379	12	dominated	
ALL – 1 dose	3.0	3.8	6.6	60.145	26.380	26	dominated	
ALL - 2 doses	3.0	3.4	6.3	60.145	26.380	41	dominated	
HIVE – Extended	3.3	2.7	5.8	60.149	26.381	12	cost-saving*,†	
ALL – 1 dose plus HIVE - Extended	3.0	2.6	5.5	60.154	26.383	25	6264	
ALL - Extended	3.0	2.2	5.1	60.160	26.384	90	57 976	
outh Africa [CET: ICER ≤ \$1131/YL	S (20% GDP per capita	), ICER < \$2828/YLS (50	)% GDP per capita)]					
Low postpartum maternal retention in								
Standard-of-care	2.3	2.8	5.0	68.827	28.467	125	Reference	
HR-HIVE – 1 dose	2.1	2.7	4.6	68.883	28.486	128	dominated	
HR-HIVE – 2 doses	2.1	2.6	4.5	68.893	28.490	127	dominated	
HR-HIVE – Extended	2.1	2.5	4.4	68.908	28.494	126	dominated	
HIVE – 1 dose	$2 \cdot 0$	2.6	4.4	68.919	28.499	117	dominated	
ALL - 1 dose	1.8	2.3	4.0	68.970	28.517	128	dominated	
HIVE – 2 doses	2.0	2.2	4.1	68.973	28.517	1120	dominated	
HIVE – Extended	1.8	1.9	3.6	69.050	28.544	132	dominated	
ALL - 2  doses	2.0	1.7	3.5	69.057	28.545	106	cost-saving	
ALL – 1 dose plus HIVE - Extended	1.8	1.5	3.2	69.109	28.563	116	575	
ALL - Extended	1.8	1.0	2.7	69.192	28.590	139	847* <sup>,</sup> †	

## Supplementary Table 22. One-way sensitivity analysis: postpartum maternal retention in care

Country/strategy	Clinical outcomes			Lifetime efficacy and costs			
	IU/IP cumulative HIV incidence (%)	Postnatal cumulative HIV incidence (%)	Total cumulative HIV incidence (%)	Undiscounted life expectancy (yrs)	Discounted life expectancy (yrs)	Discounted costs (\$)	ICER (\$/YLS
High postpartum maternal retention in	a care (100% of mothers	with known HIV status in	care at 6+ months)				
Standard-of-care	2.3	2.0	4.2	68.956	28.510	108	Reference
HR-HIVE - 1 dose	2.1	1.9	3.8	69.011	28.529	111	dominated
HR-HIVE - 2 doses	2.1	1.9	3.8	69.017	28.531	111	dominated
HR-HIVE – Extended	2.1	1.8	3.7	69.024	28.533	110	dominated
HIVE – 1 dose	2.0	1.8	3.6	69.043	28.540	101	dominated
ALL – 1 dose	2.0	1.6	3.5	69.070	28.549	100	dominated
HIVE – 2 doses	1.8	1.6	3.3	69.094	28.558	111	dominated
ALL - 2 doses	2.0	1.4	3.2	69.108	28.561	99	cost-saving
HIVE – Extended	1.8	1.3	3.0	69.147	28.576	118	dominated
ALL - 1 dose plus HIVE - Extended	1.8	1.2	2.9	69.160	28.580	109	569
ALL - Extended	1.8	0.7	2.4	69.240	28.606	133	921*,†
Zimbabwe [CET: ICER ≤ \$243/YLS (2	20% GDP per capita), I	CER≤\$607/YLS (50% C	<b>GDP per capita</b> ]				
Low postpartum maternal retention in							
Standard-of-care	4.3	7.5	11.3	68.227	28.003	86	Reference
HR-HIVE – 1 dose	3.7	7.2	10.4	68.271	28.019	85	dominated
HR-HIVE $-2$ doses	3.7	7.0	10.2	68·282	28.022	84	dominated
HIVE – 1 dose	3.7	7.0	10.2	68·288	28.025	81	dominated
HR-HIVE – Extended	3.7	6.5	9.8	68.305	28.030	81	dominated
ALL – 1 dose	3.4	6.7	9.7	68.308	28.032	93	dominated
HIVE – 2 doses	3.7	6.4	9.6	68·322	28.037	78	dominated
ALL - 2 doses	3.4	5.9	9.0	68.358	28.048	106	dominated
HIVE – Extended	3.7	4.5	7.8	68.415	28.066	68	cost-saving*,†
ALL - 1 dose plus HIVE - Extended	3.4	4.2	7.3	68.435	28.074	81	1738
ALL - Extended	3.4	3.4	6.5	68.474	28.087	140	4438
High postpartum maternal retention in	a care (100% of mothers	with known HIV status in					
Standard-of-care	4.3	4.9	8.8	68.356	28.045	66	Reference
HR-HIVE – 1 dose	3.7	4.6	7.9	68.401	28.062	65	dominated
HR-HIVE – 2 doses	3.7	4.5	7.8	68.407	28.064	65	dominated
HIVE – 1 dose	3.7	4.5	7.7	68.415	28.066	61	dominated
HR-HIVE – Extended	3.7	4.3	7.6	68.418	28.067	64	dominated
HIVE - 2 doses	3.7	4.1	7.4	68.433	28.073	61	dominated
ALL - 1 dose	3.4	4.2	7.3	68.435	28.074	74	dominated
ALL - 2  doses	3.4	3.7	6.8	68.469	28.084	88	dominated
HIVE – Extended	3.7	3.3	6.6	68.475	28.086	59	cost-saving*'†
ALL – 1 dose plus HIVE - Extended	3.4	3.0	6.1	68.495	28.093	71	1724
ALL - Extended	3.4	2.2	5.4	68.534	28.095	131	4539

# Supplementary Table 22. One-way sensitivity analysis: postpartum maternal retention in care (cont.)

bNAb: broadly neutralizing antibody; IU/IP: intrauterine/intrapartum; yr: year; ICER: incremental cost-effectiveness ratio; YLS: years of life saved; CET: cost-effectiveness threshold; HR-HIVE: high-risk HIV-exposed infants; HIVE: all HIV-exposed infants; ALL: all live infants at birth.

Pediatric HIV incidence is rounded to the nearest tenth of a percent. IU/IP HIV incidence is calculated based on the number of infants exposed to HIV at birth. Postnatal and total HIV incidence is calculated based on the number of infants ever exposed to HIV through 36 months of life. Undiscounted and discounted life expectancies are rounded to the nearest tent thousandth. Costs are rounded to the nearest dollar and are presented in 2020 USD. Discounted values are discounted at 3% per year. ICERs are rounded to the nearest dollar and are calculated using unrounded discounted life expectancy and discounted costs. The cost-effective bNAb strategy was the strategy that offered the greatest increase in overall population life expectancy while still having an ICER less than the cost-effectiveness threshold when compared to the next best performing, non-dominated strategy. \*Indicates the cost-effective strategy using a cost-effectiveness threshold of 20% GDP per capita.

# References

- 1 Ciaranello AL, Morris BL, Walensky RP, et al. Validation and calibration of a computer simulation model of pediatric HIV infection. PLoS one. 2013 Dec 13;8(12):e83389.
- 2 Ciaranello AL, Doherty K, Penazzato M, et al. Cost-effectiveness of first-line antiretroviral therapy for HIV-infected African children less than 3 years of age. AIDS. 2015 Jun 6;29(10):1247.
- 3 Francke JA, Penazzato M, Hou T, et al. Clinical impact and cost-effectiveness of diagnosing HIV infection during early infancy in South Africa: test timing and frequency. J Infect Dis. 2016 Nov 1;214(9):1319-28.
- 4 Frank SC, Cohn J, Dunning L, et al. Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling study. Lancet HIV. 2019 Mar 1;6(3):e182-90.
- 5 Walensky RP, Borre ED, Bekker LG, et al. The anticipated clinical and economic effects of 90–90–90 in South Africa. Ann Intern Med. 2016 Sep 6;165(5):325-33.
- 6 Ciaranello AL, Perez F, Keatinge J, et al. What will it take to eliminate pediatric HIV? Reaching WHO target rates of mother-tochild HIV transmission in Zimbabwe: a model-based analysis. PLoS Med. 2012 Jan 10;9(1):e1001156.
- 7 Dugdale CM, Ciaranello AL, Bekker LG, et al. Risks and benefits of dolutegravir-and efavirenz-based strategies for South African women with HIV of child-bearing potential: a modeling study. Ann Intern Med. 2019 May 7;170(9):614-25.
- 8 Dunning L, Francke JA, Mallampati D, et al. The value of confirmatory testing in early infant HIV diagnosis programmes in South Africa: a cost-effectiveness analysis. PLoS Med. 2017 Nov 21;14(11):e1002446.
- 9 Dunning L, Gandhi AR, Penazzato M, et al. Optimizing infant HIV diagnosis with additional screening at immunization clinics in three sub-Saharan African settings: a cost-effectiveness analysis. J Int AIDS Soc. 2021 Jan;24(1):e25651.
- 10 Flanagan CF, McCann N, Stover J, Freedberg KA, Ciaranello AL. Do not forget the children: a model-based analysis on the potential impact of COVID-19-associated interruptions in paediatric HIV prevention and care. J Int AIDS Soc. 2022 Jan;25(1):e25864.
- 11 Stanic T, McCann N, Penazzato M, et al. Cost-effectiveness of routine provider-initiated testing and counseling for children with undiagnosed HIV in South Africa. Open Forum Infect Dis. 2022 Jan 1 (Vol. 9, No. 1, p. ofab603).
- 12 World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring. Accessed April 23, 2021. https://www.who.int/publications/i/item/9789240022232
- 13 Beste S, Essajee S, Siberry G, et al. Optimal antiretroviral prophylaxis in infants at high risk of acquiring HIV. Pediatr Infect Dis J. 2018 Feb 1;37(2):169-75.
- 14 Kumwenda NI, Hoover DR, Mofenson LM, et al. Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission. N Engl J Med. 2008 Jul 10;359(2):119-29.
- 15 Hudgens MG, Taha TE, Omer SB, et al. Pooled individual data analysis of 5 randomized trials of infant nevirapine prophylaxis to prevent breast-milk HIV-1 transmission. Clin Infectious Dis. 2013 Jan 1;56(1):131-9.
- 16 Cunningham C, Capparelli E, McFarland E, et al. Extended safety and PK of anti-HIV monoclonal Ab VRC07-523LS in HIVexposed infants. Accessed October 6, 2022. https://www.croiconference.org/abstract/extended-safety-and-pk-of-anti-hivmonoclonal-ab-vrc07-523ls-in-hiv-exposed-infants/
- 17 McFarland EJ, Cunningham CK, Muresan P, et al. Safety, Tolerability, and Pharmacokinetics of a Long-Acting Broadly Neutralizing Human Immunodeficiency Virus Type 1 (HIV-1). Monoclonal Antibody VRC01LS in HIV-1–Exposed Newborn Infants. J Infect Dis. 2021 Dec 1;224(11):1916-24.
- 18 Cunningham CK, McFarland EJ, Morrison RL, et al. Safety, tolerability, and pharmacokinetics of the broadly neutralizing human immunodeficiency virus (HIV)-1 monoclonal antibody VRC01 in HIV-exposed newborn infants. J Infect Dis. 2020 Jul 23;222(4):628-36.

- 19 Abrams EJ, Capparelli E, Ruel T, Mirochnick M. Potential of long-acting products to transform the treatment and prevention of human immunodeficiency virus (HIV) in infants, children, and adolescents. Clin Infect Dis. 2022 Dec 1;75:S562-70.
- 20 Corey L, Gilbert PB, Juraska M, et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N Engl J Med. 2021 Mar 18;384(11):1003-14.
- 21 Lorenzi JCC, Mendoza P, Cohen YZ, et al. Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates. J Virol. 2021 Feb 10;95(5):e01909-20.
- 22 Hessell AJ, Jaworski JP, Epson E, et al. Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nat Med. 2016 Apr;22(4):362-8.
- 23 Shapiro MB, Cheever T, Malherbe DC, et al. Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nat Commun. 2020 Jan 7;11(1):70.
- 24 Anderson DJ, Politch JA, Zeitlin L, et al. Systemic and topical use of monoclonal antibodies to prevent the sexual transmission of HIV. AIDS. 2017 Jul 7;31(11):1505.
- 25 COVAX Working Group on delivery costs. *Costs of delivering COVID-19 vaccine in 92 AMC countries*. Accessed April 23, 2021. https://www.who.int/publications/m/item/costs-of-delivering-covid-19-vaccine-in-92-amc-countries
- 26 Mvundura M, Lorenson K, Chweya A, et al. Estimating the costs of the vaccine supply chain and service delivery for selected districts in Kenya and Tanzania. Vaccine. 2015 May 28;33(23):2697-703.
- 27 Cunnama L, Abrams EJ, Myer L, et al. Provider-and patient-level costs associated with providing antiretroviral therapy during the postpartum phase to women living with HIV in South Africa: a cost comparison of three postpartum models of care. Trop Med Int Health. 2020 Dec;25(12):1553-67.
- 28 Neumann P, Sanders G, Russell L, Siegel J, Ganiats T. Cost-Effectiveness in Health and Medicine, Second Edition, 2nd ed. Oxford and New York: Oxford University Press, 2016.
- 29 Woods B, Revill P, Sculpher M, Claxton K. Country-level cost-effectiveness thresholds: initial estimates and the need for further research. Value Health. 2016 Dec 1;19(8):929-35.
- 30 Robinson LA, Hammitt JK, Chang AY, Resch S. Understanding and improving the one and three times GDP per capita costeffectiveness thresholds. Health Policy Plan. 2017 Feb 1;32(1):141-5.
- 31 Meyer-Rath G, Van Rensburg C, Larson B, Jamieson L, Rosen S. Revealed willingness-to-pay versus standard cost-effectiveness thresholds: Evidence from the South African HIV Investment Case. PLoS One. 2017 Oct 26;12(10):e0186496.
- 32 Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost–effectiveness of interventions: alternative approaches. Bull World Health Organ. 2014 Dec 15;93:118-24.
- 33 Ochalek J, Lomas J, Claxton K. Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country data. BMJ Global Health. 2018 Nov 1;3(6):e000964.
- 34 Jit M. Informing global cost-effectiveness thresholds using country investment decisions: human papillomavirus vaccine introductions in 2006-2018. Value Health. 2021 Jan 1;24(1):61-6.
- 35 Edoka IP, Stacey NK. Estimating a cost-effectiveness threshold for health care decision-making in South Africa. Health Policy Plan. 2020 Jun;35(5):546-55.
- 36 Dugdale CM, Ufio O, Alba C, et al. Cost-effectiveness of broadly neutralizing antibody prophylaxis for HIV-exposed infants in sub-Saharan African settings. J Int AIDS Soc. 2023 Jan;26(1):e26052.
- 37 The World Bank. GDP per capita (current US\$) South Africa, Zimbabwe, Cote d'Ivoire. Accessed September 9, 2020. https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?end=2019&locations=ZA-ZW-CI&start=2019&view=bar

- 38 Mandala J, Kasonde P, Badru T, Dirks R, Torpey K. HIV Retesting of HIV-negative pregnant women in the context of prevention of mother-to-child transmission of HIV in primary health centers in rural Zambia: what did we learn? J Int Assoc Provid AIDS Care. 2019 Jan 25;18:2325958218823530.
- 39 Rogers AJ, Akama E, Weke E, et al. Implementation of repeat HIV testing during pregnancy in southwestern Kenya: progress and missed opportunities. J Int AIDS Soc. 2017 Dec;20(4):e25036.
- 40 Heemelaar S, Habets N, Makukula Z, van Roosmalen J, van den Akker T. Repeat HIV testing during pregnancy and delivery: missed opportunities in a rural district hospital in Zambia. Trop Med Int Health. 2015 Mar;20(3):277-83.
- 41 de Beer S, Kalk E, Kroon M, et al. A longitudinal analysis of the completeness of maternal HIV testing, including repeat testing in Cape Town, South Africa. J Int AIDS Soc. 2020 Jan;23(1):e25441.
- 42 Ministère du Plan et du Développement. La Situation des Femmes et des Enfants en Côte d'Ivoire Enquête à Indicateurs Multiples 2016 - MICS5. Accessed October 6, 2022. https://mics-surveysprod.s3.amazonaws.com/MICS5/West%20and%20Central%20Africa/C%C3%B4te%20d%27Ivoire/2016/Final/Cote%20d%27Ivoi re%202016%20MICS\_French.pdf
- 43 South Africa National Department of Health. *South Africa Demographic and Health Survey 2016*. Accessed October 6, 2022. https://dhsprogram.com/pubs/pdf/FR337/FR337.pdf
- 44 Zimbabwe National Statistics Agency (ZIMSTAT), UNICEF. Zimbabwe Multiple Indicator Cluster Survey 2019, Survey Findings Report. Accessed August 4, 2020. https://mics-surveysprod.s3.amazonaws.com/MICS6/Eastern%20and%20Southern%20Africa/Zimbabwe/2019/Survey%20findings/Zimbabwe%20201 9%20MICS%20Survey%20Findings%20Report-31012020\_English.pdf
- 45 Dinh T-H, Delaney KP, Goga A, et al. Impact of maternal HIV seroconversion during pregnancy on early mother to child transmission of HIV (MTCT) measured at 4-8 weeks postpartum in South Africa 2011-2012: a national population-based evaluation. PLoS One. 2015 May 5;10(5):e0125525.
- 46 Mbizvo MT, Kasule J, Mahomed K, Nathoo K. HIV-1 seroconversion incidence following pregnancy and delivery among women seronegative at recruitment in Harare, Zimbabwe. Cent Afr J Med. 2001;47:115-8
- 47 Morrison CS, Wang J, Van Der Pol B, Padian N, Salata RA, Richardson BA. Pregnancy and the risk of HIV-1 acquisition among women in Uganda and Zimbabwe. AIDS. 2007 May 11;21(8):1027-34.
- 48 Teasdale CA, Abrams EJ, Chiasson MA, Justman J, Blanchard K, Jones HE. Incidence of sexually transmitted infections during pregnancy. PLoS One. 2018 May 24;13(5):e0197696.
- 49 South Africa National Department of Health. *National Antenatal Sentinel HIV Survey Key Findings*. Accessed October 6, 2022. https://www.nicd.ac.za/wp-content/uploads/2019/07/Antenatal\_survey-report\_24July19.pdf
- 50 McCoy S, Koyuncu A, Kang-Dufour M, et al. Approaching eMTCT in Zimbabwe: Expansion of PMTCT services and declining MTCT, 2012-2018. Accessed October 6, 2022. http://programme.ias2019.org/Abstract/Abstract/1921
- 51 Moyo F, Mazanderani AH, Murray T, Sherman GG, Kufa T. Achieving maternal viral load suppression for elimination of motherto-child transmission of HIV in South Africa. AIDS. 2021 Feb 2;35(2):307-16.
- 52 Zimbabwe Ministry of Health and Child Care (MOHCC). Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2020: Summary Sheet. Accessed December 28, 2020. https://phia.icap.columbia.edu/wp-content/uploads/2020/11/ZIMPHIA-2020-Summary-Sheet\_Web.pdf
- 53 Zimbabwe Ministry of Health and Child Care (MOHCC). Zimbabwe Population-Based HIV Impact Assessment (ZIMPHIA) 2015-2016: Final Report. Accessed October 6, 2022. https://phia.icap.columbia.edu/wp-content/uploads/2019/08/ZIMPHIA-Final-Report\_integrated\_Web-1.pdf
- 54 Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2021. Accessed May 10, 2022. https://www.unaids.org/en/resources/documents/2021/2021\_unaids\_data

- 55 Ministère de Santé et de l'Hygiène Publique (MSHP). Côte d'Ivoire Population-Based HIV Impact Assessment (CIPHIA) 2017-2018: Final Report. October 6, 2022. [cited 2022 October 6]. https://phia.icap.columbia.edu/wp-content/uploads/2021/05/CIPHIA-Final-Report\_En.pdf
- 56 Elizabeth Glaser Pediatric AIDS Foundation. *The Elizabeth Glaser Pediatric AIDS Foundation Zimbabwe Annual Report, January December 2018*. Elizabeth Glaser Pediatric AIDS Foundation, 2019. Accessed August 4, 2020. https://www.pedaids.org/resource/the-elizabeth-glaser-pediatric-aids-foundation-zimbabwe-annual-report/
- 57 Chetty T, Vandormael A, Thorne C, Coutsoudis A. Incident HIV during pregnancy and early postpartum period: a populationbased cohort study in a rural area in KwaZulu-Natal, South Africa. BMC Pregnancy Childbirth. 2017 Dec;17(1):248.
- 58 Fatti G, Shaikh N, Jackson D, et al. Low HIV incidence in pregnant and postpartum women receiving a community-based combination HIV prevention intervention in a high HIV incidence setting in South Africa. PLoS One. 2017 Jul 27;12(7):e0181691.
- 59 le Roux SM, Abrams EJ, Nguyen KK, Myer L. HIV incidence during breastfeeding and mother-to-child transmission in Cape Town, South Africa. AIDS. 2019 Jul 1;33(8):1399-401.
- 60 Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS Data 2020. Accessed August 9, 2021. https://www.unaids.org/en/resources/documents/2020/unaids-data
- 61 Desmonde S, Bangali M, Amorissani-Folquet M, et al. Effectiveness of a web-based information system to improve HIV early diagnosis and hepatitis B immunization coverages in Abidjan, Cote d'Ivoire. The DEPISTNEO project. Accessed October 6, 2022. https://academicmedicaleducation.com/meeting/international-workshop-hiv-pediatrics-2019/abstract/effectiveness-web-based-information
- 62 Joint United Nations Programme on HIV/AIDS (UNAIDS). *AIDSinfo 2021*. Accessed December 9, 2021. https://aidsinfo.unaids.org/
- 63 Elizabeth Glaser Pediatric AIDS Foundation. *Cote d'Ivoire Annual Report 2018*. Accessed August 4, 2020. https://www.pedaids.org/resource/cote-divoire-annual-report-2018/
- 64 ICAP at Columbia University. Cote d'Ivoire Population-Based HIV Impact Assessment (CIPHIA) 2017-2018: Summary Sheet. Accessed October 6, 2022. https://phia.icap.columbia.edu/wp-content/uploads/2018/08/CIPHIA\_Cote-DIvoire-SS\_FINAL.pdf
- 65 Dinh T, Mushavi A, Balachandra S, et al. Impact of option B+ and maternal HIV RNA viral load on mother-to-child HIV transmission: Findings from an 18-month prospective cohort study of a nationally representative sample of mother-infant pairs, Zimbabwe 2016-2017. Accessed October 6, 2022. http://programme.aids2018.org/Abstract/Abstract/6374
- 66 Nguyen K, Abrams EJ, Brittain K, et al. Breastfeeding cessation, maternal adherence to antiretroviral therapy and HIV viremia in the early postpartum period: a prospective cohort study [abstract P\_100]. 8<sup>th</sup> International Workshop on HIV and Pediatrics.
- 67 Watt MH, Cichowitz C, Kisigo G, et al. Predictors of postpartum HIV care engagement for women enrolled in prevention of mother-to-child transmission (PMTCT) programs in Tanzania. AIDS Care. 2019 Jun 3;31(6):687-98.
- 68 Myer L, Phillips TK, Zerbe A, et al. Integration of postpartum healthcare services for HIV-infected women and their infants in South Africa: a randomised controlled trial. PLoS Med. 2018 Mar 30;15(3):e1002547.
- 69 Harrington BJ, Pence BW, Maliwichi M, et al. Probable antenatal depression at antiretroviral initiation and postpartum viral suppression and engagement in Option B+. AIDS. 2018 Nov 11;32(18):2827.
- 70 Luoga E, Vanobberghen F, Bircher R, et al. Brief report: no HIV transmission from virally suppressed mothers during breastfeeding in rural Tanzania. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e17-20.
- 71 Gill MM, Hoffman HJ, Ndatimana D, et al. 24-month HIV-free survival among infants born to HIV-positive women enrolled in Option B+ program in Kigali, Rwanda: The Kabeho Study. Medicine (Baltimore). 2017 Dec;96(51).
- 72 Hosseinipour M, Nelson JA, Trapence C, et al. Viral suppression and HIV drug resistance at 6 months among women in Malawi's Option B+ program: results From the PURE Malawi study. J Acquir Immune Defic Sydr. 2017 Jun 6;75(Suppl 2):S149.

- 73 Onoya D, Sineke T, Brennan AT, Long L, Fox MP. Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women. AIDS. 2017 Jul 7;31(11):1593.
- 74 Davis NL, Miller WC, Hudgens MG, et al. Maternal and breast milk viral load: impacts of adherence on peri-partum HIV infections Averted-the ban study. J Acquir Immune Defic Syndr. 2016 Dec 12;73(5):572.
- 75 Stover J, Glaubius R, Kassanjee R, Dugdale CM. Updates to the Spectrum/AIM model for the UNAIDS 2020 HIV estimates. J Int AIDS Soc. 2021 Sep;24:e25778.
- 76 UNICEF. Countdown to 2030 Countdown Country Dashboards. Accessed October 6, 2022. https://www.countdown2030.org/landing\_page
- 77 Ciaranello A, Lu Z, Ayaya S, et al. Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) east Africa regional analysis. Pediatr Infect Dis J. 2014 Jun 1;33(6):623-9.
- 78 West NS, Schwartz SR, Yende N, et al. Infant feeding by South African mothers living with HIV: implications for future training of health care workers and the need for consistent counseling. Int Breastfeed J. 2019 Dec;14(1):1-7.
- 79 Patel MR, Mushavi A, Balachandra S, et al. HIV-exposed Uninfected Infant Morbidity and Mortality within a Nationally Representative Prospective Cohort of Mother-Infant Pairs in Zimbabwe, 2013–2014. AIDS. 2020 Jul 7;34(9):1339.
- 80 World Health Organization. *Consolidated guidelines on the use of antiretroviral drugs for the treating and preventing HIV infection: recommendations for a public health approach, 2nd ed.* Accessed July 23, 2020. https://apps.who.int/iris/handle/10665/208825
- 81 UNAIDS Reference Group on Estimates, Modelling, and Projections. *Modelling Paediatric HIV and the need for ART*. Accessed April 21, 2021. http://epidem.org/modelling-paediatric-hiv-and-the-need-for-art-october-2020.
- 82 Stover J, Glaubius R, Mofenson L, et al. Updates to the Spectrum/AIM model for estimating key HIV indicators at national and subnational levels. AIDS. 2019 Dec 12;33(Suppl 3):S227.
- 83 Komtenza B, Satyanarayana S, Takarinda KC, et al. Identifying high or low risk of mother to child transmission of HIV: How Harare City, Zimbabwe is doing? PLoS One. 2019 Mar 13;14(3):e0212848.
- 84 Moyo F, Mazanderani AH, Barron P, et al. Introduction of routine HIV birth testing in the South African National Consolidated Guidelines. Pediatr Infect Dis J. 2018 Jun 1;37(6):559-63.
- 85 Kalk E, Kroon M, Boulle A, et al. Neonatal and infant diagnostic HIV-PCR uptake and associations during three sequential policy periods in Cape Town, South Africa: a longitudinal analysis. J Int AIDS Soc. 2018 Nov;21(11):e25212.
- 86 Phelanyane F, Boulle A, Kalk E. Prevention of mother-to-child-transmission (PMTCT) of HIV in Khayelitsha, South Africa: A contemporary review of the service 20 years later. Accessed July 28, 2020. https://www.aids2020.org/wp-content/uploads/2020/09/AIDS2020\_Abstracts.pdf
- 87 Tait CL, Peters RP, McIntyre JA, et al. Implementation of a PMTCT programme in a high HIV prevalence setting in Johannesburg, South Africa: 2002–2015. South Afr J HIV Med. 2020 Jan 1;21(1):1-7.
- 88 Spooner E, Govender K, Reddy T, et al. Point-of-care HIV testing best practice for early infant diagnosis: an implementation study. BMC Public Health. 2019 Dec;19(1):1-4.
- 89 Coulon J, Isaacs Z, Bisschoff C, et al. HIV testing at birth: Are we getting it right? South Afr J HIV Med. 2019 Jan 1;20(1):1-5.
- 90 Onoya D, Jinga N, Nattey C, Mongwenyana C, Mngadi S, Sherman GG. Motivational interviewing retention counseling and child HIV testing in South Africa. Accessed July 24, 2020. https://www.croiconference.org/wpcontent/uploads/sites/2/resources/2020/ebook/croi2020-boston-abstract-ebook.pdf
- 91 Massyn N, Pillay Y, Padarath A. District Health Barometer 2017/18. Durban, South Africa: Health Systems Trust, 2019. Accessed August 11, 2020. https://www.hst.org.za/publications/Pages/DHB20172018.aspx

- 92 Mallampati D, Ford N, Hanaford A, Sugandhi N, Penazzato M. Performance of virological testing for early infant diagnosis: a systematic review. J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):308-14.
- 93 Bianchi F, Nzima V, Chadambuka A, et al. Comparing conventional to point-of-care (POC) early infant diagnosis (EID): Pre and post intervention data from a multi-country evaluation (Abstract #TUSA1302). Accessed October 14, 2020. 9th International AIDS Society Conference on HIV Science, 2017.
- 94 Mazanderani A, Moyo F, Sherman GG. Missed diagnostic opportunities within South Africa's early infant diagnosis program, 2010–2015. PloS One. 2017 May 11;12(5):e0177173.
- 95 Bianchi F, Cohn J, Sacks E, et al. Evaluation of a routine point-of-care intervention for early infant diagnosis of HIV: an observational study in eight African countries. Lancet HIV. 2019 Jun 1;6(6):e373-81.
- 96 Ngoma K, Moyo F, Haeri Mazanderani A, et al. Monitoring diagnosis, retention in care and viral load suppression in children testing HIV polymerase chain reaction-positive in two districts in South Africa. S Afr Med J. 2019 Sep 1;109(9):686-92.
- 97 Smith ER, Sheahan AD, Heyderman RS, et al. Performance of HIV rapid tests among breastfeeding, Malawian infants. Pediatr Infect Dis J. 2017 Apr 1;36(4):405-11.
- 98 Buchanan AM, Nadjm B, Amos B, et al. Utility of rapid antibody tests to exclude HIV-1 infection among infants and children aged< 18 months in a low-resource setting. J Clin Virol. 2012 Nov 1;55(3):244-9.
- 99 Desmond AC, Moodley D, Conolly CA, Castel SA, Coovadia HM. Evaluation of adherence measures of antiretroviral prophylaxis in HIV exposed infants in the first 6 weeks of life. BMC Pediatr. 2015 Dec;15(1):1-8.
- 100 World Health Organization. Immunization coverage survey data. Accessed December 13, 2021. https://data.unicef.org/wp-content/uploads/2021/07/Immunization-coverage-data.xls
- 101 Coovadia HM, Brown ER, Fowler MG, et al. Efficacy and safety of an extended nevirapine regimen in infant children of breastfeeding mothers with HIV-1 infection for prevention of postnatal HIV-1 transmission (HPTN 046): a randomised, doubleblind, placebo-controlled trial. Lancet. 2012 Jan 21;379(9812):221-8.
- 102 Chasela CS, Hudgens MG, Jamieson DJ, et al. Maternal or infant antiretroviral drugs to reduce HIV-1 transmission. N Engl J Med. 2010 Jun 17;362(24):2271-81.
- 103 Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open label, clinical trial. J Acquir Immune Defic Syndr. 2018 Apr 4;77(4):383.
- 104 Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997 Jun 15;126(12):946-54.
- 105 Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):464-9.
- 106 Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Lancet. 1999 May 1;353(9163):1463-8.
- 107 Marston M, Becquet R, Zaba B, et al. Net survival of perinatally and postnatally HIV-infected children: a pooled analysis of individual data from sub-Saharan Africa. Int J Epidemiol. 2011 Apr 1;40(2):385-96.
- 108 Becquet R, Marston M, Dabis F, et al. Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis. PloS One. 2012 Feb 23;7(2):e28510.
- 109 United Nations, Department of Economic and Social Affairs, Population Division. World Population Prospects 2019, Online Edition. Rev. 1. 2019. Accessed July 27, 2021. https://population.un.org/wpp/Download/Standard/CSV/

- 110 World Health Organization. Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. Accessed July 27, 2021. https://www.who.int/data/maternal-newborn-child-adolescent-ageing/advisory-groups/gama/gamaadvisory-group-members
- 111 Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of co-trimoxazole prophylaxis in patients with HIV/AIDS in Côte d'Ivoire: a trial-based analysis. AIDS. 2005 Aug 12;19(12):1299-308.
- 112 Amani-Bosse C, Dahourou DL, Malateste K, et al. Virological response and resistances over 12 months among HIV-infected children less than two years receiving first-line lopinavir/ritonavir-based antiretroviral therapy in Cote d'Ivoire and Burkina Faso: the MONOD ANRS 12206 cohort. J Int AIDS Soc. 2017;20(1):21362.
- 113 Mulenga V, Musiime V, Kekitiinwa A, et al. Abacavir, zidovudine, or stavudine as paediatric tablets for African HIVinfected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial. Lancet Infect Dis. 2016 Feb 1;16(2):169-79.
- 114 Ferrand RA, Simms V, Dauya E, et al. The effect of community-based support for caregivers on the risk of virological failure in children and adolescents with HIV in Harare, Zimbabwe (ZENITH): an open-label, randomised controlled trial. Lancet Child Adolesc Health. 2017 Nov 1;1(3):175-83.
- 115 Jiamsakul A, Kariminia A, Althoff KN, et al. HIV viral load suppression in adults and children receiving antiretroviral therapy–results from the IeDEA collaboration. J Acquir Defic Syndr. 2017 Nov 11;76(3):319.
- 116 Kityo C, Boerma RS, Sigaloff KC, et al. Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children. J Antimicrob Chemother. 2017 Sep 1;72(9):2587-95.
- 117 Teasdale CA, Sogaula N, Yuengling KA, et al. HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa. J Int AIDS Soc. 2018 Aug;21(8):e25168.
- 118 Moyo S, Ncube RT, Shewade HD, et al. Children and adolescents on anti-retroviral therapy in Bulawayo, Zimbabwe: How many are virally suppressed by month six? F1000Res. 2020;9.
- 119 Boerma RS, Bunupuradah T, Dow D, et al. Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure. J Int AIDS Soc. 2017;20(1):21930.
- 120 Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus two different prodrugs of tenofovir to treat HIV. N Engl J Med. 2019 Aug 29;381(9):803-15.
- 121 NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-based or low-dose efavirenzbased regimen for the treatment of HIV-1. N Engl J Med. 2019 Aug 29;381(9):816-26.
- 122 Stockdale AJ, Saunders MJ, Boyd MA, et al. Effectiveness of protease inhibitor/nucleos (t) ide reverse transcriptase inhibitor-based second-line antiretroviral therapy for the treatment of human immunodeficiency virus type 1 infection in sub-Saharan Africa: a systematic review and meta-analysis. Clin Infect Dis. 2018 Jun 1;66(12):1846-57.
- 123 Venter WDF, Sokhela S, Simmons B, et al. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 Oct 1;7(10):e666-76.
- 124 Calmy A, Sanchez TT, Kouanfack C, et al. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Lancet HIV. 2020 Oct 1;7(10):e677-87.
- 125 Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med. 2014 Jul 17;371(3):234-47.
- 126 Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc. 2019 Nov;22(11):e25415.
- 127 Pepperrell T, Venter WD, McCann K, et al. Participants on dolutegravir resuppress human immunodeficiency virus RNA after virologic failure: updated data from the ADVANCE Trial. Clin Infect Dis. 2021 Aug 15;73(4):e1008-10.

- 128 Eholie SP, Moh R, Benalycherif A, et al. Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort study. Lancet HIV. 2019 Nov 1;6(11):e750-9.
- 129 Violari A, Lindsey JC, Hughes MD, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med. 2012 Jun 21;366(25):2380-9.
- 130 Palumbo P, Lindsey JC, Hughes MD, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med. 2010 Oct 14;363(16):1510-20.
- 131 Walmsley SL, Antela A, Clumeck N, et al. Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013 Nov 7;369(19):1807-18.
- 132 Losina E, Yazdanpanah Y, Deuffic-Burban S, et al. The independent effect of highly active antiretroviral therapy on severe opportunistic disease incidence and mortality in HIV-infected adults in Côte d'Ivoire. Antiviral Therapy. 2007 May;12(4):543-51.
- 133 Carlucci JG, Liu Y, Clouse K, Vermund SH. Attrition of HIV-positive children from HIV services in low-and middle-income countries: a systematic review and meta-analysis. AIDS. 2019 Dec 12;33(15):2375.
- 134 Makurumidze R, Mutasa-Apollo T, Decroo T, et al. Retention and predictors of attrition among patients who started antiretroviral therapy in Zimbabwe's national antiretroviral therapy programme between 2012 and 2015. PLoS One. 2020 Jan 7;15(1):e0222309.
- 135 Fenner L, Brinkhof MW, Keiser O, et al. Early mortality and loss to follow-up in HIV-infected children starting antiretroviral therapy in Southern Africa. J Acquir Immune Defic Syndr. 2010 Aug 8;54(5):524.
- 136 Sengayi M, Dwane N, Marinda E, Sipambo N, Fairlie L, Moultrie H. Predictors of loss to follow-up among children in the first and second years of antiretroviral treatment in Johannesburg, South Africa. Glob Health Action. 2013 Dec 1;6(1):19248.
- 137 Chhagan MK, Kauchali S, Van den Broeck J. Clinical and contextual determinants of anthropometric failure at baseline and longitudinal improvements after starting antiretroviral treatment among South African children. Trop Med Int Health. 2012 Sep;17(9):1092-9.
- 138 Janssen N, Ndirangu J, Newell ML, Bland RM. Successful paediatric HIV treatment in rural primary care in Africa. Arch Dis Child. 2010 Jun 1;95(6):414-21.
- 139 Zanoni BC, Phungula T, Zanoni HM, France H, Feeney ME. Risk factors associated with increased mortality among HIV infected children initiating antiretroviral therapy (ART) in South Africa. PloS One. 2011 Jul 29;6(7):e22706.
- 140 Meyer-Rath G, Brennan A, Long L, et al. Cost and outcomes of paediatric antiretroviral treatment in South Africa. AIDS. 2013 Jan 14;27(2):243-50.
- 141 Chandiwana N, Sawry S, Chersich M, Kachingwe E, Makhathini B, Fairlie L. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine (Baltimore). 2018 Jul;97(29).
- 142 Kalawan V, Naidoo K, Archary M. Impact of routine birth early infant diagnosis on neonatal HIV treatment cascade in eThekwini district, South Africa. South Afr J HIV Med. 2020;21(1).
- 143 Bernard C, Balestre E, Coffie PA, et al. Aging with HIV: what effect on mortality and loss to follow-up in the course of antiretroviral therapy? The IeDEA West Africa Cohort Collaboration. HIV AIDS (Auckl). 2018 Nov 16:239-52.
- 144 Matare T, Shewade HD, Ncube RT, et al. Anti-retroviral therapy after "Treat All" in Harare, Zimbabwe: What are the changes in uptake, time to initiation and retention? F1000Res. 2020;9.
- 145 Makurumidze R, Buyze J, Decroo T, et al. Patient-mix, programmatic characteristics, retention and predictors of attrition among patients starting antiretroviral therapy (ART) before and after the implementation of HIV "Treat All" in Zimbabwe. PLoS One. 2020 Oct 19;15(10):e0240865.
- 146 Dorward J, Sookrajh Y, Gate K, et al. HIV treatment outcomes among people with initiation CD4 counts> 500 cells/µL after implementation of Treat All in South African public clinics: a retrospective cohort study. J Int AIDS Soc. 2020 Apr;23(4):e25479.

- 147 Hirasen K, Fox MP, Hendrickson CJ, Sineke T, Onoya D. HIV treatment outcomes among patients initiated on antiretroviral therapy pre and post-universal test and treat guidelines in South Africa. Ther Clin Risk Manag. 2020 Mar 4;16:169-80.
- 148 Ambia J, Kabudula C, Risher K, et al. Outcomes of patients lost to follow-up after antiretroviral therapy initiation in rural north-eastern South Africa. Trop Med Int Health. 2019 Jun;24(6):747-56.
- 149 The Global Fund. HIV Viral Load and Early Infant Diagnosis Selection and Procurement Information Tool. Accessed August 5, 2020. https://www.theglobalfund.org/media/5765/psm\_viralloadearlyinfantdiagnosis\_content\_en.pdf?u=637298970370000000
- 150 National Health Laboratory Service. NHLS State Price List 2019/20. South African National Health Laboratory Service, 2019.
- 151 Bassett IV, Giddy J, Nkera J, et al. Routine voluntary HIV testing in Durban, South Africa: the experience from an outpatient department. J Acquir Immune Defic Syndr. 2007 Oct 10;46(2):181.
- 152 The Global Fund. *Price list*. Accessed October 27, 2020. https://public.tableau.com/profile/the.global.fund#!/vizhome/PQRPricelist\_English/PriceList
- 153 Doherty K, Essajee S, Penazzato M, Holmes C, Resch S, Ciaranello A. Estimating age-based antiretroviral therapy costs for HIV-infected children in resource-limited settings based on World Health Organization weight-based dosing recommendations. BMC Health Serv Res. 2014 Dec;14(1):1-2.
- 154 The Global Fund. *Pooled procurement mechanism reference pricing: ARVs (version: quarter 3 2020).* Accessed October 27, 2020. https://www.theglobalfund.org/media/5813/ppm\_arvreferencepricing\_table\_en.pdf.
- 155 Desmonde S, Avit D, Petit J, et al. Costs of care of HIV-infected children initiating lopinavir/ritonavir-based antiretroviral therapy before the age of two in Cote d'Ivoire. PLos One. 2016 Dec 9;11(12):e0166466.
- 156 Menzies NA, Berruti AA, Berzon R, et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS. 2011 Sep 9;25(14):1753.
- 157 Magure T, Manenji A, Gboun M, et al. Zimbabwe National AIDS Spending Assessment: Consolidated Report 2011 and 2012. National AIDS Council of Zimbabwe and UNAIDS, 2012.
- 158 Massyn N, Barron P, Day C, Padarath A. District Health Barometer 2018/19. Durban, South Africa: Health Systems Trust, 2020. Accessed August 17, 2020. https://www.hst.org.za/publications/Pages/DISTRICT-HEALTH-BAROMETER-201819.aspx.
- 159 The Global Fund. Pooled Procurement Mechanism Reference Pricing: Advanced HIV disease products. Accessed August 20, 2020. https://www.theglobalfund.org/media/9274/ppm advancedhivproductsreferencepricing table en.pdf?u=637319004622070000
- 160 Clinton Health Access Initiative. Unitaid and CHAI announce agreement with Omega Diagnostics to increase access to new, instrument-free CD4 test for people living with HIV in over 130 low- and middle-income countries. Accessed August 4, 2020. https://www.clintonhealthaccess.org/unitaid-and-chai-announce-agreement-with-omega-diagnostics-to-increase-access-to-newportable-cd4-testing-device-for-people-living-with-hiv-in-over-130-low-and-middle-income-countries/
- 161 Tibuyile Sigudia (Central Medical Stores Swaziland). Personal communication. 2016.
- 162 Thomas LS. *Costing of HIV/AIDS services at a tertiary level hospital in Gauteng Province; 2007.* Accessed October 27, 2020. http://hdl.handle.net/10539/2008.
- 163 Cleary S, Chitha W, Jikwana S, Okorafor OA, Boulle A. South African Health Review 2005: Financing. Durban, South Africa: Health Systems Trust, 2005. https://www.hst.org.za/publications/South%20African%20Health%20Reviews/sahr05.pdf
- 164 World Health Organization. *WHO-CHOICE: Country-specific unit costs; 2011*. Accessed August 18, 2021. https://www.who.int/teams/health-systems-governance-and-financing/economic-analysis/costing-and-technicalefficiency/quantities-and-unit-prices-(cost-inputs)/econometric-estimation-of-who-choice-country-specific-costs-for-inpatient-andoutpatient-health-service-delivery.

- 165 Zimbabwe National Statistics Agency. *Demographic and Health Survey 2015; 2016.* Accessed October 27, 2020. https://dhsprogram.com/pubs/pdf/FR322/FR322.pdf.
- 166 Zunza M, Esser M, Slogrove A, et al. Cotton. Early breastfeeding cessation among HIV-infected and HIV-uninfected women in Western Cape Province, South Africa. AIDS Behav. 2018 Jul;22:114-20.
- 167 Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012 Jun 21;366(25):2368-79.

Lallemant M, Amzal B, Sripan P, et al. Perinatal antiretroviral intensification to prevent intrapartum HIV transmission when antenatal antiretroviral therapy is initiated less than 8 weeks before delivery. J Acquir Immune Defic Syndr. 2020 Jul 7;84(3):313.